asrt	researchStatementLabel	assertType	objectURI	valueURI	label	homepage	source	dateAnnotated	whoAnnotated	evidence	evidenceRole	evidenceSource	evidenceType	evidenceStatement
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1	R-citalopram_substrate_of_cyp2d6	substrate_of		http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-citalopram_substrate_of_cyp2d6.html	DIKB	"06/12/2009 19:20:37
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1	support	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

reaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram

Quote:

Chemical Inhibition of CT and DCT Biotransformation in
Microsomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by
ketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/7	ziprasidone_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/9	desacetyldiltiazem_substrate_of_cyp2d6	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/71	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/desacetyldiltiazem_substrate_of_cyp2d6.html	DIKB	"08/09/2007 07:08:28
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/10	support	http://www.ncbi.nlm.nih.gov/pubmed/12235455	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Genotype	"Route of administration: oral

polymorphic enzyme: yes

study duration: single 120mg oral dose of diltiazem with 24 hours of plasma level monitoring

population: 15 individuals; 5 for each genetically based phenotype. Study does not state gender of participants

ages: 20-30

description: 
The aim of this study was to compare the pharmacokinetics of diltiazem and its major metabolites in healthy human volunteers representing different CYP2D6 genotypes. METHODS: Norwegians of Caucasian origin were screened for their CYP2D6 genotype on the LightCycler (Roche Diagnostics, Mannheim, Germany) by melting-curve analysis of allele-specific fluorescence resonance energy transfer probes hybridized to polymerase chain reaction-amplified deoxyribonucleic acid. The first 5 individuals identified with genotypes corresponding to a homozygous extensive, heterozygous extensive, or homozygous poor CYP2D6-metabolizing phenotype, respectively, were voluntarily enrolled in the pharmacokinetic study. The participants received diltiazem, 120 mg, as a single oral dose, and plasma samples were collected up to 24 hours after administration. Plasma samples were purified by solid phase extraction. Diltiazem and 7 phase I metabolites were analyzed by liquid chromatography-mass spectrometry. RESULTS: The pharmacokinetics of diltiazem was not significantly different between the subgroups. However, the systemic exposure of the pharmacologically active metabolites desacetyl diltiazem and N-demethyldesacetyl diltiazem was &gt; or = 5 times higher in poor CYP2D6 metabolizers than in extensive CYP2D6 metabolizers (P &lt;.01). CONCLUSIONS: CYP2D6 activity does not have a major impact on the disposition of diltiazem. In contrast, desacetyl diltiazem and N-demethyldesacetyl diltiazem are markedly accumulated in individuals expressing a deficient CYP2D6 phenotype. Because these metabolites exhibit pharmacologic properties of possible importance, individual CYP2D6 activity might be an aspect to consider in the clinical use of diltiazem."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/34	clarithromycin_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_substrate_of_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/36	simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	"05/16/2007 15:02:11
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/45	support	http://www.ncbi.nlm.nih.gov/pubmed/9542477	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

polymorphic enzyme: NO

study duration: 4 days

population: 7 male, 3 female

ages:19-29

description:
Two randomized, double-blind, two-phase crossover studies were performed with use of an identical design, one with simvastatin (study I) and one with pravastatin (study II). In both studies, 10 healthy volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a single 40 mg dose of simvastatin (study I) or pravastatin (study II). Serum concentrations of simvastatin, simvastatin acid, pravastatin, HMG-CoA reductase inhibitors, itraconazole, and hydroxyitraconazole were determined. RESULTS: In study I, itraconazole increased the peak serum concentrations (Cmax) and the areas under the serum concentration-time curve [AUC(0-infinity)] of simvastatin and simvastatin acid at least tenfold (p < 0.001)."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/36	simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	"05/29/2007 14:58:01
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/46	support	http://www.ncbi.nlm.nih.gov/pubmed/9321523	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human enzymes in Supersomes

NADPH added: yes

inhibitor used: no

This study showed the formation of 3',5'-dihydrodiol, 3'-hydroxy, and 6'-exomethylene metabolites using a recombinant CYP3A4 system
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/36	simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	"05/29/2007 15:23:02
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/47	support	http://www.ncbi.nlm.nih.gov/pubmed/15518608	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_Par_Grps	"Route of administration: oral

polymorphic enzyme: NO

study duration: 7 days simvastatin only, 8 days simva and clarithromycin

dose: .040g simvastatin 1xday
      .5g clarithromycin 2xday

population: 45 men and women (15 received simvastatin)

ages:18-60 

(mean AUC_i)/(mean AUC) = 219/22 

description: Clarithromycin significantly (p <0.001) increased the AUC (and C(max)) of all 3 statins, most markedly simvastatin ( approximately 10-fold increase in AUC)
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/39	nefazodone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/42	desvenlafaxine_substrate_of_cyp2d6	substrate_of		http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/desvenlafaxine_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/47	atorvastatin_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a5.html	DIKB	"09/25/2007 07:59:50
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/64	support	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes
inhibitor used: itraconazole

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
itraconazole effected a dramatic decrease in the formation of both metabolites from both lactone and acid forms of atorvastatin"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/47	atorvastatin_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a5.html	DIKB	"09/25/2007 08:35:33
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/65	support	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human CYP3A5 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
According to the authors, this enzyme system catalyzed the above reactions similar to that of the CYP3A4 recombinant enzyme system whose Km values ranged from 1.4micM/L for atorvastatin lactone--&gt;para-hydroxy-atorvastatin to 29.7micM/L for the atorvastatin acid--&gt;ortho-hydroxy-atorvastatin

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/48	atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	"09/25/2007 07:52:24
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/66	support	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"Enzyme system: human liver microsomes

NADPH added: yes
inhibitor used: itraconazole

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
itraconazole effected a dramatic decrease in the formation of both metabolites from both lactone and acid forms of atorvastatin"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/48	atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	"09/25/2007 08:33:11
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/67	support	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP3A4 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system catalyzed the above reactions with Km values ranging from 1.4micM/L for atorvastatin lactone--&gt;para-hydroxy-atorvastatin to 29.7micM/L for the atorvastatin acid--&gt;ortho-hydroxy-atorvastatin

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/48	atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	"09/27/2007 10:18:37
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/68	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/8a201c80-a51d-4c1c-963b-488c071908c0	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	&quot;In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following coadministration with erythromycin, a known inhibitor of this isozyme&quot;
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/58	fluvastatin_substrate_of_cyp2c8	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01095	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvastatin_substrate_of_cyp2c8.html	DIKB	"10/20/2007 09:40:46
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/81	support	http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"&quot;
Fluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-dealkylation and beta-oxidation of the side-chain also occurs. The hydroxy metabolites have some pharmacologic activity, but do not circulate in the blood. Both enantiomers of fluvastatin are metabolized in a similar manner.

      In vitro studies demonstrated that fluvastatin undergoes oxidative metabolism, predominantly via 2C9 isozyme systems (75%). Other isozymes that contribute to fluvastatin metabolism are 2C8 (~5%) and 3A4 (~20%).&quot;"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/59	fluvastatin_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01095	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvastatin_substrate_of_cyp2c9.html	DIKB	"10/20/2007 09:37:05
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/82	support	http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"&quot;
Fluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-dealkylation and beta-oxidation of the side-chain also occurs. The hydroxy metabolites have some pharmacologic activity, but do not circulate in the blood. Both enantiomers of fluvastatin are metabolized in a similar manner.

      In vitro studies demonstrated that fluvastatin undergoes oxidative metabolism, predominantly via 2C9 isozyme systems (75%). Other isozymes that contribute to fluvastatin metabolism are 2C8 (~5%) and 3A4 (~20%).&quot;"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/73	aripiprazole_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/74	aripiprazole_substrate_of_cyp1a1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006101		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp1a1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/82	atorvastatin_substrate_of_cyp2b6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006116		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp2b6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/89	N-desalkylquetiapine_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/24	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/N-desalkylquetiapine_substrate_of_cyp3a4.html	DIKB	"05/14/2009 14:23:32
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/112	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Quetiapine is extensively metabolized by the liver. The major metabolic pathways are sulfoxidation to the sulfoxide metabolite and oxidation to the parent acid metabolite; both metabolites are pharmacologically inactive. In vitro studies using human liver microsomes revealed that the cytochrome P450 3A4 isoenzyme is involved in the metabolism of quetiapine to its major, but inactive, sulfoxide metabolite and in the metabolism of its active metabolite N-desalkyl quetiapine .
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/93	ziprasidone_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp1a2.html	DIKB	"06/19/2009 17:46:18
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/116	support	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes

inhibitor used: furafylline

reaction: 1) ziprasidone --&gt; ziprasidone sulphoxide/sulphone
2) ziprasidone --&gt; oxindole acetic acid

Quote:
Inhibition of metabolite formation by each inhibitor is
summarized in Table 2. Ketoconazole (10micM) inhibited
the formation of ziprasidone sulphoxide (sulphoxide and
sulphone) by 79% and oxindole acetic acid N-dealkylated
product) completely. Sulphaphenazole an furafylline did
not inhibit the formation of ziprasidone sulphoxide. The formation of oxindole acetic acid was inhibited (~50%) by furafylline. The formation of ziprasidone metabolites was not inhibited by quinidine but rather increased. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/94	atorvastatin_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/97	alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB	"06/26/2007 07:11:48
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/122	support	http://www.ncbi.nlm.nih.gov/pubmed/12124305	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human enzymes in Supersomes

NADPH added: yes

inhibitor used: no

This study showed the formation of both 1'-OH-triazolam and  4-OH-triazolam in a recombinant cyp3a4 Supersome system"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/97	alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB	"06/26/2007 07:39:29
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/123	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/b5e516a0-d0f4-4613-ab56-b1bb440fcb78	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
&quot;Alprazolam is extensively metabolized in humans, primarily by cytochrome P450 3A4 (CYP3A4), to two major metabolites in the plasma: 4-hydroxyalprazolam and alpha-hydroxyalprazolam.&quot;"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/97	alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB	"07/02/2007 10:51:34
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/124	support	http://www.ncbi.nlm.nih.gov/pubmed/10548453	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (p. 394 `chemical inhibition`

inhibitor used: 

reaction: alprazolam --&gt; 4-OH-alprazolam
          alprazolam --&gt; 1'-OH-alprazolam

Quote: 

&quot;Co-incubation of human liver microsomes with the prototypic 3A4 inhibitor, troleandomycin, ( &gt; 50microM) resulted in no detectable formation of 1'-OH-alprazolam and 4-OH-alprazolam&quot;"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/98	alprazolam_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a5.html	DIKB	"06/26/2007 06:27:38
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/125	support	http://www.ncbi.nlm.nih.gov/pubmed/16765147	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Genotype	"
Route of administration: oral

polymorphic enzyme: yes

study duration: single dose with 72 hours of plasma level monitoring

population: study does not state gender of participants

ages: 22-30

description: 
Our objective was to evaluate the effect of the CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy volunteers. METHODS: Nineteen healthy male volunteers were divided into 3 groups on the basis of the genetic polymorphism of CYP3A5. The groups comprised subjects with CYP3A5*1/*1 (n=5), CYP3A5*1/*3 (n=7), or CYP3A5*3/*3 (n=7). After a single oral 1-mg dose of alprazolam, plasma concentrations of alprazolam were measured up to 72 hours, together with assessment of psychomotor function by use of the Digit Symbol Substitution Test, according to CYP3A5 genotype. RESULTS: The area under the plasma concentration-time curve for alprazolam was significantly greater in subjects with CYP3A5*3/*3 (830.5+/-160.4 ng . h/mL [mean+/-SD]) than in those with CYP3A5*1/*1 (599.9+/-141.0 ng . h/mL) (P=.030). The oral clearance of alprazolam was also significantly different between the CYP3A5*1/*1 group (3.5+/-0.8 L/h) and CYP3A5*3/*3 group (2.5+/-0.5 L/h) (P=.036). Although a trend was noted for the area under the Digit Symbol Substitution Test score change-time curve (area under the effect curve) to be greater in subjects with CYP3A5*3/*3 (177.2+/-84.6) than in those with CYP3A5*1/*1 (107.5+/-44), the difference did not reach statistical significance (P=.148). CONCLUSIONS: The CYP3A5*3 genotype affects the disposition of alprazolam and thus influences the plasma levels of alprazolam."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/98	alprazolam_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a5.html	DIKB	"06/26/2007 07:14:26
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/126	support	http://www.ncbi.nlm.nih.gov/pubmed/12124305	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human enzymes in Supersomes

NADPH added: yes

inhibitor used: no

This study showed the formation of both 1'-OH-triazolam and  4-OH-triazolam in a recombinant cyp3a5 Supersome system"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/99	R-demethylcitalopram_substrate_of_cyp2c19	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/19	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-demethylcitalopram_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/127	duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	"05/05/2009 17:43:52
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/159	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.2 Inhibitors of CYP2D6

Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see Warnings and Precautions (5.10)]."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/127	duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	"06/20/2009 13:36:32
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/160	support	http://www.ncbi.nlm.nih.gov/pubmed/12621382	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"

route of administration: oral

study duration: &quot;In study 2, there were 2 study periods separated by a least 4 days. In period 1, subjects received 40 mg duloxetine every day for 5 days. Blood samples for the measurement of duloxetine plasma concentrations were taken immediately before duloxetine dosing on days 3 4, and 5 and at 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours after dosing on day 5. In period 2, subjects received 20 mg paroxetine every day for 20 days Beginning on day 12 of this period, subjects again received duloxetine 40 mg every day for 5 days and samples were taken as in period 1, except that additional samples were taken 96 and 120 hours after the &amp;#64257;nal duloxetine dose. On the &amp;#64257;nal day of duloxetine dosing in each period, subjects fasted from midnigh until 4 hours after dosing. All doses of study drugs were supervised by study site personnel. &quot;

population: 12 male; 11 of 12 were of Chinese or Malay decent NOTE: only 10 completed the study

tested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.

ages: 21 - 27

description:
&quot;Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration-time curve at steady state 1.6-fold.&quot;

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/139	nefazodone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp3a4.html	DIKB	"02/13/2010 09:12:03
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/175	support	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: ketoconazole

reaction: nefazodone --&gt; OH-NEF and nefazodone --&gt; mCPP

Quote: 
Incubations of human liver microsomes with NEF and
the CYP3A4 inhibitor ketoconazole resulted in a concentration-dependent inhibition of the formation of mCPP and OH-NEF (Fig. 3).



"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/148	R-citalopram_substrate_of_cyp2c19	substrate_of		http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-citalopram_substrate_of_cyp2c19.html	DIKB	"06/12/2009 19:19:09
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/184	support	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"

Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

reaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram

Quote:

Chemical Inhibition of CT and DCT Biotransformation in
Microsomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by
ketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/152	modafinil_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_substrate_of_cyp3a4.html	DIKB	"09/24/2009 12:45:45
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/187	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drug-Drug Interactions:

Based on in vitro data, modafinil is metabolized partially by the 3A isoform subfamily of hepatic cytochrome P450 (CYP3A4). I"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/155	lovastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lovastatin_substrate_of_cyp3a4.html	DIKB	"09/28/2007 14:01:54
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/192	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/d3620ebe-87e1-4a93-96cc-ff20ddbb30b2	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"&quot;Potent inhibitors of CYP3A4: Lovastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of cytochrome P450 3A4 (CYP3A4). When lovastatin is used with a potent inhibitor of CYP3A4, elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of lovastatin.&quot;
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/155	lovastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lovastatin_substrate_of_cyp3a4.html	DIKB	"10/29/2007 13:18:39
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/193	support	http://www.ncbi.nlm.nih.gov/pubmed/8689812	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

study duration: 4 days pretreatment with 200mg oral itraconazole; a single, oral, 40mg dose of lovastatin on day 4

population: 12
male: 5
female: 7 (2 on contraceptive steroids)

ages: 20-29

AUC_i/AUC: 546/15 = &gt;36.4
NOTE: AUC of lovastatin w/ placebo could not be measured but was known to be &lt; 15ng/ml*h"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/174	quetiapine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/181	eszopiclone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp3a4.html	DIKB	"09/23/2009 15:48:01
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/225	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/181	eszopiclone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp3a4.html	DIKB	"09/23/2009 16:09:10
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/226	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drugs That Inhibit CYP3A4 (Ketoconazole)

CYP3A4 is a major metabolic pathway for elimination of eszopiclone. The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days. Cmax and t1/2 were increased 1.4-fold and 1.3-fold, respectively. Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/187	escitalopram_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp3a4.html	DIKB	"06/12/2009 19:11:52
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/233	support	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

reaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram

Quote:

Chemical Inhibition of CT and DCT Biotransformation in
Microsomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by
ketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/190	bupropion_substrate_of_cyp2b6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01156	http://purl.obolibrary.org/obo/PR_000006116		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/bupropion_substrate_of_cyp2b6.html	DIKB	"06/20/2009 15:22:12
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/236	support	http://www.ncbi.nlm.nih.gov/pubmed/10997944	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant CYP450 enzymes in baculovirus-infected insect cells

NADPH added: yes

reaction: bupropion --&gt; hydroxybupropion

NOTE: the experiment provides no clear minimum Km CYP2B6 catalysis of the mentioned reaction

Quote:
&quot;Evaluation of BUP Hydroxylation by Individual cDNA-Expressed Human P450s. Because the biphasic kinetic data observed with low activity HLMs (HLMs 20 and 24) indicated the contribution of more than one enzyme to BUP hydroxylation at higher substrate concentrations, a panel of eight cDNA-expressed enzymes (SUPER- SOMES) was screened for BUP hydroxylase activity at 12 mM to identify enzymes requiring further investigation (Fig. 7). This sub- strate concentration was selected to ensure saturation of any high Km isozyme capable of catalyzing BUP hydroxylation. cDNA-expressed CYP2B6 demonstrated the highest rate of HBUP formation (7.0 pmol/min/pmol of P450). cDNA-expressed CYP2E1 and CYP3A4 catalyzed BUP hydroxylation at the second and third highest rates, although at 3- and 30-fold lower rates than cDNA-expressed CYP2B6 (2.4 and 0.23 pmol/min/pmol of P450, respectively). Of note, CYP2E1 was the only cDNA-expressed enzyme in which cytochrome b5 was coexpressed. Rates of BUP hydroxylation by CYP1A2, CYP2A6, CYP2C9, CYP2C19, and CYP2D6 were greater than 30-fold lower than CYP2B6 (Fig. 7). HBUP formation in control microsomes was negligible.&quot;"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/194	cinacalcet_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_substrate_of_cyp1a2.html	DIKB	009242009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/240	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism and Excretion

Cinacalcet is metabolized by multiple enzymes, primarily CYP3A4, CYP2D6 and CYP1A2."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/209	aripiprazole_substrate_of_cyp2c8	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2c8.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/223	S-demethylcitalopram_substrate_of_cyp2c19	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/35	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-demethylcitalopram_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/239	celecoxib_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_substrate_of_cyp2c9.html	DIKB	"09/24/2009 10:57:14
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/293	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism: Celecoxib metabolism is primarily mediated via CYP2C9. Three metabolites, a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate, have been identified in human plasma. These metabolites are inactive as COX-1 or COX-2 inhibitors.

CYP2C9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the CYP2C9*2 and CYP2C9*3 polymorphisms. Limited data from 4 published reports that included a total of 8 subjects with the homozygous CYP2C9*3/*3 genotype showed celecoxib systemic levels that were 3- to 7-fold higher in these subjects compared to subjects with CYP2C9*1/*1 or *I/*3 genotypes. The pharmacokinetics of celecoxib have not been evaluated in subjects with other CYP2C9 polymorphisms, such as *2, *5, *6, *9 and *11. It is estimated that the frequency of the homozygous *3/*3 genotype is 0.3% to 1.0% in various ethnic groups. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/245	demethylcitalopram_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/68	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/demethylcitalopram_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/254	pantoprazole_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_substrate_of_cyp2c19.html	DIKB	"09/24/2009 13:17:14
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/310	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/742ca9f4-9fba-44d4-29a8-1fe3a04f1af6	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

Pantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. Pantoprazole metabolism is independent of the route of administration (intravenous or oral). The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/258	S-demethylcitalopram_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/35	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-demethylcitalopram_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/262	clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	"05/15/2009 11:01:27
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/319	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Pharmacokinetic-related Interactions

Clozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/262	clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	"06/20/2009 14:35:57
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/320	support	http://www.ncbi.nlm.nih.gov/pubmed/11147928	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"
Route of administration: oral

study duration: three weeks

population: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks

ages: 29 - 55


Quote:

The effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/265	dehydro-aripiprazole_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/58	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/dehydro-aripiprazole_substrate_of_cyp3a4.html	DIKB	"04/29/2009 19:27:27
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/323	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Coadministration of ketoconazole (200 mg/day for 14 days) with a 15 mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/265	dehydro-aripiprazole_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/58	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/dehydro-aripiprazole_substrate_of_cyp3a4.html	DIKB	"05/06/2009 14:22:53
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/324	support	http://www.ncbi.nlm.nih.gov/pubmed/15770075	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"Route of administration: oral

study duration: Two phases : Phase I - a single dose of aripiprazole; Phase II - 7 days pre-treatment with ITZ, single dose of aripiprazole with ITZ, then ITZ alone or 14 more days; a 35 day washout between Phase I and II

population: 24 healthy adult Japanese males

mean age (SD): 23.2 (2.4)

AUC_i/AUC (336hr): 365/269 = 1.36

Description:
The objective of the present study was to investigate the influence of itraconazole (hereafter referred to as ITZ) co-administration (CYP3A4 inhibition) on the pharmacokinetics of ARIPIPRAZOLE administered to 24 healthy adult male volunteers in a fasting condition. The influence of CYP3A4 inhibition was also examined by CYP2D6 genotype. All subjects were administered a single oral dose of ARIPIPRAZOLE alone in Period I and a single oral dose of ARIPIPRAZOLE following administration of ITZ at 100 mg/day for 7 consecutive days in Period II. The pharmacokinetic parameters of ARIPIPRAZOLE and its main metabolite OPC-14857 were determined. Co-administration of ITZ increased the Cmax, AUC336 hr, and t1/2,z of ARIPIPRAZOLE and OPC-14857 by 19.4%, 48.0%, and 18.6% and by 18.6%, 38.8%, and 53.4%, respectively. By co-administration of ITZ, the CL/F of ARIPIPRAZOLE in extensive metabolizers was decreased by 26.6%, with an even greater decrease (47.3%) in intermediate metabolizers. For the co-administration period, the CL/F of ARIPIPRAZOLE in intermediate metabolizers was about half of that in extensive metabolizers. For Cmax, there was no significant difference between extensive metabolizers and intermediate metabolizers, and the percent change by co-administration of ITZ was less than 20% in both extensive metabolizers and intermediate metabolizers. For OPC-14857, the t(max) in intermediate metabolizers was longer than that in extensive metabolizers, with the difference being amplified by co-administration of ITZ. The AUC336 hr showed similar increases by co-administration of ITZ in all genotypes. The urinary 6beta-hydroxycortisol/cortisol concentration ratio following ITZ administration for 7 consecutive days was about half of that before the start of ITZ administration, indicating that CYP3A4 metabolic activity was inhibited by administration of ITZ. The influence of CYP3A4 inhibition on the pharmacokinetics of ARIPIPRAZOLE was not considered to be clinically significant. On the other hand, definite differences in pharmacokinetics were observed between CYP2D6 genotypes. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/266	alprazolam_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/291	aripiprazole_substrate_of_cyp2e1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2e1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/297	perphenazine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp1a2.html	DIKB	"06/15/2009 14:26:44
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/359	support	http://www.ncbi.nlm.nih.gov/pubmed/11136295	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: furafylline

reaction: perphenazine N-dealkylation

Quote: 
To identify the human cytochrome P450 (CYP) isoforms mediating the N-dealkylation of the antipsychotic drug perphenazine in vitro and estimate the relative contributions of the CYP isoforms involved. METHODS: cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction... Ketoconazole inhibition of N-dealkylation mediated by a mixed HLM indicated that CYP3A4 accounted for about 40% of perphenazine N-dealkylation at therapeutically relevant concentrations.The contribution of the CYP isoforms 1A2, 2C19 and 2D6 amounted to 20-25% each as measured by the percentage inhibition obtained by addition of furafylline, fluvoxamine or quinidine, respectively.

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/297	perphenazine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp1a2.html	DIKB	"06/15/2009 16:29:22
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/360	support	http://www.ncbi.nlm.nih.gov/pubmed/11136295	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human CYP enzymes in baculovirus-infected insect cells

NADPH added: yes 

Quote:
cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/298	voriconazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_substrate_of_cyp3a4.html	DIKB	009242009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/361	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

In vitro studies showed that voriconazole is metabolized by the human hepatic cytochrome P450 enzymes, CYP2C19, CYP2C9 and CYP3A4 "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/300	asenapine_substrate_of_cyp2d6	substrate_of		http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/asenapine_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/302	mirtazapine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp1a2.html	DIKB	"06/15/2009 15:23:39
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/365	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/31f48378-27db-424f-a4c5-82584a553c35	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Mirtazapine is extensively metabolized after oral administration. Major pathways of biotransformation are demethylation and hydroxylation followed by glucuronide conjugation. In vitro data from human liver microsomes indicate that cytochrome 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite of mirtazapine, whereas cytochrome 3A is considered to be responsible for the formation of the N-desmethyl and N-oxide metabolite."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/302	mirtazapine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp1a2.html	DIKB	"02/13/2010 07:59:40
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/366	support	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: alpha-napthoflavone

reaction: mirtazapine 8-hydroxylation (25 and 250 micM) 

Quote: 
Incubations of MIR with human liver microsomes resulted in the formation of OHM, DMM, and MIR-N-
oxide (Fig. 1). Quinidine (5 micM) and alpha-naphthoflavone (0.5 micM),specific inhibitors of CYP2D6 and CYP1A2, respectively, partially inhibited MIR-hydroxylation. Ketoconazole (1 micM), a specific inhibitor of CYP3A4, inhibited MIR-N-demethylation and MIR-N-oxidation. 

NOTE: lowest MIR concentration tested was 25 micM

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/331	quetiapine_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/367	clozapine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp3a4.html	DIKB	"05/15/2009 11:02:18
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/442	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Pharmacokinetic-related Interactions

Clozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/367	clozapine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp3a4.html	DIKB	"02/12/2010 18:20:56
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/443	support	http://www.ncbi.nlm.nih.gov/pubmed/9384460	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: ketoconazole

reaction: clozapine demethylation and N-oxidation

Quote: 
Ketconazole inhibited [clozapine] demethylation by 28+/-20% and 68+/-15% at 0.2 and 2 micM, respectively... CLZ-NO formation was inhibited by ketoconazole by 41+/-14% and 51+/-13% at 0.2 and 2 micM, respectively. 


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/370	aripiprazole_substrate_of_cyp2a6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2a6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/376	S-demethylcitalopram_substrate_of_cyp2d6	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/35	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-demethylcitalopram_substrate_of_cyp2d6.html	DIKB	"06/12/2009 19:29:37
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/453	support	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"

Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

reaction: R- and S-desmethylcitalopram (aka demethylcitalopram) --&gt; R- and S- didemethylcitalopram

Quote:

Quinidine (5micM) reduced formation of DDCT from R- or S-DCT to only 70 to 80% of control (Fig. 7), whereas the same concentration of quinidine reduced formation of R- and S-DCT to less than 10% of control values in heterologously expressed CYP2D6.

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/383	voriconazole_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_substrate_of_cyp2c19.html	DIKB	009242009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/461	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

In vitro studies showed that voriconazole is metabolized by the human hepatic cytochrome P450 enzymes, CYP2C19, CYP2C9 and CYP3A4 "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/407	escitalopram_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp2d6.html	DIKB	"06/12/2009 19:07:47
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/488	support	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

reaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram

Quote:

Chemical Inhibition of CT and DCT Biotransformation in
Microsomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by
ketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/408	atorvastatin_substrate_of_cyp2e1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp2e1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/413	ziprasidone_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/422	beta-hydroxy-simvastatin_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/21	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/beta-hydroxy-simvastatin_substrate_of_cyp3a4.html	DIKB	"05/29/2007 15:29:12
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/506	support	http://www.ncbi.nlm.nih.gov/pubmed/15518608	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_Par_Grps	"Route of administration: oral

polymorphic enzyme: NO

study duration: 7 days simvastatin only, 8 days simva and clarithromycin

dose: .040g simvastatin 1xday
.5g clarithromycin 2xday

population: 45 men and women

ages:18-60

(mean AUC_i)/(mean AUC) = 73/6

description: Clarithromycin significantly increased the AUC (and C(max)) of all 3 statins, most markedly simvastatin ( approximately 10-fold increase in AUC) and simvastatin acid (12-fold)"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/422	beta-hydroxy-simvastatin_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/21	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/beta-hydroxy-simvastatin_substrate_of_cyp3a4.html	DIKB	"06/25/2007 15:56:14
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/507	support	http://www.ncbi.nlm.nih.gov/pubmed/9542477	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"Route of administration: oral

polymorphic enzyme: NO

study duration: 4 days

population: 7 male, 3 female

ages:19-29

description:
Two randomized, double-blind, two-phase crossover studies were performed with use of an identical design, one with simvastatin (study I) and one with pravastatin (study II). In both studies, 10 healthy volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a single 40 mg dose of simvastatin (study I) or pravastatin (study II). Serum concentrations of simvastatin, simvastatin acid, pravastatin, HMG-CoA reductase inhibitors, itraconazole, and hydroxyitraconazole were determined. RESULTS: In study I, itraconazole increased the peak serum concentrations (Cmax) and the areas under the serum concentration-time curve [AUC(0-infinity)] of simvastatin and simvastatin acid at least tenfold (p < 0.001)."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/458	nefazodone_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/465	escitalopram_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp2c19.html	DIKB	"05/15/2009 10:09:13
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/553	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.18 CYP3A4 and -2C19 Inhibitors

In vitro studies indicated that CYP3A4 and -2C19 are the primary enzymes involved in the metabolism of escitalopram. However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram. Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance.

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/465	escitalopram_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp2c19.html	DIKB	"06/12/2009 19:03:08
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/554	support	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

reaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram

Quote:

Chemical Inhibition of CT and DCT Biotransformation in
Microsomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by
ketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/469	rabeprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01129	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rabeprazole_substrate_of_cyp3a4.html	DIKB	"09/24/2009 13:56:23
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/558	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5d103551-978f-472a-9c62-51e6e4dea068	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
7.6 Combined Administration with Clarithromycin

Combined administration consisting of rabeprazole, amoxicillin, and clarithromycin resulted in increases in plasma concentrations of rabeprazole and 14-hydroxyclarithromycin.{See CLINICAL PHARMACOLOGY, Combined Administration with Antimicrobials (12.3)}.

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/469	rabeprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01129	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rabeprazole_substrate_of_cyp3a4.html	DIKB	"09/24/2009 13:58:07
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/559	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5d103551-978f-472a-9c62-51e6e4dea068	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism: 
...
In vitro studies have demonstrated that rabeprazole is metabolized in the liver primarily by cytochromes P450 3A (CYP3A) to a sulphone metabolite and cytochrome P450 2C19 (CYP2C19) to desmethyl rabeprazole."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/480	risperidone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/risperidone_substrate_of_cyp2d6.html	DIKB	"06/17/2009 13:29:24
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/570	support	http://www.ncbi.nlm.nih.gov/pubmed/7690693	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Phenotype	"
route of administration: oral

study duration: single dose

population: 12 males, phenotyped using dextromethorphan (9 2D6 EMs, 2 PMs, 1 IM)

ages: 24 (SD:6) 

Quote:
The pharmacokinetics of a novel antipsychotic agent, risperidone, and the prolactin response were studied in 12 dextromethorphan-phenotyped healthy men after administration of 1 mg risperidone intravenously, intramuscularly, and orally. The formation of the equipotent major metabolite, 9-hydroxyrisperidone, exhibited CYP2D6-related polymorphism. The plasma area under the concentration-time curve from time zero to infinity ratio of 9-hydroxyrisperidone to risperidone averaged 3 (intravenous and intramuscular) and 6 (oral administration) in the extensive metabolizers and 0.2 in the poor metabolizers"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/480	risperidone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/risperidone_substrate_of_cyp2d6.html	DIKB	"02/13/2010 09:39:40
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/571	support	http://www.ncbi.nlm.nih.gov/pubmed/10048600	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: not mentioned but acceptable methods assumed

inhibitor used: quinidine

reaction: risperidone 9-hydroxylation

NOTE: experiment used 100micM of risperidone which is likely well above C_max based on PMID 7690693

Quote: 
risperidone was incubated with human liver microsomes in the presence of different concentrations of   inhibitors of CYP enzymes. Both quinidine (inhibitor of CYP2D6) and ketoconazole (inhibitor of CYP3A) inhibited the formation of 9-hydroxyrisperidone in a concentration-dependent manner (Fig. 4).



"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/481	aripiprazole_substrate_of_cyp2b6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006116		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2b6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/483	R-demethylcitalopram_substrate_of_cyp2d6	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/19	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-demethylcitalopram_substrate_of_cyp2d6.html	DIKB	"06/12/2009 19:30:06
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/574	support	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"

Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

reaction: R- and S-desmethylcitalopram (aka demethylcitalopram) --&gt; R- and S- didemethylcitalopram

Quote:

Quinidine (5micM) reduced formation of DDCT from R- or S-DCT to only 70 to 80% of control (Fig. 7), whereas the same concentration of quinidine reduced formation of R- and S-DCT to less than 10% of control values in heterologously expressed CYP2D6.

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/494	sertraline_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01104	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/sertraline_substrate_of_cyp2c19.html	DIKB	"09/28/2009 11:38:05
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/590	support	http://www.ncbi.nlm.nih.gov/pubmed/11452243	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Genotype	"

route of administration: oral

study duration: single dose of 100 mg sertraline 

population: 12 healthy Chinese male, non-smokers

tested for known CYP450 polymorphisms? Patients were genotyped for CYP2C19 polymorphisms and also phenotyped using the omeprazole/5-hydroxy-omeprazole metabolic ratio. 6 extensive metabolizers (EM) and 6 poor metabolizers (PM) were chosen using stratified random selection from a pool of 66 EMs and 11 PMs.

ages: 19 - 22 years

description:
The poor metabolizers had a 41% increase in sertraline AUC(0-inf) (983.6 ï¿½ 199.3 micg ï¿½ h/L versus 697.6 ï¿½ 133.0 mcg ï¿½ h/L; P &lt; .05) and a 51% increase in sertraline terminal elimination half-life (t_1/2) (35.5 ï¿½ 5.6 hours 2 versus 23.5 ï¿½ 4.4 hours; P &lt; .01) compared with extensive metabolizers. The oral clearance (CL_oral) of sertraline in poor metabolizers was significantly lower than that in extensive metabolizers (105.3 ï¿½ 19.4 L/h versus 148.4 ï¿½ 28.6 L/h; P &lt; .05). The AUC0-144 and Cmax of desmethylsertraline in poor metabolizers were significantly lower than the values in extensive metabolizers (627.6 ï¿½ 203.8 ï¿½g ï¿½ h/L versus 972.1 ï¿½ 270.3 ï¿½g ï¿½ h/L; P &lt; .05; 23.6 ï¿½ 6.5 nmol/L versus 32.4 ï¿½ 8.2 nmol/L; P &lt; .01; respectively). In addition, desmethylsertraline Tmax (time to reach Cmax) in poor metabolizers was markedly higher than that in extensive metabolizers (70.0 ï¿½ 24.5 hours versus 26.4 ï¿½ 5.4 hours; P &lt; .01). 


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/513	nefazodone_substrate_of_cyp2c8	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2c8.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/532	iloperidone_substrate_of_cyp2d6	substrate_of		http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp2d6.html	DIKB	"01/11/2010 18:29:32
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/630	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Fluoxetine: Co-administration of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy volunteers, ages 29-44, who were classified as CYP2D6 extensive metabolizers, increased the AUC of iloperidone and its metabolite P88, by about 2-3 fold, and decreased the AUC of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with fluoxetine. When fluoxetine is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level. Other strong inhibitors of CYP2D6 would be expected to have similar effects and would need appropriate dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, iloperidone dose could then be increased to the previous level.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/532	iloperidone_substrate_of_cyp2d6	substrate_of		http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp2d6.html	DIKB	"01/11/2010 18:32:05
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/631	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paroxetine: Co-administration of paroxetine (20 mg/day for 5-8 days), a potent inhibitor of CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18-65 resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6 fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with paroxetine. When paroxetine is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level. Other strong inhibitors of CYP2D6 would be expected to have similar effects and would need appropriate dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, iloperidone dose could then be increased to previous levels.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/533	pantoprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_substrate_of_cyp3a4.html	DIKB	"09/24/2009 13:18:40
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/632	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/742ca9f4-9fba-44d4-29a8-1fe3a04f1af6	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"

Metabolism

Pantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. Pantoprazole metabolism is independent of the route of administration (intravenous or oral). The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/546	venlafaxine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_substrate_of_cyp2d6.html	DIKB	"05/15/2009 10:28:04
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/648	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drugs that Inhibit Cytochrome P450 Isoenzymes

CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants. Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism and venlafaxine. However, although imipramine partially inhibited the CYP2D6-mediated metabolism of venlafaxine, resulting in higher plasma concentrations of venlafaxine and lower plasma concentrations of ODV, the total concentration of active compounds (venlafaxine plus ODV) was not affected. Additionally, in a clinical study involving CYP2D6-poor and -extensive metabolizers, the total concentration of active compounds (venlafaxine plus ODV), was similar in the two metabolizer groups. Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/546	venlafaxine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_substrate_of_cyp2d6.html	DIKB	"06/20/2009 14:01:46
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/649	support	http://www.ncbi.nlm.nih.gov/pubmed/10192828	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: paroxetine

reaction: venlafaxine --&gt; O-desmethylvenlafaxine

Quote: 
&quot;All six SSRIs inhibited the formation of ODV with PX being the most potent and DES being the least potent (Table 3).&quot;

K_i for paroxetine vs O-desmethylvenlafaxine formation: 0.17micM"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/546	venlafaxine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_substrate_of_cyp2d6.html	DIKB	"06/20/2009 14:04:45
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/650	support	http://www.ncbi.nlm.nih.gov/pubmed/10192828	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"

Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: quinidine

reaction: venlafaxine --&gt; O-desmethylvenlafaxine

Quote: 
&quot;All six SSRIs [including quinidine] inhibited the formation of ODV with PX being the most potent and DES being the least potent (Table 3).&quot;

K_i for quinidine vs O-desmethylvenlafaxine formation: 0.04micM"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/547	voriconazole_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_substrate_of_cyp2c9.html	DIKB	009242009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/651	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

In vitro studies showed that voriconazole is metabolized by the human hepatic cytochrome P450 enzymes, CYP2C19, CYP2C9 and CYP3A4 "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/552	aripiprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp3a4.html	DIKB	"04/29/2009 19:50:52
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/655	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism. Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.

Ketoconazole and Other CYP3A4 Inhibitors

Coadministration of ketoconazole (200 mg/day for 14 days) with a 15 mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied. When ketoconazole is given concomitantly with aripiprazole, the aripiprazole dose should be reduced to one-half of its normal dose. Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have similar effects and need similar dose reductions; moderate inhibitors (erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased.

Quinidine and Other CYP2D6 Inhibitors

Coadministration of a 10 mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydro-aripiprazole, by 35%. Aripiprazole dose should be reduced to one-half of its normal dose when quinidine is given concomitantly with aripiprazole. Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and should lead to similar dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased. When adjunctive ABILIFY is administered to patients with Major Depressive Disorder, ABILIFY should be administered without dosage adjustment as specified in DOSAGE AND ADMINISTRATION (2.3).

Carbamazepine and Other CYP3A4 Inducers

Coadministration of carbamazepine (200 mg twice daily), a potent CYP3A4 inducer, with aripiprazole (30 mg/day) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole. When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from the combination therapy, the aripiprazole dose should be reduced."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/552	aripiprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp3a4.html	DIKB	"05/06/2009 14:19:26
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/656	support	http://www.ncbi.nlm.nih.gov/pubmed/15770075	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"Route of administration: oral

study duration: Two phases : Phase I - a single dose of aripiprazole; Phase II - 7 days pre-treatment with ITZ, single dose of aripiprazole with ITZ, then ITZ alone or 14 more days; a 35 day washout between Phase I and II

population: 24 healthy adult Japanese males

meean age (SD): 23.2 (2.4)

AUC_i/AUC (336hr): 1075/736 = 1.48

Description:
The objective of the present study was to investigate the influence of itraconazole (hereafter referred to as ITZ) co-administration (CYP3A4 inhibition) on the pharmacokinetics of ARIPIPRAZOLE administered to 24 healthy adult male volunteers in a fasting condition. The influence of CYP3A4 inhibition was also examined by CYP2D6 genotype. All subjects were administered a single oral dose of ARIPIPRAZOLE alone in Period I and a single oral dose of ARIPIPRAZOLE following administration of ITZ at 100 mg/day for 7 consecutive days in Period II. The pharmacokinetic parameters of ARIPIPRAZOLE and its main metabolite OPC-14857 were determined. Co-administration of ITZ increased the Cmax, AUC336 hr, and t1/2,z of ARIPIPRAZOLE and OPC-14857 by 19.4%, 48.0%, and 18.6% and by 18.6%, 38.8%, and 53.4%, respectively. By co-administration of ITZ, the CL/F of ARIPIPRAZOLE in extensive metabolizers was decreased by 26.6%, with an even greater decrease (47.3%) in intermediate metabolizers. For the co-administration period, the CL/F of ARIPIPRAZOLE in intermediate metabolizers was about half of that in extensive metabolizers. For Cmax, there was no significant difference between extensive metabolizers and intermediate metabolizers, and the percent change by co-administration of ITZ was less than 20% in both extensive metabolizers and intermediate metabolizers. For OPC-14857, the t(max) in intermediate metabolizers was longer than that in extensive metabolizers, with the difference being amplified by co-administration of ITZ. The AUC336 hr showed similar increases by co-administration of ITZ in all genotypes. The urinary 6beta-hydroxycortisol/cortisol concentration ratio following ITZ administration for 7 consecutive days was about half of that before the start of ITZ administration, indicating that CYP3A4 metabolic activity was inhibited by administration of ITZ. The influence of CYP3A4 inhibition on the pharmacokinetics of ARIPIPRAZOLE was not considered to be clinically significant. On the other hand, definite differences in pharmacokinetics were observed between CYP2D6 genotypes. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/573	clarithromycin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_substrate_of_cyp3a4.html	DIKB	"10/20/2007 08:21:46
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/682	support	http://www.ncbi.nlm.nih.gov/pubmed/9152603	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes 

NADPH added: yes 

inhibitor used: ketoconazole 

reaction: 
clarithromycin --&gt; 14-(R)-hydroxylase-clarithromycin clarithromycin --&gt; 14-N-demethylase-clarithromycin 

description: clarithromycin oxidative metabolism was nearly completely wiped out by the addition of this selective inhibitor "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/573	clarithromycin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_substrate_of_cyp3a4.html	DIKB	"10/20/2007 08:39:39
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/683	support	http://www.ncbi.nlm.nih.gov/pubmed/12124305	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human enzymes in Supersomes

NADPH added: yes

inhibitor used: no

This study showed the formation of both 14-(R)-hydroxylase-clarithromycin and  14-N-demethylase-clarithromycin in a recombinant cyp3a4 Supersome system"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/577	perphenazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp2d6.html	DIKB	"06/15/2009 14:27:57
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/687	support	http://www.ncbi.nlm.nih.gov/pubmed/11136295	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: ketoconazole

reaction: perphenazine N-dealkylation

Quote: 
To identify the human cytochrome P450 (CYP) isoforms mediating the N-dealkylation of the antipsychotic drug perphenazine in vitro and estimate the relative contributions of the CYP isoforms involved. METHODS: cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction... Ketoconazole inhibition of N-dealkylation mediated by a mixed HLM indicated that CYP3A4 accounted for about 40% of perphenazine N-dealkylation at therapeutically relevant concentrations.The contribution of the CYP isoforms 1A2, 2C19 and 2D6 amounted to 20-25% each as measured by the percentage inhibition obtained by addition of furafylline, fluvoxamine or quinidine, respectively.

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/577	perphenazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp2d6.html	DIKB	"06/15/2009 16:31:59
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/688	support	http://www.ncbi.nlm.nih.gov/pubmed/11136295	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP enzymes in baculovirus-infected insect cells

NADPH added: yes 

Quote:
cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/577	perphenazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp2d6.html	DIKB	"06/16/2009 18:11:05
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/689	support	http://www.ncbi.nlm.nih.gov/pubmed/9333110	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
route of administration: oral

study duration: single dose of perphenazine (0.11 mg/kg orally) or placebo following a randomized double-blind design. Perphenazine plasma concentrations and effects were assessed for a period of 8 hours. Subsequently, subjects were treated with a standard therapeutic dose of paroxetine (20 mg/day orally) for 10 days and test sessions with perphenazine and placebo were repeated.

population: 8 adults (5 female, 3 male); all CYP2D6 EMs as determined by the dextromethorphan metabolite ration

ages: 21 - 49

Description: 
Paroxetine treatment resulted in a twofold to 21-fold decrease in CYP2D6 activity (p &lt; 0.001). After pretreatment with paroxetine, perphenazine peak plasma concentrations increased twofold to 13-fold (p &lt; 0.01). This was associated with a significant increase in central nervous system side effects of perphenazine, including oversedation, extrapyramidal symptoms, and impairment of psychomotor performance and memory (p &lt; 0.05). 
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/577	perphenazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp2d6.html	DIKB	"06/20/2009 12:43:54
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/690	support	http://www.ncbi.nlm.nih.gov/pubmed/17429316	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Genotype	"

route of administration: oral

study duration: single-dose of perphenazine (0.1mg/kg)

population: 22 healthy, non-smoking, adult males of chinese ancestry

tested for known CYP450 polymorphisms? yes...&quot;DNA samples from all participants were genotyped for
CYP2D6*10 and CYP2D6*5 using a nested and allele-
specific PCR-restriction fragment length polymorphism
analysis as described previously [34,35]. Alleles not being CYP2D6*5 or CYP2D6*10 were called CYP2D6*1. Geno-
typing for these three alleles has been shown in the past to be adequate for a reliable determination of CYP2D6 genotypes in Asians [8,15,34,35]. The invest igators did not have access to data on CYP2D6 genotype during ascertainment of the pharmacological phenotypes (i.e. perphenazine and prolactin concentration data); genotyping was also performed blind to the prolactin or plasma concentration data.&quot;

ages: 21 - 50

description:
&quot;In volunteers with CYP2D6*10/CYP2D6*10 genotype, the mean area under curve (AUC0-6) for perphenazine concentration was 2.9-fold higher than those who carry the CYP2D6*1 allele (P&lt;0.01).&quot;

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/577	perphenazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp2d6.html	DIKB	"09/28/2009 12:08:09
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/691	support	http://www.ncbi.nlm.nih.gov/pubmed/8689810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Genotype	"
route of administration: oral

study duration: During a 1-year period a blood sample was taken for genotyping together with blood for serum monitoring. Blood samples were taken from 151 patients

population: patients undergoing therapeutic drug monitoring of orally-administered perphenazine. The analysis included 56 EMs and 3 PMs taking a drug that could potentially affect perphenazine metabolism, 32 EMs and 6 PMs taking a no drug known to affect perphenazine metabolism. All PMs were grouped for analysis since they did not carry a functional CYP2D6 allele.

tested for known CYP450 polymorphisms? yes, genotyping found 142 CYP2D6 extensive metabolizers (EM) and 9 poor metabolizers (PM)

ages: 12 - 75; median of 38 years

description:
The poor metabolizer group had the highest median steady-state serum concentration value (0.195 nmol/L per milligram), which was about twice the value of the extensive metablolizer group without potentially interacting medicine (0.098 nmol/L per milligram; p &lt; 0.01)

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/580	tamoxifen_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00675	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/tamoxifen_substrate_of_cyp2d6.html	DIKB	009242009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/694	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/407a372d-4448-4d53-afd4-eb0e74bbc336	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

Tamoxifen is extensively metabolized after oral administration. N-desmethyl tamoxifen is the major metabolite found in patientsâ€™ plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to that of tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6, and an inhibitor of P-glycoprotein."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/588	mirtazapine_substrate_of_cyp2b6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006116		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2b6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/591	zolpidem_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00425	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zolpidem_substrate_of_cyp3a5.html	DIKB	"11/09/2009 12:48:23
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/708	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/de965605-268a-4479-86f7-84de949cf36f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drugs that affect drug metabolism via cytochrome P450:
Some compounds known to inhibit CYP3A may increase exposure to zolpidem. The effect of inhibitors of other P450 enzymes has not been carefully evaluated."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/592	zolpidem_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00425	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zolpidem_substrate_of_cyp3a4.html	DIKB	"11/09/2009 12:45:49
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/709	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/de965605-268a-4479-86f7-84de949cf36f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drugs that affect drug metabolism via cytochrome P450:
Some compounds known to inhibit CYP3A may increase exposure to zolpidem. The effect of inhibitors of other P450 enzymes has not been carefully evaluated.

A randomized, double-blind, crossover interaction study in ten healthy volunteers between itraconazole (200 mg once daily for 4 days) and a single dose of zolpidem tartrate (10 mg) given 5 hours after the last dose of itraconazole resulted in a 34% increase in AUC0-inf of zolpidem tartrate. There were no significant pharmacodynamic effects of zolpidem on subjective drowsiness, postural sway, or psychomotor performance."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/592	zolpidem_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00425	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zolpidem_substrate_of_cyp3a4.html	DIKB	"11/09/2009 12:51:14
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/710	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/de965605-268a-4479-86f7-84de949cf36f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Co-administration of a single dose of zolpidem tartrate with 4 doses of ketoconazole, a potent CYP3A4 inhibitor increased Cmax of zolpidem (30%) and the total AUC of zolpidem (70%) compared to zolpidem alone and prolonged the elimination half-life (30%) along with an increase in the pharmacodynamic effects of zolpidem. Consideration should be given to using a lower dose of zolpidem when ketoconazole and zolpidem are given together. Patients should be advised that use of Edluar with ketoconazole may enhance the sedative effects."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/597	aripiprazole_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/611	N-demethyldesacetyl-diltiazem_substrate_of_cyp2d6	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/12	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/N-demethyldesacetyl-diltiazem_substrate_of_cyp2d6.html	DIKB	"08/09/2007 07:10:32
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/733	support	http://www.ncbi.nlm.nih.gov/pubmed/12235455	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Genotype	"
Route of administration: oral

polymorphic enzyme: yes

study duration: single 120mg oral dose of diltiazem with 24 hours of plasma level monitoring

population: 15 individuals; 5 for each genetically based phenotype. Study does not state gender of participants

ages: 20-30

description:
The aim of this study was to compare the pharmacokinetics of diltiazem and its major metabolites in healthy human volunteers representing different CYP2D6 genotypes. METHODS: Norwegians of Caucasian origin were screened for their CYP2D6 genotype on the LightCycler (Roche Diagnostics, Mannheim, Germany) by melting-curve analysis of allele-specific fluorescence resonance energy transfer probes hybridized to polymerase chain reaction-amplified deoxyribonucleic acid. The first 5 individuals identified with genotypes corresponding to a homozygous extensive, heterozygous extensive, or homozygous poor CYP2D6-metabolizing phenotype, respectively, were voluntarily enrolled in the pharmacokinetic study. The participants received diltiazem, 120 mg, as a single oral dose, and plasma samples were collected up to 24 hours after administration. Plasma samples were purified by solid phase extraction. Diltiazem and 7 phase I metabolites were analyzed by liquid chromatography-mass spectrometry. RESULTS: The pharmacokinetics of diltiazem was not significantly different between the subgroups. However, the systemic exposure of the pharmacologically active metabolites desacetyl diltiazem and N-demethyldesacetyl diltiazem was &gt; or = 5 times higher in poor CYP2D6 metabolizers than in extensive CYP2D6 metabolizers (P &lt;.01). CONCLUSIONS: CYP2D6 activity does not have a major impact on the disposition of diltiazem. In contrast, desacetyl diltiazem and N-demethyldesacetyl diltiazem are markedly accumulated in individuals expressing a deficient CYP2D6 phenotype. Because these metabolites exhibit pharmacologic properties of possible importance, individual CYP2D6 activity might be an aspect to consider in the clinical use of diltiazem."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/618	atorvastatin_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/632	aripiprazole_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2d6.html	DIKB	"04/29/2009 19:51:34
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/764	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism. Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.

Ketoconazole and Other CYP3A4 Inhibitors

Coadministration of ketoconazole (200 mg/day for 14 days) with a 15 mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied. When ketoconazole is given concomitantly with aripiprazole, the aripiprazole dose should be reduced to one-half of its normal dose. Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have similar effects and need similar dose reductions; moderate inhibitors (erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased.

Quinidine and Other CYP2D6 Inhibitors

Coadministration of a 10 mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydro-aripiprazole, by 35%. Aripiprazole dose should be reduced to one-half of its normal dose when quinidine is given concomitantly with aripiprazole. Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and should lead to similar dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased. When adjunctive ABILIFY is administered to patients with Major Depressive Disorder, ABILIFY should be administered without dosage adjustment as specified in DOSAGE AND ADMINISTRATION (2.3).

Carbamazepine and Other CYP3A4 Inducers

Coadministration of carbamazepine (200 mg twice daily), a potent CYP3A4 inducer, with aripiprazole (30 mg/day) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole. When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from the combination therapy, the aripiprazole dose should be reduced."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/640	zafirlukast_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_substrate_of_cyp2c9.html	DIKB	"09/24/2009 15:17:23
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/773	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

Zafirlukast is extensively metabolized. The most common metabolic products are hydroxylated metabolites which are excreted in the feces. The metabolites of zafirlukast identified in plasma are at least 90 times less potent as LTD4 receptor antagonists than zafirlukast in a standard in vitro test of activity. In vitro studies using human liver microsomes showed that the hydroxylated metabolites of zafirlukast excreted in the feces are formed through the cytochrome P450 2C9 (CYP2C9) pathway. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/646	atorvastatin_substrate_of_cyp1a1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006101		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp1a1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/648	iloperidone_substrate_of_cyp2a6	substrate_of		http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp2a6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/654	trazodone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00656	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/trazodone_substrate_of_cyp3a4.html	DIKB	"05/14/2009 14:33:26
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/790	support	http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=4844	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions

In vitro drug metabolism studies suggest that there is a potential for drug interactions when trazodone is given with CYP3A4 inhibitors. Ritonavir, a potent CYP3A4 inhibitor, increased the Cmax, AUC, and elimination half-life, and decreased clearance of trazodone after administration of ritonavir twice daily for 2 days. Adverse effects including nausea, hypotension, and syncope were observed when ritonavir and trazodone were co-administered. It is likely that ketoconazole, indinavir, and other CYP3A4 inhibitors such as itraconazole or nefazodone may lead to substantial increases in trazodone plasma concentrations, with the potential for adverse effects. If trazodone is used with a potent CYP3A4 inhibitor, a lower dose of trazodone should be considered.

Carbamazepine reduced plasma concentrations of trazodone when co-administered. Patients should be closely monitored to see if there is a need for an increased dose of trazodone when taking both drugs."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/657	quetiapine_substrate_of_cyp2e1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp2e1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/670	risperidone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/risperidone_substrate_of_cyp3a4.html	DIKB	"02/13/2010 09:43:11
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/810	support	http://www.ncbi.nlm.nih.gov/pubmed/10048600	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: note explicitly mentioned but acceptable methods assumed

inhibitor used: ketoconazole

reaction: risperidone 9-hydroxylation

NOTE: experiment used 100micM of risperidone which is likely well above C_max based on PMID 7690693 

Quote:
risperidone was incubated with human liver microsomes in the presence of different concentrations of inhibitors of CYP enzymes. Both quinidine (inhibitor of CYP2D6) and ketoconazole (inhibitor of CYP3A) inhibited the formation of 9-hydroxyrisperidone in a concentration-dependent manner (Fig. 4). 

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/682	R-demethylcitalopram_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/19	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-demethylcitalopram_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/691	haloperidol_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00502	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/haloperidol_substrate_of_cyp3a4.html	DIKB	"06/17/2009 07:57:02
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/832	support	http://www.ncbi.nlm.nih.gov/pubmed/9431831	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes

inhibitor used: ketoconazole

reaction: haloperidol --&gt; 4-(4-chlorophenyl)-4-
hydroxypiperidine

Quote: 
Ketoconazole was a potent inhibitor of CPHP (4-(4-chlorophenyl)-4-hydroxypiperidine) formation with IC50 values of 0,10, 0,23 and 0,14 micM in microsomes HL-1, HL-6 and HL-9 respectively, wheras sulphaphenazole, furafylline and quinidine showed little inhibition (IC50 &gt; 100micM)"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/700	duloxetine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp1a2.html	DIKB	"05/05/2009 17:51:26
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/846	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"12.3 Pharmacokinetics

Duloxetine has an elimination half-life of about 12 hours (range 8 to 17 hours) and its pharmacokinetics are dose proportional over the therapeutic range. Steady-state plasma concentrations are typically achieved after 3 days of dosing. Elimination of duloxetine is mainly through hepatic metabolism involving two P450 isozymes, CYP1A2 and CYP2D6."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/712	fluvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01095	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvastatin_substrate_of_cyp3a4.html	DIKB	"10/20/2007 09:39:51
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/860	support	http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"&quot;
Fluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-dealkylation and beta-oxidation of the side-chain also occurs. The hydroxy metabolites have some pharmacologic activity, but do not circulate in the blood. Both enantiomers of fluvastatin are metabolized in a similar manner.

      In vitro studies demonstrated that fluvastatin undergoes oxidative metabolism, predominantly via 2C9 isozyme systems (75%). Other isozymes that contribute to fluvastatin metabolism are 2C8 (~5%) and 3A4 (~20%).&quot;"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/719	zaleplon_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00962	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zaleplon_substrate_of_cyp3a4.html	DIKB	"11/09/2009 12:41:35
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/872	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71be4cb7-a42f-43be-9b9b-f090edb2fd21	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

After oral administration, zaleplon is extensively metabolized, with less than 1% of the dose excreted unchanged in urine. Zaleplon is primarily metabolized by aldehyde oxidase to form 5-oxo-zaleplon. Zaleplon is metabolized to a lesser extent by cytochrome P450 (CYP) 3A4 to form desethylzaleplon, which is quickly converted, presumably by aldehyde oxidase, to 5-oxo-desethylzaleplon. These oxidative metabolites are then converted to glucuronides and eliminated in urine. All of zaleplon's metabolites are pharmacologically inactive. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/721	reduced-haloperidol_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/14	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/reduced-haloperidol_substrate_of_cyp3a4.html	DIKB	"06/22/2009 12:33:59
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/874	support	http://www.ncbi.nlm.nih.gov/pubmed/9825830	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor: troleandomycin

reaction: reduced-haloperidol --&gt; 4-(4-chlorophenyl)-4-hydroxypiperidine 

Description:
Troleandomycin was a potent inhibitor of both HAL and 4-(4-chlorophenyl)-4-hydroxypiperidine formation, see p.387

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/721	reduced-haloperidol_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/14	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/reduced-haloperidol_substrate_of_cyp3a4.html	DIKB	"06/22/2009 12:36:26
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/875	support	http://www.ncbi.nlm.nih.gov/pubmed/9825830	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor: ketoconazole

reaction: reduced-haloperidol --&gt; 4-(4-chlorophenyl)-4-hydroxypiperidine

Description:
ketoconazole was a potent inhibitor of both HAL and 4-(4-chlorophenyl)-4-hydroxypiperidine formation, see p.387 "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/737	zaleplon_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00962	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zaleplon_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/750	eszopiclone_substrate_of_cyp2e1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp2e1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/753	iloperidone_substrate_of_cyp3a4	substrate_of		http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp3a4.html	DIKB	"01/11/2010 18:27:15
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/919	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Both CYP3A4 and CYP2D6 are responsible for iloperidone metabolism. Inhibitors of CYP3A4 (e.g., ketoconazole) or CYP2D6 (e.g., fluoxetine, paroxetine) can inhibit iloperidone elimination and cause increased blood levels.

Ketoconazole: Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18-45, increased the AUC of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively. Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole). Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/761	perphenazine_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp2c19.html	DIKB	"06/15/2009 16:30:47
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/928	support	http://www.ncbi.nlm.nih.gov/pubmed/11136295	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP enzymes in baculovirus-infected insect cells

NADPH added: yes 

Quote:
cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/779	mirtazapine_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/780	fluvoxamine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_substrate_of_cyp2d6.html	DIKB	"05/15/2009 08:46:10
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/952	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/53664f8d-3a93-9f2b-daee-380707e4062c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Approximately 7% of the normal population has a genetic defect that leads to reduced levels of activity of cytochrome P450IID6 isozyme. Such individuals have been referred to as &quot;poor metabolizers&quot; (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants. While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in thirteen PM subjects demonstrated altered pharmacokinetic properties compared to sixteen &quot;extensive metabolizers&quot; (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group. This suggests that fluvoxamine is metabolized, at least in part, by IID6 isozyme. Caution is indicated in patients known to have reduced levels of P450IID6 activity and those receiving concomitant drugs known to inhibit this isozyme (e.g., quinidine).
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/780	fluvoxamine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_substrate_of_cyp2d6.html	DIKB	"06/16/2009 18:52:14
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/953	support	http://www.ncbi.nlm.nih.gov/pubmed/8823236	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Phenotype	"
route of administration: oral

study duration: single 50mg dose fluvoxamine 

population: 7 male and 7 female; 10 CYP2D6 EMs and four PMs according to debrisoquine metabolism. 5 EMs smoked during the study as did 3 PMs

ages: 25 - 49

Description: 
Compared with nonsmoking extensive metabolizers, nonsmoking poor metabolizers had a statistically significant (p = 0.02, Mann-Whitney U test) about twofold higher maximum plasma concentration, longer half-life, and fivefold lower oral clearance of fluvoxamine.
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/782	rosuvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01098	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosuvastatin_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/796	tamoxifen_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00675	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/tamoxifen_substrate_of_cyp3a5.html	DIKB	009242009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/970	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/407a372d-4448-4d53-afd4-eb0e74bbc336	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

Tamoxifen is extensively metabolized after oral administration. N-desmethyl tamoxifen is the major metabolite found in patientsâ€™ plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to that of tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6, and an inhibitor of P-glycoprotein."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/802	fluoxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00472	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluoxetine_substrate_of_cyp2d6.html	DIKB	"05/14/2009 14:29:52
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/977	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5f356c1b-96bd-4ef1-960c-91cf4905e6b1	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Variability in metabolism ï¿½ A subset (about 7%) of the population has reduced activity of the drug metabolizing enzyme cytochrome P450 2D6 (CYP2D6). Such individuals are referred to as ï¿½poor metabolizersï¿½ of drugs such as debrisoquin, dextromethorphan, and the TCAs. In a study involving labeled and unlabeled enantiomers administered as a racemate, these individuals metabolized Sï¿½fluoxetine at a slower rate and thus achieved higher concentrations of Sï¿½fluoxetine. Consequently, concentrations of Sï¿½norfluoxetine at steady state were lower. The metabolism of Rï¿½fluoxetine in these poor metabolizers appears normal. When compared with normal metabolizers, the total sum at steady state of the plasma concentrations of the 4 active enantiomers was not significantly greater among poor metabolizers. Thus, the net pharmacodynamic activities were essentially the same. Alternative, nonsaturable pathways (nonï¿½2D6) also contribute to the metabolism of fluoxetine. This explains how fluoxetine achieves a steadyï¿½state concentration rather than increasing without limit.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/802	fluoxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00472	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluoxetine_substrate_of_cyp2d6.html	DIKB	"06/22/2009 15:33:44
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/978	support	http://www.ncbi.nlm.nih.gov/pubmed/8941024	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Phenotype	"

route of administration: oral

study duration: 

population: 20 healthy, non-smoking, males

tested for known CYP450 polymorphisms? Yes, using debrisoquin / 4-hydroxydebrisoquin metabolite ratio; 10 were CYP2D6 EMs and 10 PMs

ages: 18 - 32

description:

&quot;Poor metabolizers had significantly greater fluoxetine peak plasma concentrations (Cmax; increases 57%), area under the concentration versus time curve (AUCzero--&gt;infinity; increases 290%), and terminal elimination half-life (increases 216%) compared with extensive metabolizers. The total amount of fluoxetine excreted in the urine during 8 days was almost three times higher in poor metabolizers than in extensive metabolizers (719 versus 225 micrograms; p &lt; 0.05), whereas the total amount of norfluoxetine excreted in urine of poor metabolizers was about half of that of extensive metabolizers (524 versus 1047 micrograms; p &lt; 0.05). Norfluoxetine Cmax and AUCzero--&gt;t were significantly smaller in poor metabolizers (decreases 55% and decreases 53%, respectively), and the partial metabolic clearance of fluoxetine into norfluoxetine was 10 times smaller in this group (4.3 +/- 1.9 versus 0.4 +/- 0.1 L/hr; p &lt; 0.05).&quot;

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/805	midazolam_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00683	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/midazolam_substrate_of_cyp3a5.html	DIKB	"07/02/2007 11:06:38
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/980	support	http://www.ncbi.nlm.nih.gov/pubmed/12124305	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in Supersomes

NADPH added: yes

inhibitor used: no

This study showed the formation of both 1'-OH-midazolam and 4-OH-midazolam in a recombinant cyp3a4 Supersome system"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/838	lansoprazole_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00448	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lansoprazole_substrate_of_cyp2c19.html	DIKB	"09/24/2009 10:17:24
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1027	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71ba78cb-7e46-43eb-9425-fa130f537f84	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
12.5 Drug-Drug Interactions
...
PREVACID is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/856	cinacalcet_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_substrate_of_cyp3a4.html	DIKB	009242009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1047	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism and Excretion

Cinacalcet is metabolized by multiple enzymes, primarily CYP3A4, CYP2D6 and CYP1A2."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/856	cinacalcet_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_substrate_of_cyp3a4.html	DIKB	"09/24/2009 10:51:26
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1048	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Ketoconazole: Cinacalcet AUC(0-inf) and Cmax increased 2.3 and 2.2 times, respectively, when a single 90 mg cinacalcet dose on Day 5 was administered to subjects treated with 200 mg ketoconazole twice daily for 7 days compared to 90 mg cinacalcet given alone."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/857	quetiapine_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/863	iloperidone_substrate_of_cyp1a2	substrate_of		http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/864	R-citalopram_substrate_of_cyp3a4	substrate_of		http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-citalopram_substrate_of_cyp3a4.html	DIKB	"06/12/2009 19:22:19
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1056	support	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

reaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram

Quote:

Chemical Inhibition of CT and DCT Biotransformation in
Microsomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by
ketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/866	iloperidone_substrate_of_cyp1a1	substrate_of		http://purl.obolibrary.org/obo/PR_000006101		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp1a1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/885	iloperidone_substrate_of_cyp2c9	substrate_of		http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/886	iloperidone_substrate_of_cyp2c8	substrate_of		http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp2c8.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/888	clozapine-N-oxide_substrate_of_cyp2d6	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/36	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine-N-oxide_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/890	lansoprazole_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00448	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lansoprazole_substrate_of_cyp3a5.html	DIKB	"09/24/2009 10:16:14
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1089	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71ba78cb-7e46-43eb-9425-fa130f537f84	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
12.5 Drug-Drug Interactions
...
PREVACID is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/895	thioridazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00679	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/thioridazine_substrate_of_cyp2d6.html	DIKB	"04/29/2009 20:08:03
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1094	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	thioridizine is listed in table 4 (p21) as a CYP2D6 substrate with a narrow therapeutic range
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/895	thioridazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00679	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/thioridazine_substrate_of_cyp2d6.html	DIKB	"06/15/2009 15:36:15
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1095	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/56b3f4c2-52af-4947-b225-6808ae9f26f5	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
&quot;Drugs That Inhibit Cytochrome P450 2D6

In a study of 19 healthy male subjects, which included 6 slow and 13 rapid hydroxylators of debrisoquin, a single 25 mg oral dose of thioridazine produced a 2.4-fold higher Cmax and a 4.5-fold higher AUC for thioridazine in the slow hydroxylators compared to rapid hydroxylators. The rate of debrisoquin hydroxylation is felt to depend on the level of cytochrome P450 2D6 isozyme activity. Thus, this study suggests that drugs that inhibit P450 2D6 or the presence of reduced activity levels of this isozyme will produce elevated plasma levels of thioridazine. Therefore, the co-administration of drugs that inhibit P450 2D6 with thioridazine and the use of thioridazine in patients known to have reduced activity of P450 2D6 are contraindicated.&quot;"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/922	clozapine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp1a2.html	DIKB	"05/15/2009 11:00:35
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1132	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Pharmacokinetic-related Interactions

Clozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/922	clozapine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp1a2.html	DIKB	"02/12/2010 18:15:23
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1133	support	http://www.ncbi.nlm.nih.gov/pubmed/9384460	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: fluvoxamine

reaction: clozapine demethylation and N-oxidation

Quote: 
Fluvoxamine inhibited the demethylation [of clozapine] by 34+/-27% at 1 micM and 53+/-28% at 10 micM...Fluvoxamine caused an inhibition by 12+/-21% and 22+/-18% at 1 and 10 micM respectively. 



"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/923	nefazodone_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/939	nefazodone_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/957	tamoxifen_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00675	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/tamoxifen_substrate_of_cyp3a4.html	DIKB	009242009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1175	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/407a372d-4448-4d53-afd4-eb0e74bbc336	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

Tamoxifen is extensively metabolized after oral administration. N-desmethyl tamoxifen is the major metabolite found in patientsâ€™ plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to that of tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6, and an inhibitor of P-glycoprotein."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/966	citalopram_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_substrate_of_cyp2c19.html	DIKB	"05/15/2009 10:38:46
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1186	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro studies using human liver microsomes indicated that CYP3A4 and CYP2C19 are the primary isozymes involved in the N-demethylation of citalopram.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/974	atorvastatin_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/988	iloperidone_substrate_of_cyp2c19	substrate_of		http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/997	clarithromycin_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/999	mirtazapine_substrate_of_cyp2a6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2a6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1002	paroxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00715	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paroxetine_substrate_of_cyp2d6.html	DIKB	"06/16/2009 16:42:46
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1226	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/08320ea3-8f93-6f04-5d1c-f69af3eb5a81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
&quot;Paroxetine is extensively metabolized and the metabolites are considered to be inactive. Nonlinearity in pharmacokinetics is observed with increasing doses. Paroxetine metabolism is mediated in part by CYP2D6, and the metabolites are primarily excreted in the urine and to some extent in the feces.&quot;"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1019	cinacalcet_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_substrate_of_cyp2d6.html	DIKB	009242009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1245	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism and Excretion

Cinacalcet is metabolized by multiple enzymes, primarily CYP3A4, CYP2D6 and CYP1A2."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1027	mirtazapine_substrate_of_cyp2e1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2e1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1029	mirtazapine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp3a4.html	DIKB	"06/15/2009 15:24:41
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1257	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/31f48378-27db-424f-a4c5-82584a553c35	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Mirtazapine is extensively metabolized after oral administration. Major pathways of biotransformation are demethylation and hydroxylation followed by glucuronide conjugation. In vitro data from human liver microsomes indicate that cytochrome 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite of mirtazapine, whereas cytochrome 3A is considered to be responsible for the formation of the N-desmethyl and N-oxide metabolite."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1029	mirtazapine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp3a4.html	DIKB	"02/13/2010 07:52:43
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1258	support	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: ketoconazole

reaction: mirtazapine N-demethylation (25 and 250 micM) and mirtazapine N-oxidation (250micM) 

Quote: 
Incubations of MIR with human liver microsomes resulted in the formation of OHM, DMM, and MIR-N-
oxide (Fig. 1). Quinidine (5 micM) and alpha-naphthoflavone (0.5 micM),specific inhibitors of CYP2D6 and CYP1A2, respectively, partially inhibited MIR-hydroxylation. Ketoconazole (1 micM), a specific inhibitor of CYP3A4, inhibited MIR-N-demethylation and MIR-N-oxidation. 

NOTE: lowest MIR concentration tested was 25 micM

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1030	mirtazapine_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp3a5.html	DIKB	"06/15/2009 15:25:44
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1259	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/31f48378-27db-424f-a4c5-82584a553c35	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Mirtazapine is extensively metabolized after oral administration. Major pathways of biotransformation are demethylation and hydroxylation followed by glucuronide conjugation. In vitro data from human liver microsomes indicate that cytochrome 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite of mirtazapine, whereas cytochrome 3A is considered to be responsible for the formation of the N-desmethyl and N-oxide metabolite."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1040	ziprasidone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp3a4.html	DIKB	"05/15/2009 11:20:22
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1270	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism and Elimination

... In vitro studies using human liver microsomes and recombinant enzymes indicate that CYP3A4 is the major CYP contributing to the oxidative metabolism of ziprasidone. CYP1A2 may contribute to a much lesser extent. Based on in vivo abundance of excretory metabolites, less than one-third of ziprasidone metabolic clearance is mediated by cytochrome P450 catalyzed oxidation and approximately two-thirds via reduction by aldehyde oxidase. There are no known clinically relevant inhibitors or inducers of aldehyde oxidase."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1040	ziprasidone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp3a4.html	DIKB	"06/19/2009 12:45:00
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1271	support	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"

Enzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19,2D6, and 3A4 - recombinant CYP450 enzymes expressed in insect cells

NADPH added: yes

reaction: 1) ziprasidone --&gt; ziprasidone sulphoxide 
          2) ziprasidone --&gt; ziprasidone sulphone 

Quote: 
&quot;The ability of specific CYP isoforms to metabolize
ziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1040	ziprasidone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp3a4.html	DIKB	"06/19/2009 17:43:12
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1272	support	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes

inhibitor used: ketoconazole

reaction: 1) ziprasidone --&gt; ziprasidone sulphoxide/sulphone
2) ziprasidone --&gt; oxindole acetic acid

Quote: 
Inhibition of metabolite formation by each inhibitor is
summarized in Table 2. Ketoconazole (10micM) inhibited
the formation of ziprasidone sulphoxide (sulphoxide and
sulphone) by 79% and oxindole acetic acid N-dealkylated
product) completely. Sulphaphenazole an furafylline did
not inhibit the formation of ziprasidone sulphoxide. The formation of oxindole acetic acid was inhibited (~50%) by furafylline. The formation of ziprasidone metabolites was not inhibited by quinidine but rather increased.


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1040	ziprasidone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp3a4.html	DIKB	"06/20/2009 13:13:40
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1273	support	http://www.ncbi.nlm.nih.gov/pubmed/10771458	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"

route of administration: oral

study duration: 

population: 14 healthy, non-smoking, adults (6 male, 8 female); only 13 completed the study

tested for known CYP450 polymorphisms? 

ages: 18 - 45

description:
&quot;Co-administration of ziprasidone with ketoconazole was associated with a modest increase in ziprasidone exposure; mean ziprasidone AUC(0,infinity) increased by 33%, from 899 ng ml(-1) h with placebo to 1199 ng ml(-1) h with ketoconazole. Mean Cmax increased by 34%, from 89 ng ml(-1) to 119 ng ml(-1), respectively. The treatment effect on both of these parameters was statistically significant (P&lt;0.02).&quot;
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1044	olanzapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00334	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/olanzapine_substrate_of_cyp2d6.html	DIKB	"06/16/2009 16:55:20
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1279	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/d5051fbc-846b-4946-82df-341fb1216341	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
&quot;Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. The magnitude of the impact of this factor is small in comparison to the overall variability between individuals, and therefore dose modification is not routinely recommended. When using ZYPREXA and fluoxetine in combination, also refer to the Drug Interactions section of the package insert for Symbyax.&quot;"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1048	clarithromycin_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_substrate_of_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1051	citalopram_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_substrate_of_cyp3a4.html	DIKB	"02/12/2010 18:32:55
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1287	support	http://www.ncbi.nlm.nih.gov/pubmed/10494454	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: ketoconazole

reaction: citalopram --&gt; desmethylcitalopram

Quote: 
Ketoconazole produced concentration-dependent inhibition of DCT formation (Figure 4). The mean (+/-SE) IC50 values for ketoconazole were 0.81 (+/-.24) micM/L at
CT = 10 micM/L, and 1.54 (+/-.35) micM/L CT = 100 micM/L; these values were not significantly different.



"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1112	quetiapine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp3a4.html	DIKB	"05/15/2009 09:50:28
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1359	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism and Elimination:

...

Quetiapine is extensively metabolized by the liver. The major metabolic pathways are sulfoxidation to the sulfoxide metabolite and oxidation to the parent acid metabolite; both metabolites are pharmacologically inactive. In vitro studies using human liver microsomes revealed that the cytochrome P450 3A4 isoenzyme is involved in the metabolism of quetiapine to its major, but inactive, sulfoxide metabolite."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1112	quetiapine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp3a4.html	DIKB	"06/16/2009 17:22:10
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1360	support	http://www.ncbi.nlm.nih.gov/pubmed/15834460	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"
Route of administration: oral

study duration: multiple doses of QTP with or without concomitant erythromycin

population: 19; 10 female and 9 male NOTE:no participants were tested for known CYP phenotypes

ages:18-55 

Quote:
In presence of erythromycin, activity of CYP3A4 decreased significantly; for QTP, C(max), AUC(0-24), and t(1/2) increased significantly, CL decreased significantly, and variations in AUC(0-24) and CL showed, respectively, significant negative and positive correlation to that of CYP3A4 activity;"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1112	quetiapine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp3a4.html	DIKB	"02/13/2010 09:22:55
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1361	support	http://www.ncbi.nlm.nih.gov/pubmed/16390352	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"

route of administration: oral

study duration: An 8-day crossover trial -- in each branch participants were give 25 mg quetiapine before and after 4 days of treatment with ketoconazole 200 mg daily.

population:12 healthy male volunteers

tested for known CYP450 polymorphisms?

ages: mean 33 years

description:
...concomitant use of ketoconazole resulted in  substantial increases in plasma concentrations of quetiapine (Figure 3A). The mean Cmax and AUC of quetiapine were increased by 235% and 522%, respectively. Conversely, the geometric mean AUC and Cmax of the sulfoxide metabolite were decreased by 46% and 87%, respectively (Figure 3B). Mean CL/F of quetiapine was decreased by 84%, and mean t1/2 was increased from 2.61 to 6.76 h.


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1129	rabeprazole_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01129	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rabeprazole_substrate_of_cyp3a5.html	DIKB	"09/24/2009 13:59:22
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1386	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5d103551-978f-472a-9c62-51e6e4dea068	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"

Metabolism: 
...
In vitro studies have demonstrated that rabeprazole is metabolized in the liver primarily by cytochromes P450 3A (CYP3A) to a sulphone metabolite and cytochrome P450 2C19 (CYP2C19) to desmethyl rabeprazole."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1135	demethylcitalopram_substrate_of_cyp2d6	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/68	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/demethylcitalopram_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1138	diltiazem_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00343	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/diltiazem_substrate_of_cyp3a5.html	DIKB	"05/29/2007 09:02:40
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1394	support	http://www.ncbi.nlm.nih.gov/pubmed/12124305	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human enzymes in Supersomes

NADPH added: yes

inhibitor used: no

This study showed the formation of N-Desmethyl diltiazem using a recombinant CYP3A5 Supersome system."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1139	diltiazem_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00343	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/diltiazem_substrate_of_cyp3a4.html	DIKB	"05/29/2007 08:49:06
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1395	support	http://www.ncbi.nlm.nih.gov/pubmed/12124305	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in Supersomes

NADPH added: yes

inhibitor used: no

This study showed the formation of N-Desmethyl diltiazem   using a recombinant CYP3A4 Supersome system. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1143	mirtazapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2d6.html	DIKB	"06/15/2009 15:22:05
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1399	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/31f48378-27db-424f-a4c5-82584a553c35	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
&quot;Mirtazapine is extensively metabolized after oral administration. Major pathways of biotransformation are demethylation and hydroxylation followed by glucuronide conjugation. In vitro data from human liver microsomes indicate that cytochrome 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite of mirtazapine, whereas cytochrome 3A is considered to be responsible for the formation of the N-desmethyl and N-oxide metabolite.&quot;"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1143	mirtazapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2d6.html	DIKB	"02/13/2010 07:56:10
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1400	support	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: quinidine

reaction: mirtazapine 8-hydroxylation (25 and 250 micM) 

Quote: 
Incubations of MIR with human liver microsomes resulted in the formation of OHM, DMM, and MIR-N-
oxide (Fig. 1). Quinidine (5 micM) and alpha-naphthoflavone (0.5 micM),specific inhibitors of CYP2D6 and CYP1A2, respectively, partially inhibited MIR-hydroxylation. Ketoconazole (1 micM), a specific inhibitor of CYP3A4, inhibited MIR-N-demethylation and MIR-N-oxidation. 

NOTE: lowest MIR concentration tested was 25 micM

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1144	iloperidone_substrate_of_cyp2e1	substrate_of		http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp2e1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1169	tamoxifen_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00675	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/tamoxifen_substrate_of_cyp2c9.html	DIKB	009242009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1431	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/407a372d-4448-4d53-afd4-eb0e74bbc336	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

Tamoxifen is extensively metabolized after oral administration. N-desmethyl tamoxifen is the major metabolite found in patientsâ€™ plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to that of tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6, and an inhibitor of P-glycoprotein."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1175	citalopram_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1188	ranolazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00243	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ranolazine_substrate_of_cyp2d6.html	DIKB	"09/24/2009 15:49:33
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1458	support	http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
CYP2D6 Inhibitors

The potent CYP2D6 inhibitor, paroxetine (20 mg once daily), increases ranolazine concentrations 1.2-fold. No dose adjustment of Ranexa is required in patients treated with CYP2D6 inhibitors."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1194	aripiprazole_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1201	perphenazine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp3a4.html	DIKB	"06/15/2009 14:25:13
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1476	support	http://www.ncbi.nlm.nih.gov/pubmed/11136295	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: ketoconazole

reaction: perphenazine N-dealkylation

Quote: 
To identify the human cytochrome P450 (CYP) isoforms mediating the N-dealkylation of the antipsychotic drug perphenazine in vitro and estimate the relative contributions of the CYP isoforms involved. METHODS: cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction... Ketoconazole inhibition of N-dealkylation mediated by a mixed HLM indicated that CYP3A4 accounted for about 40% of perphenazine N-dealkylation at therapeutically relevant concentrations.The contribution of the CYP isoforms 1A2, 2C19 and 2D6 amounted to 20-25% each as measured by the percentage inhibition obtained by addition of furafylline, fluvoxamine or quinidine, respectively.

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1201	perphenazine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp3a4.html	DIKB	"06/15/2009 16:27:12
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1477	support	http://www.ncbi.nlm.nih.gov/pubmed/11136295	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant CYP enzymes in baculovirus infected insect cells

NADPH added: yes 

Quote:
cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1206	lansoprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00448	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lansoprazole_substrate_of_cyp3a4.html	DIKB	"09/24/2009 10:14:47
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1483	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71ba78cb-7e46-43eb-9425-fa130f537f84	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
12.5 Drug-Drug Interactions
...
PREVACID is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1225	venlafaxine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_substrate_of_cyp3a4.html	DIKB	"06/20/2009 14:13:20
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1512	support	http://www.ncbi.nlm.nih.gov/pubmed/10192828	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: ketoconazole

reaction: venlafaxine --&gt; N-desmethylvenlafaxine

NOTE: the concentration of venlafaxine used in this experiment is very high relative to that expected in clinical use of the drug

Quote: 
&quot;Formation of NDV had a mean Vmax of 2.14 nmol min mg protein, and a mean Km of 2504 M (Table 2). Incubations of 750micM VF with SFZ and QUI led to 18% and 23% reduction in NDV production respectively, while increasing concentrations of ANA led to an 11% increase in NDV formation over baseline. KET [ketoconazole] had a more profound effect on NDV formation, leading to a 65% mean reduction in production of this metabolite (Figure 5).&quot;"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1227	beta-hydroxy-lovastatin_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/43	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/beta-hydroxy-lovastatin_substrate_of_cyp3a4.html	DIKB	"09/28/2007 13:32:46
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1515	support	http://www.ncbi.nlm.nih.gov/pubmed/9929499	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes

inhibitor used: ketoconazole

reaction: beta-OH-lovastatin--&gt;6'beta-hydroxy-lovastatin

Quote:

Lovastatin was metabolized by human liver microsomes to two major metabolites: 6'beta-hydroxy [Michaelis-Menten constant (Km): 7.8 +/- 2.7 microM] and 6'-exomethylene lovastatin (Km,10.3 +/- 2.6 microM). 6'beta-Hydroxylovastatin formation in the liver was inhibited by the specific CYP3A inhibitors cyclosporine (Ki, 7.6 +/- 2.3 microM), ketoconazole (Ki, 0.25 +/- 0.2 microM), and troleandomycin (Ki, 26.6 +/- 18.5 microM).

NOTE: the authors mention that lovastatin is a lactone that is completely converted to its &quot;open acid&quot; form in vivo - we in the DIKB infer this form to be beta-OH-lovastatin"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1227	beta-hydroxy-lovastatin_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/43	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/beta-hydroxy-lovastatin_substrate_of_cyp3a4.html	DIKB	"10/29/2007 13:20:44
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1516	support	http://www.ncbi.nlm.nih.gov/pubmed/8689812	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

study duration: 4 days pretreatment with 200mg oral itraconazole; a single, oral, 40mg dose of lovastatin on day 4

population: 12
male: 5
female: 7 (2 on contraceptive steroids)

ages: 20-29

AUC_i/AUC: 1212/54.8 = 22.117

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1228	rabeprazole_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01129	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rabeprazole_substrate_of_cyp2c19.html	DIKB	"09/24/2009 13:53:17
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1517	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5d103551-978f-472a-9c62-51e6e4dea068	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
7.5 Drugs metabolized by CYP2C19

In a clinical study in Japan evaluating rabeprazole in patients categorized by CYP2C19 genotype (n=6 per genotype category), gastric acid suppression was higher in poor metabolizers as compared to extensive metabolizers. This could be due to higher rabeprazole plasma levels in poor metabolizers. Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1249	demethylcitalopram_substrate_of_cyp2c19	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/68	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/demethylcitalopram_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1255	ziprasidone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1256	iloperidone_substrate_of_cyp2b6	substrate_of		http://purl.obolibrary.org/obo/PR_000006116		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp2b6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1	R-citalopram_substrate_of_cyp2d6	substrate_of		http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-citalopram_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/7	ziprasidone_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp2c19.html	DIKB	"06/19/2009 12:33:21
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/8	refute	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"

Enzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19, and 2D6 - recombinant CYP450 enzymes expressed in insect cells

NADPH added: yes

reaction: 1) ziprasidone --&gt; ziprasidone sulphoxide 
          2) ziprasidone --&gt; ziprasidone sulphone 

Quote: 
&quot;The ability of specific CYP isoforms to metabolize
ziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/9	desacetyldiltiazem_substrate_of_cyp2d6	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/71	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/desacetyldiltiazem_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/34	clarithromycin_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_substrate_of_cyp2c9.html	DIKB	"10/20/2007 08:13:36
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/43	refute	http://www.ncbi.nlm.nih.gov/pubmed/9152603	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes

inhibitor used: sulphaphenazole

reaction:
clarithromycin --&gt; 14-(R)-hydroxylase-clarithromycin
clarithromycin --&gt; 14-N-demethylase-clarithromycin

description: 
clarithromycin oxidative metabolism was only very slightly affected by the addition of the selective inhibitor"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/36	simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/39	nefazodone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2d6.html	DIKB	02/12/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/50	refute	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19
NADPH added:yes

inhibitor used: no

When NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4)."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/39	nefazodone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2d6.html	DIKB	"02/12/2010 13:56:37
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/51	refute	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: quinidine

reaction: nefazodone --&gt; OH-NEF ; nefazodone --&gt; mCPP

Quote: 
Incubations of human liver microsomes with NEF and the CYP3A4 inhibitor ketoconazole resulted in a concentration-dependent inhibition of the formation of mCPP and OH-NEF (Fig. 3). Incubations of human liver microsomes with NEF and the CYP2D6 inhibitor quinidine did not affect the production of OH-NEF and mCPP. Incubations of OH-NEF with the CYP3A4 inhibitor ketoconazole resulted in the inhibition of metabolite formation, and incubations with the CYP2D6 inhibitor quinidine did not, similar to what was found with NEF metabolism (data not presented).



"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/42	desvenlafaxine_substrate_of_cyp2d6	substrate_of		http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/desvenlafaxine_substrate_of_cyp2d6.html	DIKB	"09/22/2009 18:18:19
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/56	refute	http://www.ncbi.nlm.nih.gov/pubmed/19142106	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Genotype	"
Route of administration: oral

polymorphic enzyme: yes

study duration: 100 mg desvenlafaxine on day 1 followed by 120 hours of PK data sampling; repeated on day 11

population: healthy adults, non-smokers (&gt; 1yr), genotyped (7 CYP2D6 extensive metabolizers and 7 poor metabolizers)

ages: 18-55

description: 
Results: After administration of venlafaxine ER, mean Cmax and AUC of venlafaxine were significantly greater in PMs compared with EMs, whereas mean Cmax and AUC of its metabolite, desvenlafaxine, were significantly lower for PMs than for EMs (P = 0.001, all comparisons). In contrast, mean Cmax and AUC of desvenlafaxine after administration of desvenlafaxine were comparable between EMs and PMs.
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/47	atorvastatin_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/48	atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/58	fluvastatin_substrate_of_cyp2c8	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01095	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvastatin_substrate_of_cyp2c8.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/59	fluvastatin_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01095	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvastatin_substrate_of_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/73	aripiprazole_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp1a2.html	DIKB	"04/29/2009 19:44:42
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/96	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/74	aripiprazole_substrate_of_cyp1a1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006101		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp1a1.html	DIKB	"04/29/2009 19:44:07
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/97	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/82	atorvastatin_substrate_of_cyp2b6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006116		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp2b6.html	DIKB	"09/25/2007 08:58:04
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/105	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP2B6 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system FAILED TO catalyze the above reactions to any measurable extent
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/89	N-desalkylquetiapine_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/24	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/N-desalkylquetiapine_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/93	ziprasidone_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp1a2.html	DIKB	"05/14/2009 13:40:01
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/117	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Smoking

Based on in vitro studies utilizing human liver enzymes, ziprasidone is not a substrate for CYP1A2; smoking should therefore not have an effect on the pharmacokinetics of ziprasidone. Consistent with these in vitro results, population pharmacokinetic evaluation has not revealed any significant pharmacokinetic differences between smokers and nonsmokers."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/93	ziprasidone_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp1a2.html	DIKB	"06/19/2009 12:30:38
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/118	refute	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19, and 2D6 - recombinant CYP450 enzymes expressed in insect cells

NADPH added: yes

reaction: 1) ziprasidone --&gt; ziprasidone sulphoxide 
          2) ziprasidone --&gt; ziprasidone sulphone 

Quote: 
&quot;The ability of specific CYP isoforms to metabolize
ziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/94	atorvastatin_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp2c19.html	DIKB	"09/25/2007 08:59:05
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/119	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP2C19 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system FAILED TO catalyze the above reactions to any measurable extent
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/97	alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/98	alprazolam_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/99	R-demethylcitalopram_substrate_of_cyp2c19	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/19	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-demethylcitalopram_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/127	duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/139	nefazodone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/148	R-citalopram_substrate_of_cyp2c19	substrate_of		http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-citalopram_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/152	modafinil_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/155	lovastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lovastatin_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/174	quetiapine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp1a2.html	DIKB	02/12/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/216	refute	http://www.ncbi.nlm.nih.gov/pubmed/16390352	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid
NADPH added: not explicitly mentioned but assumed

inhibitor used: no

Quetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/181	eszopiclone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/187	escitalopram_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/190	bupropion_substrate_of_cyp2b6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01156	http://purl.obolibrary.org/obo/PR_000006116		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/bupropion_substrate_of_cyp2b6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/194	cinacalcet_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_substrate_of_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/209	aripiprazole_substrate_of_cyp2c8	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2c8.html	DIKB	"04/29/2009 19:46:49
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/261	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/223	S-demethylcitalopram_substrate_of_cyp2c19	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/35	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-demethylcitalopram_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/239	celecoxib_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_substrate_of_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/245	demethylcitalopram_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/68	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/demethylcitalopram_substrate_of_cyp3a4.html	DIKB	"06/12/2009 12:39:36
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/302	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"

Enzyme system: recombinant human enzymes (human lymphoblastoid)

NADPH added: yes (a dehydrogenase generating system) 

inhibitor used: no

This study showed NO formation of didesmethylcitalopram (aka didemethylcitalopram) in a recombinant human lymphoblastoid cell system"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/254	pantoprazole_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/258	S-demethylcitalopram_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/35	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-demethylcitalopram_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/262	clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/265	dehydro-aripiprazole_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/58	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/dehydro-aripiprazole_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/266	alprazolam_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp1a2.html	DIKB	"08/14/2007 06:08:03
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/325	refute	http://www.ncbi.nlm.nih.gov/pubmed/10548453	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"Enzyme system: human liver microsomes

NADPH added: yes

inhibitor used: alpha-napthoflavone

reaction: alprazolam --&gt; 4-OH-alprazolam
alprazolam --&gt; 1'-OH-alprazolam

Inhibition of CYP1A2 by in vitro selective inhibitor alpha-napthoflavone had no effect on the transformation of alprazolam to its two major metabolites

NOTE: the use of a NADPH generating system is inferred from paragraph 2 of p. 934 &quot;Alprazolam hydrozylase assay&quot;
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/291	aripiprazole_substrate_of_cyp2e1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2e1.html	DIKB	"04/29/2009 19:49:12
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/353	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/297	perphenazine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/298	voriconazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/300	asenapine_substrate_of_cyp2d6	substrate_of		http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/asenapine_substrate_of_cyp2d6.html	DIKB	"01/11/2010 19:02:26
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/363	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/17209c32-56eb-4f84-954d-aed7b7a1b18d	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Table 4 shows that paroxetine (20mg 1xd X 9) effected no increase (and in fact a slight decrease) of the AUC of asenapine in vivo
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/302	mirtazapine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/331	quetiapine_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp2c9.html	DIKB	02/12/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/398	refute	http://www.ncbi.nlm.nih.gov/pubmed/16390352	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid
NADPH added: not explicitly mentioned but assumed

inhibitor used: no

Quetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/367	clozapine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/370	aripiprazole_substrate_of_cyp2a6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2a6.html	DIKB	"04/29/2009 19:45:20
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/446	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/376	S-demethylcitalopram_substrate_of_cyp2d6	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/35	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-demethylcitalopram_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/383	voriconazole_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/407	escitalopram_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/408	atorvastatin_substrate_of_cyp2e1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp2e1.html	DIKB	"09/25/2007 09:01:13
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/489	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP2E1 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system FAILED TO catalyze the above reactions to any measurable extent
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/413	ziprasidone_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp2c9.html	DIKB	"06/19/2009 12:32:07
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/494	refute	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"

Enzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19, and 2D6 - recombinant CYP450 enzymes expressed in insect cells

NADPH added: yes

reaction: 1) ziprasidone --&gt; ziprasidone sulphoxide 
          2) ziprasidone --&gt; ziprasidone sulphone 

Quote: 
&quot;The ability of specific CYP isoforms to metabolize
ziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/422	beta-hydroxy-simvastatin_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/21	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/beta-hydroxy-simvastatin_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/458	nefazodone_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2c19.html	DIKB	02/12/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/546	refute	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19
NADPH added:yes

inhibitor used: no

When NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4)."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/465	escitalopram_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/469	rabeprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01129	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rabeprazole_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/480	risperidone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/risperidone_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/481	aripiprazole_substrate_of_cyp2b6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006116		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2b6.html	DIKB	"04/29/2009 19:46:08
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/572	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/483	R-demethylcitalopram_substrate_of_cyp2d6	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/19	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-demethylcitalopram_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/494	sertraline_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01104	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/sertraline_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/513	nefazodone_substrate_of_cyp2c8	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2c8.html	DIKB	02/12/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/610	refute	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19
NADPH added:yes

inhibitor used: no

When NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4)."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/532	iloperidone_substrate_of_cyp2d6	substrate_of		http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/533	pantoprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/546	venlafaxine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/547	voriconazole_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_substrate_of_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/552	aripiprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/573	clarithromycin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/577	perphenazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/580	tamoxifen_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00675	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/tamoxifen_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/588	mirtazapine_substrate_of_cyp2b6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006116		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2b6.html	DIKB	02/12/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/704	refute	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid cells
NADPH added:yes

inhibitor used: no

Table 2 shows that CYP2C19, CYP2B6, CYP2A6, AND CYP3E1 each contributed less than 1% to the formation of metabolites by the three metabolic pathways examined. NOTE: Formation of MIR-N+-glucuronide, a metabolite found in significant concentrations in humans, was not examined however, this metabolite is likely the product of the either the dirct glucuronidation of mirtazapine or a metabolite produced by the three pathways examined. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/591	zolpidem_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00425	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zolpidem_substrate_of_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/592	zolpidem_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00425	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zolpidem_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/597	aripiprazole_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2c19.html	DIKB	"04/29/2009 19:48:02
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/717	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/611	N-demethyldesacetyl-diltiazem_substrate_of_cyp2d6	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/12	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/N-demethyldesacetyl-diltiazem_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/618	atorvastatin_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp2d6.html	DIKB	"09/25/2007 09:00:02
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/740	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP2D6 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system FAILED TO catalyze the above reactions to any measurable extent
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/632	aripiprazole_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/640	zafirlukast_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_substrate_of_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/646	atorvastatin_substrate_of_cyp1a1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006101		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp1a1.html	DIKB	"09/25/2007 08:56:58
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/783	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP1A1 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system FAILED TO catalyze the above reactions to any measurable extent
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/648	iloperidone_substrate_of_cyp2a6	substrate_of		http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp2a6.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/785	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/654	trazodone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00656	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/trazodone_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/657	quetiapine_substrate_of_cyp2e1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp2e1.html	DIKB	02/12/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/795	refute	http://www.ncbi.nlm.nih.gov/pubmed/16390352	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid
NADPH added: not explicitly mentioned but assumed

inhibitor used: no

Quetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/670	risperidone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/risperidone_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/682	R-demethylcitalopram_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/19	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-demethylcitalopram_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/691	haloperidol_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00502	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/haloperidol_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/700	duloxetine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/712	fluvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01095	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvastatin_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/719	zaleplon_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00962	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zaleplon_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/721	reduced-haloperidol_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/14	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/reduced-haloperidol_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/737	zaleplon_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00962	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zaleplon_substrate_of_cyp2d6.html	DIKB	"11/09/2009 12:39:21
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/900	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71be4cb7-a42f-43be-9b9b-f090edb2fd21	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Paroxetine

Coadministration of a single dose of zaleplon 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance. Additionally, paroxetine did not alter the pharmacokinetics of zaleplon, reflecting the absence of a role of CYP2D6 in zaleplon's metabolism. 

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/750	eszopiclone_substrate_of_cyp2e1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp2e1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/753	iloperidone_substrate_of_cyp3a4	substrate_of		http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/761	perphenazine_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/779	mirtazapine_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2c19.html	DIKB	02/12/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/951	refute	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid cells
NADPH added:yes

inhibitor used: no

Table 2 shows that CYP2C19, CYP2B6, CYP2A6, AND CYP3E1 each contributed less than 1% to the formation of metabolites by the three metabolic pathways examined. NOTE: Formation of MIR-N+-glucuronide, a metabolite found in significant concentrations in humans, was not examined however, this metabolite is likely the product of the either the dirct glucuronidation of mirtazapine or a metabolite produced by the three pathways examined. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/780	fluvoxamine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/782	rosuvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01098	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosuvastatin_substrate_of_cyp3a4.html	DIKB	"09/28/2007 12:06:44
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/955	refute	http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3249	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"&quot;Cytochrome P450 3A4: In vitro and in vivo data indicate that rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically significant extent. This has been confirmed in studies with known cytochrome P450 3A4 inhibitors (ketoconazole, erythromycin, itraconazole).

Ketoconazole: Coadministration of ketoconazole (200 mg twice daily for 7 days) with rosuvastatin (80 mg) resulted in no change in plasma concentrations of rosuvastatin.

Erythromycin: Coadministration of erythromycin (500 mg four times daily for 7 days) with rosuvastatin (80 mg) decreased AUC and Cmax of rosuvastatin by 20% and 31%, respectively. These reductions are not considered clinically significant.&quot;"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/796	tamoxifen_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00675	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/tamoxifen_substrate_of_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/802	fluoxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00472	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluoxetine_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/805	midazolam_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00683	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/midazolam_substrate_of_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/838	lansoprazole_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00448	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lansoprazole_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/856	cinacalcet_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/857	quetiapine_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp2c19.html	DIKB	02/12/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1049	refute	http://www.ncbi.nlm.nih.gov/pubmed/16390352	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid
NADPH added: not explicitly mentioned but assumed

inhibitor used: no

Quetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/863	iloperidone_substrate_of_cyp1a2	substrate_of		http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp1a2.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1055	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/864	R-citalopram_substrate_of_cyp3a4	substrate_of		http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-citalopram_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/866	iloperidone_substrate_of_cyp1a1	substrate_of		http://purl.obolibrary.org/obo/PR_000006101		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp1a1.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1062	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/885	iloperidone_substrate_of_cyp2c9	substrate_of		http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp2c9.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1083	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/886	iloperidone_substrate_of_cyp2c8	substrate_of		http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp2c8.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1084	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/888	clozapine-N-oxide_substrate_of_cyp2d6	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/36	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine-N-oxide_substrate_of_cyp2d6.html	DIKB	"06/16/2009 14:26:57
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1087	refute	http://www.ncbi.nlm.nih.gov/pubmed/11147928	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"
Route of administration: oral

study duration: three weeks

population: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks

ages: 29 - 55


Quote:

The effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/890	lansoprazole_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00448	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lansoprazole_substrate_of_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/895	thioridazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00679	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/thioridazine_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/922	clozapine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/923	nefazodone_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2c9.html	DIKB	02/12/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1134	refute	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19
NADPH added:yes

inhibitor used: no

When NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4)."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/939	nefazodone_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp1a2.html	DIKB	02/12/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1151	refute	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19
NADPH added:yes

inhibitor used: no

When NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4)."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/957	tamoxifen_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00675	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/tamoxifen_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/966	citalopram_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/974	atorvastatin_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp2c9.html	DIKB	"09/25/2007 09:02:14
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1194	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP2C9 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system FAILED TO catalyze the above reactions to any measurable extent
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/988	iloperidone_substrate_of_cyp2c19	substrate_of		http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp2c19.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1210	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/997	clarithromycin_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_substrate_of_cyp2d6.html	DIKB	"10/20/2007 08:16:32
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1221	refute	http://www.ncbi.nlm.nih.gov/pubmed/9152603	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes 
NADPH added: yes 

inhibitor used: quinidine 
reaction: 
clarithromycin --&gt; 14-(R)-hydroxylase-clarithromycin clarithromycin --&gt; 14-N-demethylase-clarithromycin 

description: clarithromycin oxidative metabolism was only very slightly affected by the addition of the selective inhibitor "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/999	mirtazapine_substrate_of_cyp2a6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2a6.html	DIKB	02/12/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1223	refute	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid cells
NADPH added:yes

inhibitor used: no

Table 2 shows that CYP2C19, CYP2B6, CYP2A6, AND CYP3E1 each contributed less than 1% to the formation of metabolites by the three metabolic pathways examined. NOTE: Formation of MIR-N+-glucuronide, a metabolite found in significant concentrations in humans, was not examined however, this metabolite is likely the product of the either the dirct glucuronidation of mirtazapine or a metabolite produced by the three pathways examined. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1002	paroxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00715	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paroxetine_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1019	cinacalcet_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1027	mirtazapine_substrate_of_cyp2e1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2e1.html	DIKB	02/12/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1255	refute	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid cells
NADPH added:yes

inhibitor used: no

Table 2 shows that CYP2C19, CYP2B6, CYP2A6, AND CYP3E1 each contributed less than 1% to the formation of metabolites by the three metabolic pathways examined. NOTE: Formation of MIR-N+-glucuronide, a metabolite found in significant concentrations in humans, was not examined however, this metabolite is likely the product of the either the dirct glucuronidation of mirtazapine or a metabolite produced by the three pathways examined. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1029	mirtazapine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1030	mirtazapine_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1040	ziprasidone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1044	olanzapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00334	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/olanzapine_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1048	clarithromycin_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_substrate_of_cyp1a2.html	DIKB	"10/20/2007 08:15:16
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1284	refute	http://www.ncbi.nlm.nih.gov/pubmed/9152603	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"Enzyme system: human liver microsomes 

NADPH added: yes 

inhibitor used: furafylline 
reaction: 
clarithromycin --&gt; 14-(R)-hydroxylase-clarithromycin clarithromycin --&gt; 14-N-demethylase-clarithromycin 

description: clarithromycin oxidative metabolism was only very slightly affected by the addition of the selective inhibitor "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1051	citalopram_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_substrate_of_cyp3a4.html	DIKB	"06/12/2009 13:16:14
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1288	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Ketoconazole

Combined administration of citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1112	quetiapine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1129	rabeprazole_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01129	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rabeprazole_substrate_of_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1135	demethylcitalopram_substrate_of_cyp2d6	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/68	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/demethylcitalopram_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1138	diltiazem_substrate_of_cyp3a5	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00343	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/diltiazem_substrate_of_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1139	diltiazem_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00343	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/diltiazem_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1143	mirtazapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1144	iloperidone_substrate_of_cyp2e1	substrate_of		http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp2e1.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1401	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1169	tamoxifen_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00675	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/tamoxifen_substrate_of_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1175	citalopram_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1188	ranolazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00243	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ranolazine_substrate_of_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1194	aripiprazole_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2c9.html	DIKB	"04/29/2009 19:48:35
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1467	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1201	perphenazine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1206	lansoprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00448	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lansoprazole_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1225	venlafaxine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1227	beta-hydroxy-lovastatin_substrate_of_cyp3a4	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/43	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/beta-hydroxy-lovastatin_substrate_of_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1228	rabeprazole_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01129	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rabeprazole_substrate_of_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1249	demethylcitalopram_substrate_of_cyp2c19	substrate_of	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/68	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/demethylcitalopram_substrate_of_cyp2c19.html	DIKB	"06/12/2009 12:36:17
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1539	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human enzymes (human lymphoblastoid)

NADPH added: yes (a dehydrogenase generating system) 

inhibitor used: no

This study showed NO formation of didesmethylcitalopram (aka didemethylcitalopram) in a recombinant human lymphoblastoid cell system"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1255	ziprasidone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp2d6.html	DIKB	"06/19/2009 12:41:48
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1546	refute	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"

Enzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19, and 2D6 - recombinant CYP450 enzymes expressed in insect cells

NADPH added: yes

reaction: 1) ziprasidone --&gt; ziprasidone sulphoxide 
          2) ziprasidone --&gt; ziprasidone sulphone 

Quote: 
&quot;The ability of specific CYP isoforms to metabolize
ziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1256	iloperidone_substrate_of_cyp2b6	substrate_of		http://purl.obolibrary.org/obo/PR_000006116		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_substrate_of_cyp2b6.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1547	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/2	eszopiclone_inhibits_CYP2E1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP2E1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/5	R-didemethylcitalopram_inhibits_cyp1a2	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/26	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-didemethylcitalopram_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/11	nefazodone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/13	topiramate_inhibits_cyp2b6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006116		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2b6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/22	mirtazapine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/24	topiramate_inhibits_cyp2e1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2e1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/29	fluconazole_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp2c9.html	DIKB	"09/27/2007 11:44:51
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/37	support	http://www.ncbi.nlm.nih.gov/pubmed/8801057	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"
Route of administration: fluconazole oral; warfarin - IV

study duration: phase 1 - 8 days of .75mg/kg warfarin alone; phase 2 (21 days later) 14 days of .75mg/kg q.d. AND 400mg q.d. of fluconazole

population: 6 male

ages: 23-29

description: 
formation of 6- and 7-OH-(s)-warfarin decreased by 70%; this reaction is considered primarily catalyzed by CYP2C9. There was also a notable increase in AUC of (S)-warfarin (mean AUC_i/AUC=7.633)"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/29	fluconazole_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp2c9.html	DIKB	"06/30/2009 13:32:26
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/38	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP2C9 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/54	quetiapine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/56	S-demethylcitalopram_inhibits_cyp2c9	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/35	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-demethylcitalopram_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/63	zafirlukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp3a4.html	DIKB	09/24/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/85	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Zafirlukast is extensively metabolized. The most common metabolic products are hydroxylated metabolites which are excreted in the feces. The metabolites of zafirlukast identified in plasma are at least 90 times less potent as LTD4 receptor antagonists than zafirlukast in a standard in vitro test of activity. In vitro studies using human liver microsomes showed that the hydroxylated metabolites of zafirlukast excreted in the feces are formed through the cytochrome P450 2C9 (CYP2C9) pathway. Additional in vitro studies utilizing human liver microsomes show that zafirlukast inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes at concentrations close to the clinically achieved total plasma concentrations"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/64	ritonavir_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a5.html	DIKB	"06/30/2009 14:07:18
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/86	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/65	ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB	"06/30/2009 14:06:14
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/87	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/65	ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB	"01/11/2010 17:43:46
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/88	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions

Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) both in vitro and in vivo. Ritonavir also inhibits CYP2D6 in vitro, but to a lesser extent than CYP3A. Co-administration of ritonavir and drugs primarily metabolized by CYP3A or CYP2D6 may result in increased plasma concentrations of other drugs that could increase or prolong its therapeutic and adverse effects "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/65	ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB	"01/11/2010 17:52:19
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/89	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Table 3 shows that the AUC of sildenafil increased 11-fold in the presence of ritonavir
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/68	R-citalopram_inhibits_cyp2e1	inhibits		http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-citalopram_inhibits_cyp2e1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/78	aripiprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/79	rosiglitazone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/80	rosiglitazone_inhibits_cyp1a1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006101		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp1a1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/83	duloxetine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/86	paliperidone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/90	verapamil_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp3a4.html	DIKB	"06/30/2009 14:26:54
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/113	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;moderate&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/92	verapamil_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp3a5.html	DIKB	"06/30/2009 14:28:00
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/115	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;moderate&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/105	atazanavir_inhibits_cyp2a6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp2a6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/111	erythromycin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00199	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/erythromycin_inhibits_cyp3a4.html	DIKB	"06/25/2007 13:47:05
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/140	support	http://www.ncbi.nlm.nih.gov/pubmed/9757151	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

study duration: 1 day pre-treatment with erythromycin 500mg 2x/day

population: 12 healthy adults 
male: 6
female: 6
ages: 21-39 years

AUC_i/AUC: 20.9/5.5

Quote:
In a randomized, double-blind, 5-trial clinical pharmacokinetic-pharmacodynamic study, 12 volunteers received 0.125 mg triazolam orally, together with placebo, azithromycin, erythromycin, or clarithromycin. In a fifth trial they received placebo plus placebo...Apparent oral clearance was significantly reduced (P < .05) during erythromycin and clarithromycin trials (146 and 95 mL/min). Peak plasma concentration was correspondingly increased, and elimination half-life was prolonged. The effects of triazolam on dynamic measures were nearly identical when triazolam was given with placebo or azithromycin, but benzodiazepine agonist effects were enhanced during erythromycin and clarithromycin trials."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/111	erythromycin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00199	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/erythromycin_inhibits_cyp3a4.html	DIKB	"10/16/2007 09:38:08
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/141	support	http://www.ncbi.nlm.nih.gov/pubmed/8720318	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

study duration: 4 days pre-treatment with erythromycin 500mg 3x/day; 5th day patients in the treatment arm received a single 15mg oral dose of MDZ

population: 12 healthy adults
male: 4
female: 8
ages: 24-53 years

AUC_i/AUC: 662.71/173.77 ng*hr/ml = 3.814

NOTE: AUC values  appear to be 0-24 hour 

Quote:
&quot;The pharmacokinetic and pharmacodynamic interaction between azithromycin (CAS 83905-01-5), an azalide antibiotic, and midazolam (CAS 59467-70-8), a short-acting hypnotic agent, was investigated in an open, three-way cross-over study, including erythromycin (CAS 114-07-8) as a positive control. Twelve healthy male and female subjects had standard doses of azithromycin (500 mg o.d. over 3 days), or erythromycin (500 mg t.i.d. over 5 days), or no pretreatment. On the day of the last dose, they ingested 15 mg midazolam. Blood samples were collected and psychometric tests performed. Erythromycin pretreatment (E) significantly changed the pharmacokinetics of midazolam compared to control (C), whereas azithromycin (A) had no such effect. The parameters are summarized as follows: area under the concentration-time curve, AUC (C) 173.8 h.ng.ml-1 vs. (E) 662.7 h.ng.ml-1*+ and (A) 220.0 h.ng.ml-1; concentration maxima (C) 67.2 ng.ml-1 vs. (E) 182.3 ng.ml-1*+ and (A) 86.7 ng.ml-1; elimination half-life (C) 2.21 h vs. (E) 4.85 h* and (A) 2.41 h (* p &lt; 0.05 vs. (C), +p &lt; 0.05 vs. (A)). Pharmacodynamic tests (digit symbol substitution test; critical flicker fusion test; subjective analog scale for rating of alertness; duration of sleep) consistently showed significant differences after erythromycin pretreatment compared to control, but not after azithromycin. Erythromycin, but not azithromycin, causes clinically significant changes in the pharmacokinetics and pharmacodynamics of midazolam.&quot;"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/112	montelukast_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/123	omeprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00338	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/omeprazole_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/145	S-demethylcitalopram_inhibits_cyp1a2	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/35	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-demethylcitalopram_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/150	S-didemethylcitalopram_inhibits_cyp3a4	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/66	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-didemethylcitalopram_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/156	cinacalcet_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/160	R-demethylcitalopram_inhibits_cyp2c19	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/19	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-demethylcitalopram_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/162	escitalopram_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/167	N-desalkylquetiapine_inhibits_cyp3a4	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/24	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/N-desalkylquetiapine_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/169	eszopiclone_inhibits_CYP2A6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP2A6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/170	ziprasidone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/171	citalopram_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/177	fluoxetine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00472	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluoxetine_inhibits_cyp2d6.html	DIKB	"05/05/2009 17:04:02
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/219	support	http://www.ncbi.nlm.nih.gov/pubmed/11910262	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_Par_Grps	"Route of administration: oral

study duration: read description below

population: (fluoxetine group) 14 healthy volunteers (7 male and 7 female), all extensive metabolizers of dextromethorphan

ages: mean(std dev): 26 (unknown)

Description: 
In an open label, parallel group study of 45 healthy volunteers, the time course of CYP2D6 inhibition of the above SSRIs was evaluated. Subjects were randomized to receive paroxetine at 20 mg/day for 10 days; sertraline at 50 mg/day for 3 days, followed by sertraline at 100 mg/day for 10 days; or fluoxetine at 20 mg/day for 28 days. CYP2D6 activity was assessed using the dextromethorphan metabolic ratio (DMR) on antidepressant days 5 and 10 for sertraline and paroxetine and at weekly intervals for fluoxetine. Following SSRI discontinuation, calculation of a CYP2D6 inhibition half-life (t(1/2)inh) revealed the time course of fluoxetine inhibition (t(1/2)inh = 7.0 +/- 1.5 days) to be significantly longer than either paroxetine (t(1/2)inh = 2.9 +/- 1.9) or sertraline (t(1/2)inh = 3.0 +/- 3.0) (p &lt; 0.01), but the latter were not significantly different from each other (p &gt; 0.05). Time for the extrapolated DMR versus time log-linear plots to return to baseline was significantly different between fluoxetine (63.2 +/- 5.6 days) and both paroxetine (20.3 +/- 6.4 days) and sertraline (25.0 +/- 11.0 days) (p &lt; 0.01), making the rank order (from longest to shortest) of time for CYP2D6 inhibition to dissipate: fluoxetine &gt; sertraline &gt;or= paroxetine. Differences between mean baseline DMR values and measured values obtained after drug discontinuation for each drug group became nonsignificant on discontinuation day 5 for both paroxetine and sertraline and on discontinuation day 42 for fluoxetine. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/177	fluoxetine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00472	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluoxetine_inhibits_cyp2d6.html	DIKB	"05/15/2009 11:16:23
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/220	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5f356c1b-96bd-4ef1-960c-91cf4905e6b1	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Drugs metabolized by CYP2D6 ï¿½ Fluoxetine inhibits the activity of CYP2D6, and may make individuals with normal CYP2D6 metabolic activity resemble a poor metabolizer. Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6, including certain antidepressants (e.g., TCAs), antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics (e.g., propafenone, flecainide, and others) should be approached with caution. Therapy with medications that are predominantly metabolized by the CYP2D6 system and that have a relatively narrow therapeutic index (see list below) should be initiated at the low end of the dose range if a patient is receiving fluoxetine concurrently or has taken it in the previous 5 weeks. Thus, his/her dosing requirements resemble those of poor metabolizers. If fluoxetine is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need for decreased dose of the original medication should be considered. Drugs with a narrow therapeutic index represent the greatest concern (e.g., flecainide, propafenone, vinblastine, and TCAs). Due to the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, thioridazine should not be administered with fluoxetine or within a minimum of 5 weeks after fluoxetine has been discontinued (see CONTRAINDICATIONS and WARNINGS).
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/177	fluoxetine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00472	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluoxetine_inhibits_cyp2d6.html	DIKB	"06/16/2009 17:07:34
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/221	support	http://www.ncbi.nlm.nih.gov/pubmed/12173784	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Phenotype	"
route of administration: oral

study duration: fluoxetine 80mg qd for eight days

population: 32 healthy adults, all extensive CYP2D6 metabolizers based on DM:DX

ages: unmentioned

Description: 
The urinary concentration ratio of dextromethorphan:dextrorphan (interpreted as an in vivo index of CYP2D6 activity) was determined for each subject before and after the 8 days of receiving SSRIs. Plasma SSRI trough concentrations were measured on days 6-9. The CYP2D6 genotype was determined in a subject with an undetectable paroxetine concentration. Inhibition of CYP2D6 correlated significantly with plasma concentrations of paroxetine and fluoxetine. In contrast, no significant correlations emerged between CYP2D6 inhibition and plasma concentrations of sertraline or fluvoxamine. The subject with an undetectable paroxetine concentration was found to carry at least three functional CYP2D6 genes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/178	celecoxib_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/184	paliperidone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/188	duloxetine_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/189	duloxetine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/201	fluconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp3a4.html	DIKB	"10/22/2007 13:08:14
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/251	support	http://www.ncbi.nlm.nih.gov/pubmed/8904618	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

study duration: four phase crossover study; each phase consisted of four days pre-treatment with placebo or fluconazole (50,100, or 200mg), on day four 0.25mg of triazolam was administered

population: 8 healthy adults 
male:3
female:5

ages: 20-32

AUC_i/AUC (0-inf): 
50mg fluconazole = 1.63
100mg fluconazole = 2.05
200mg fluconazole = 4.42

description: 
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/201	fluconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp3a4.html	DIKB	"12/10/2007 15:42:25
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/252	support	http://www.ncbi.nlm.nih.gov/pubmed/16172184	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

study duration: 4-way crossover; subjects received oral fluconazole (100, 200, or 400mg) or placebo;  2 hours later a single dose of MDZ (1mg IV or oral depending on the study arm) was given followed 30 minutes later by 4mg IV of ondansetron, followed by 15ug/kg of IV alfentanil (one arm) or 40mcg oral alfentanil.

population: 6 male, 6 female

ages: 19-36

AUC_i/AUC (0-inf; oral dosing; 100mg fluconazole): 46.1/21.3 

AUC_i/AUC (0-inf; oral dosing; 200mg fluconazole): 70.7/21.3 

AUC_i/AUC (0-inf; oral dosing; 400mg fluconazole): 105/21.3 
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/201	fluconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp3a4.html	DIKB	"06/30/2009 13:33:58
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/253	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;moderate&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/211	zafirlukast_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp2c9.html	DIKB	09/24/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/263	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Zafirlukast is extensively metabolized. The most common metabolic products are hydroxylated metabolites which are excreted in the feces. The metabolites of zafirlukast identified in plasma are at least 90 times less potent as LTD4 receptor antagonists than zafirlukast in a standard in vitro test of activity. In vitro studies using human liver microsomes showed that the hydroxylated metabolites of zafirlukast excreted in the feces are formed through the cytochrome P450 2C9 (CYP2C9) pathway. Additional in vitro studies utilizing human liver microsomes show that zafirlukast inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes at concentrations close to the clinically achieved total plasma concentrations"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/211	zafirlukast_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp2c9.html	DIKB	"09/24/2009 15:41:53
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/264	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drug-Drug Interactions:
...
Coadministration of multiple doses of zafirlukast (160 mg/day) to steady-state with a single 25 mg dose of warfarin (a substrate of CYP2C9) resulted in a significant increase in the mean AUC (+63%) and half-life (+36%) of S-warfarin. The mean prothrombin time increased by approximately 35%. The pharmacokinetics of zafirlukast were unaffected by coadministration with warfarin."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/218	R-demethylcitalopram_inhibits_cyp3a4	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/19	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-demethylcitalopram_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/221	fluvoxamine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_inhibits_cyp2c19.html	DIKB	"05/05/2009 17:27:55
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/273	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	Fluvoxamine is listed as a recommended inhibitor of CYP2C19 for in vivo studies in Table 2 (p. 19). Typically, this would qualify it as a in vivo selective inhibitor however, Table 2 also shows fluvoxamine as a recommended inhibitor of CYP1A2.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/221	fluvoxamine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_inhibits_cyp2c19.html	DIKB	"05/15/2009 08:52:34
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/274	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/53664f8d-3a93-9f2b-daee-380707e4062c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"(table from section &quot;Drug Interactions&quot;)

Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also  WARNINGS for details) and limited in vitro data for the IIIA4 isozyme, it appears that fluvoxamine inhibits the following isozymes that are known to be involved in the metabolism of the listed drugs:
IA2             IIC9	        IIIA4         IIC19
Warfarin	Warfarin	Alprazolam   Omeprazole
Theophylline			
Propranolol			
Tizanidine			"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/235	paliperidone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/236	paliperidone_inhibits_cyp2c8	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2c8.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/241	atazanavir_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp3a5.html	DIKB	"06/30/2009 12:48:44
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/296	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/241	atazanavir_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp3a5.html	DIKB	"01/11/2010 15:40:48
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/297	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.1 Potential for REYATAZ to Affect Other Drugs 

Atazanavir is an inhibitor of CYP3A and UGT1A1. Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.
type: Non_traceable_Drug_Label_Statement "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/242	atazanavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp3a4.html	DIKB	"06/30/2009 12:47:19
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/298	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/242	atazanavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp3a4.html	DIKB	"01/11/2010 15:38:56
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/299	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.1 Potential for REYATAZ to Affect Other Drugs

Atazanavir is an inhibitor of CYP3A and UGT1A1. Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/246	risperidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/risperidone_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/247	perphenazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/249	eszopiclone_inhibits_CYP3A4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP3A4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/251	voriconazole-N-oxide_inhibits_cyp3a4	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/34	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole-N-oxide_inhibits_cyp3a4.html	DIKB	09/24/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/307	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Effects of Voriconazole on Other Drugs

In vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/253	atazanavir_inhibits_cyp2e1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp2e1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/255	N-desalkylquetiapine_inhibits_cyp2d6	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/24	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/N-desalkylquetiapine_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/270	cinacalcet_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/271	cinacalcet_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/276	beta-hydroxy-simvastatin_inhibits_cyp3a4	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/21	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/beta-hydroxy-simvastatin_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/280	R-citalopram_inhibits_cyp1a2	inhibits		http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-citalopram_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/287	modafinil_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_inhibits_cyp2c19.html	DIKB	"09/24/2009 12:37:09
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/349	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
...
In vitro studies using human liver microsomes showed that modafinil reversibly inhibited CYP2C19 at pharmacologically relevant concentrations of modafinil. CYP2C19 is also reversibly inhibited, with similar potency, by a circulating metabolite, modafinil sulfone. Although the maximum plasma concentrations of modafinil sulfone are much lower than those of parent modafinil, the combined effect of both compounds could produce sustained partial inhibition of the enzyme. Drugs that are largely eliminated via CYP2C19 metabolism, such as diazepam, propranolol, phenytoin (also via CYP2C9) or S-mephenytoin may have prolonged elimination upon coadministration with PROVIGIL and may require dosage reduction and monitoring for toxicity."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/296	iloperidone_inhibits_cyp2d6	inhibits		http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_inhibits_cyp2d6.html	DIKB	"01/11/2010 18:24:21
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/358	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/33f60b40-3fca-11de-8f56-0002a5d5c51b	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Dextromethorphan: A study in healthy volunteers showed that changes in the pharmacokinetics of dextromethorphan (80 mg dose) when a 3 mg dose of iloperidone was co-administered resulted in a 17% increase in total exposure and a 26% increase in Cmax of dextromethorphan.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/306	venlafaxine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/310	demethylcitalopram_inhibits_cyp2c9	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/68	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/demethylcitalopram_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/313	ciprofloxacin_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00537	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ciprofloxacin_inhibits_cyp1a2.html	DIKB	"06/30/2009 12:58:54
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/379	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;moderate&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/313	ciprofloxacin_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00537	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ciprofloxacin_inhibits_cyp1a2.html	DIKB	"01/11/2010 16:43:17
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/380	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c103da18-a822-4944-1bd7-8ecdb5205d69	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Cytochrome P450 (CYP450)

Ciprofloxacin is an inhibitor of the hepatic CYP1A2 enzyme pathway. Coadministration of ciprofloxacin and other drugs primarily metabolized by CYP1A2 (e.g. theophylline, methylxanthines, tizanidine) results in increased plasma concentrations of the coadministered drug and could lead to clinically significant pharmacodynamic side effects of the coadministered drug."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/318	propafenone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01182	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/propafenone_inhibits_cyp1a2.html	DIKB	"06/30/2009 14:03:13
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/386	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;moderate&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/320	ritonavir_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp2d6.html	DIKB	"01/11/2010 17:46:31
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/387	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Ritonavir also inhibits CYP2D6 to a lesser extent. Co-administration of substrates of CYP2D6 with ritonavir could result in increases (up to 2-fold) in the AUC of the other agent, possibly requiring a proportional dosage reduction. 
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/320	ritonavir_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp2d6.html	DIKB	"01/11/2010 17:54:47
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/388	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Table 3 shows that the AUC of desipramine increased 145% in the presence of ritonavir
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/323	citalopram_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/324	celecoxib_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/329	R-didemethylcitalopram_inhibits_cyp2d6	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/26	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-didemethylcitalopram_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/335	escitalopram_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/337	S-didemethylcitalopram_inhibits_cyp2d6	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/66	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-didemethylcitalopram_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/345	eszopiclone_inhibits_CYP2D6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP2D6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/357	topiramate_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/359	citalopram_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/369	ranolazine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00243	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ranolazine_inhibits_cyp2d6.html	DIKB	09/25/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/445	support	http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.2 Effects of Ranolazine on Other Drugs

In vitro studies indicate that ranolazine and its O-demethylated metabolite are weak inhibitors of CYP3A, moderate inhibitors of CYP2D6 and moderate P-gp inhibitors. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/371	diltiazem_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00343	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/diltiazem_inhibits_cyp3a4.html	DIKB	"05/29/2007 11:43:17
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/447	support	http://www.ncbi.nlm.nih.gov/pubmed/9146848	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"Route of administration: oral

polymorphic enzyme: NO

study duration: 3 day pretreatment with diltiazem

population: 7 male

ages: 20-22

description: 
We investigated the interaction between triazolam and diltiazem in a randomized, three-phase crossover study. Seven healthy male volunteers received orally either a single 0.25 mg dose of triazolam, a 0.25 mg dose of triazolam after a 3-day treatment of diltiazem (180 mg day-1), or a placebo. Plasma samples were collected to determine triazolam concentration over a 24 h period. The pharmacodynamic effects of triazolam were investigated using the peak saccadic velocity of eye movements (PSV), electroencephalogram (EEG), and visual analogue scale (VAS) through 8 h. RESULTS: Diltiazem pretreatment significantly increased the area under the triazolam concentration-time curve (8.0 +/- 2.4 to 18.2 +/- 3.1 ng ml-1 h; P < 0.001; mean +/- s.d.). Peak triazolam concentration was increased (2.1 +/- 0.7 to 3.6 +/- 1.0 ng ml-1, P < 0.05) and the elimination half-life prolonged (4.1 +/- 2.1 to 7.6 +/- 1.9 h; P < 0.01). The PSV, EEG, and VAS of the triazolam plus diltiazem group revealed significant differences from the triazolam alone group or the control placebo group."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/388	celecoxib_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp2d6.html	DIKB	"09/24/2009 10:54:45
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/466	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
7. DRUG INTERACTIONS
...
In vitro studies indicate that celecoxib, although not a substrate, is an inhibitor of CYP2D6. Therefore, there is a potential for an in vivo drug interaction with drugs that are metabolized by CYP2D6. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/388	celecoxib_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp2d6.html	DIKB	"09/25/2009 09:49:39
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/467	support	http://www.ncbi.nlm.nih.gov/pubmed/12891223	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"

route of administration: oral

study duration: Controls: a single dose of 50 mg immediate-release metoprolol was given after 7-days of placebo. Exposed: a single dose of 50 mg immediate-release metoprolol was given after 7-days of 400 mg/day of celecoxib.

population: 12 male volunteers 

tested for known CYP450 polymorphisms? Yes, all participants were genotyped as having heterozygous or homozygous extensive metabolizing CYP2D6 alleles. Participants CYP2C9 was also genotyped but no classification of the alleles appears in the paper. 

ages: mean age 30.7 +/- 5.3

description:
Celecoxib increased the AUC(0-inf) of metoprolol
signi&amp;#64257;cantly in all 12 volunteers, by 64.4% +/-57.0% (P &lt; .001).




"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/391	citalopram_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/393	R-citalopram_inhibits_cyp2d6	inhibits		http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-citalopram_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/394	montelukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/397	clozapine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/403	amiodarone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/amiodarone_inhibits_cyp2c9.html	DIKB	"06/30/2009 12:43:42
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/482	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA recommends this as a CYPC9 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/403	amiodarone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/amiodarone_inhibits_cyp2c9.html	DIKB	"01/11/2010 16:39:16
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/483	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/99991CC3-7271-44FC-91C3-3CAB0BBE7645	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4. This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes. 
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/404	amiodarone_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/amiodarone_inhibits_cyp2d6.html	DIKB	"06/30/2009 12:45:54
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/484	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a weak CYP2D6 inhibitor for in vivo studies in it most recent guidance document. See Table 6, p. 23
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/404	amiodarone_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/amiodarone_inhibits_cyp2d6.html	DIKB	"01/11/2010 16:40:43
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/485	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/99991CC3-7271-44FC-91C3-3CAB0BBE7645	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4. This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes. 
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/412	celecoxib_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/428	paliperidone_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/430	sertraline_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01104	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/sertraline_inhibits_cyp2d6.html	DIKB	"04/29/2009 20:01:03
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/514	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	Sertraline is listed as a moderate inhibitor in Table 6 (p23) but does not show up in Table 2 (a table listing several selective in viVo inhibitors)
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/430	sertraline_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01104	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/sertraline_inhibits_cyp2d6.html	DIKB	"05/05/2009 17:06:30
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/515	support	http://www.ncbi.nlm.nih.gov/pubmed/11910262	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_Par_Grps	"Route of administration: oral

study duration: read description below

population: (sertraline group) 12 healthy volunteers (8 male and 4 female), all extensive metabolizers of dextromethorphan

ages: mean(std dev): 27 (unknown)

Description: 
In an open label, parallel group study of 45 healthy volunteers, the time course of CYP2D6 inhibition of the above SSRIs was evaluated. Subjects were randomized to receive paroxetine at 20 mg/day for 10 days; sertraline at 50 mg/day for 3 days, followed by sertraline at 100 mg/day for 10 days; or fluoxetine at 20 mg/day for 28 days. CYP2D6 activity was assessed using the dextromethorphan metabolic ratio (DMR) on antidepressant days 5 and 10 for sertraline and paroxetine and at weekly intervals for fluoxetine. Following SSRI discontinuation, calculation of a CYP2D6 inhibition half-life (t(1/2)inh) revealed the time course of fluoxetine inhibition (t(1/2)inh = 7.0 +/- 1.5 days) to be significantly longer than either paroxetine (t(1/2)inh = 2.9 +/- 1.9) or sertraline (t(1/2)inh = 3.0 +/- 3.0) (p &lt; 0.01), but the latter were not significantly different from each other (p &gt; 0.05). Time for the extrapolated DMR versus time log-linear plots to return to baseline was significantly different between fluoxetine (63.2 +/- 5.6 days) and both paroxetine (20.3 +/- 6.4 days) and sertraline (25.0 +/- 11.0 days) (p &lt; 0.01), making the rank order (from longest to shortest) of time for CYP2D6 inhibition to dissipate: fluoxetine &gt; sertraline &gt;or= paroxetine. Differences between mean baseline DMR values and measured values obtained after drug discontinuation for each drug group became nonsignificant on discontinuation day 5 for both paroxetine and sertraline and on discontinuation day 42 for fluoxetine. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/430	sertraline_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01104	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/sertraline_inhibits_cyp2d6.html	DIKB	"05/15/2009 10:42:02
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/516	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/b1de3ed9-1cb8-e419-3f25-5b0aeed5779a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drugs Metabolized by P450 2D6

Many drugs effective in the treatment of major depressive disorder, e.g., the SSRIs, including sertraline, and most tricyclic antidepressant drugs effective in the treatment of major depressive disorder inhibit the biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase), and, thus, may increase the plasma concentrations of coadministered drugs that are metabolized by P450 2D6. The drugs for which this potential interaction is of greatest concern are those metabolized primarily by 2D6 and which have a narrow therapeutic index, e.g., the tricyclic antidepressant drugs effective in the treatment of major depressive disorder and the Type 1C antiarrhythmics propafenone and flecainide. The extent to which this interaction is an important clinical problem depends on the extent of the inhibition of P450 2D6 by the antidepressant and the therapeutic index of the coadministered drug. There is variability among the drugs effective in the treatment of major depressive disorder in the extent of clinically important 2D6 inhibition, and in fact sertraline at lower doses has a less prominent inhibitory effect on 2D6 than some others in the class. Nevertheless, even sertraline has the potential for clinically important 2D6 inhibition. Consequently, concomitant use of a drug metabolized by P450 2D6 with sertraline may require lower doses than usually prescribed for the other drug. Furthermore, whenever sertraline is withdrawn from cotherapy, an increased dose of the coadministered drug may be required (see PRECAUTIONS: Drug Interactions: Tricyclic Antidepressant Drugs Effective in the Treatment of Major Depressive Disorder). "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/436	lansoprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00448	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lansoprazole_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/439	didemethylcitalopram_inhibits_cyp3a4	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/32	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/didemethylcitalopram_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/449	dehydro-aripiprazole_inhibits_cyp1a2	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/58	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/dehydro-aripiprazole_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/452	paliperidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/454	voriconazole_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_inhibits_cyp2c9.html	DIKB	09/24/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/542	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Effects of Voriconazole on Other Drugs

In vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/456	demethylcitalopram_inhibits_cyp2c19	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/68	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/demethylcitalopram_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/457	S-demethylcitalopram_inhibits_cyp2c19	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/35	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-demethylcitalopram_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/470	venlafaxine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/474	demethylcitalopram_inhibits_cyp1a2	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/68	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/demethylcitalopram_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/479	rosiglitazone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/485	indinavir_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00224	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/indinavir_inhibits_cyp3a5.html	DIKB	"06/30/2009 13:40:40
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/576	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP3A inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/486	indinavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00224	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/indinavir_inhibits_cyp3a4.html	DIKB	"06/30/2009 13:39:31
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/577	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP3A inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/486	indinavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00224	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/indinavir_inhibits_cyp3a4.html	DIKB	"01/11/2010 16:31:55
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/578	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Indinavir is an inhibitor of the cytochrome P450 isoform CYP3A4. Coadministration of CRIXIVAN and drugs primarily metabolized by CYP3A4 may result in increased plasma concentrations of the other drug, which could increase or prolong its therapeutic and adverse effects (see CONTRAINDICATIONS and WARNINGS). Based on in vitro data in human liver microsomes, indinavir does not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However, indinavir may be a weak inhibitor of CYP2D6.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/486	indinavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00224	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/indinavir_inhibits_cyp3a4.html	DIKB	"01/11/2010 16:59:43
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/579	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Sildenafil:  The results of one published study in HIV-infected men (n=6) indicated that coadministration of indinavir (800 mg every 8 hours chronically) with a single 25-mg dose of sildenafil resulted in an 11% increase in average AUC0-8hr of indinavir and a 48% increase in average indinavir peak concentration (Cmax) compared to 800 mg every 8 hours alone. Average sildenafil AUC was increased by 340% following coadministration of sildenafil and indinavir compared to historical data following administration of sildenafil alone (see WARNINGS, Drug Interactions and PRECAUTIONS, Drug Interactions).
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/489	ziprasidone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/502	aripiprazole_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/504	atazanavir_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/510	didemethylcitalopram_inhibits_cyp2d6	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/32	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/didemethylcitalopram_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/511	voriconazole-N-oxide_inhibits_cyp2c19	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/34	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole-N-oxide_inhibits_cyp2c19.html	DIKB	09/24/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/608	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Effects of Voriconazole on Other Drugs

In vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/516	topiramate_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/517	quetiapine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/519	norfloxacin_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01059	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/norfloxacin_inhibits_cyp1a2.html	DIKB	"06/30/2009 13:53:44
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/617	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;weak&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/521	trimethoprim_inhibits_cyp2c8	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00440	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/trimethoprim_inhibits_cyp2c8.html	DIKB	"06/30/2009 15:15:52
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/619	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;weak&quot; CYP2C8 inhibitor in vivo in it most recent guidance document. See Table 6, p23
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/524	topiramate_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/526	paliperidone_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/530	citalopram_inhibits_cyp2e1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2e1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/534	aripiprazole_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/549	mirtazapine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/551	rosiglitazone_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/563	quetiapine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/584	haloperidol_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00502	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/haloperidol_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/595	voriconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_inhibits_cyp3a4.html	DIKB	09/24/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/715	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Effects of Voriconazole on Other Drugs

In vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/596	atazanavir_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/603	duloxetine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/621	rosiglitazone_inhibits_cyp2a6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2a6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/627	atomoxetine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/630	ketoconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01026	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ketoconazole_inhibits_cyp3a4.html	DIKB	"05/21/2007 15:16:35
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/758	support	http://www.ncbi.nlm.nih.gov/pubmed/15114429	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_Par_Grps	"
Route of administration: oral

polymorphic enzyme: NO

study duration: 2 days ketoconazole pretreatment

population: 8 male, 13 female

ages:23-55

description: 
Plasma concentrations of midazolam, 1'OH-midazolam and 4'OH-midazolam were measured after the oral administration of 7.5 mg and 75 micro g midazolam in 13 healthy subjects without medication, in four subjects pretreated for 2 days with ketoconazole (200 mg b.i.d.), a CYP3A inhibitor, and in four subjects pretreated for 4 days with rifampicin (450 mg q.d.), a CYP3A inducer. RESULTS: After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively. No side effects were reported by the subjects taking this low dose of midazolam. Good correlations were observed between the 30-min total 1'OH-midazolam/midazolam ratio and midazolam clearance in the group without co-medication (r(2)=0.64, P<0.001) and in the three groups taken together (r(2)=0.91, P<0.0001)."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/630	ketoconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01026	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ketoconazole_inhibits_cyp3a4.html	DIKB	"05/21/2007 15:27:20
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/759	support	http://www.ncbi.nlm.nih.gov/pubmed/14551182	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

polymorphic enzyme: NO

study duration: 12 days

population: 17 male, 23 female

ages:18-50

description:
Forty healthy subjects were randomized to receive one of the four study drugs for 12 days in a parallel study design: fluoxetine 60 mg per day for 5 days, followed by 20 mg per day for 7 days; fluvoxamine titrated to a daily dose of 200 mg; nefazodone titrated to a daily dose of 400 mg; or ketoconazole 200 mg per day. All 40 subjects received oral midazolam solution before and after the 12-day study drug regimen. Blood samples for determination of midazolam concentrations were drawn for 24 hours after each midazolam dose and used for the calculation of pharmacokinetic parameters. The effects of the study drugs on midazolam pharmacodynamics were assessed using the symbol digit modalities test (SDMT). The mean area under the curve (AUC) for midazolam was increased 771.9% by ketoconazole..."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/630	ketoconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01026	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ketoconazole_inhibits_cyp3a4.html	DIKB	"05/21/2007 16:08:37
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/760	support	http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=1332	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"ketoconazole-janssen-2006-daily-med

Label date: 08/2006
Date of DIKB entry: 05/21/2007

Ambiguous statement? NO

description:
Ketoconazole is a potent inhibitor of the cytochrome P450 3A4 enzyme system. Coadministration of NIZORALï¿½ Tablets and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects. Therefore, unless otherwise specified, appropriate dosage adjustments may be necessary. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/630	ketoconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01026	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ketoconazole_inhibits_cyp3a4.html	DIKB	"01/11/2010 17:05:33
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/761	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8ca815a8-bccb-4ee2-a042-922373329cae	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions

Ketoconazole is a potent inhibitor of the cytochrome P450 3A4 enzyme system. Coadministration of ketoconazole tablets and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects. Therefore, unless otherwise specified, appropriate dosage adjustments may be necessary. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/638	fluconazole_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp3a5.html	DIKB	"06/30/2009 13:35:23
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/771	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;moderate&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/651	quetiapine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/667	ziprasidone_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/680	verapamil_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp1a2.html	DIKB	"06/30/2009 14:29:36
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/820	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;weak&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/688	modafinil-sulfone_inhibits_cyp2c19	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/1	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil-sulfone_inhibits_cyp2c19.html	DIKB	"09/24/2009 12:43:32
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/829	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drug Interactions
...
In vitro studies using human liver microsomes showed that modafinil reversibly inhibited CYP2C19 at pharmacologically relevant concentrations of modafinil. CYP2C19 is also reversibly inhibited, with similar potency, by a circulating metabolite, modafinil sulfone. Although the maximum plasma concentrations of modafinil sulfone are much lower than those of parent modafinil, the combined effect of both compounds could produce sustained partial inhibition of the enzyme. Drugs that are largely eliminated via CYP2C19 metabolism, such as diazepam, propranolol, phenytoin (also via CYP2C9) or S-mephenytoin may have prolonged elimination upon coadministration with PROVIGIL and may require dosage reduction and monitoring for toxicity."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/695	amiodarone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/amiodarone_inhibits_cyp3a4.html	DIKB	"01/11/2010 16:35:31
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/836	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/99991CC3-7271-44FC-91C3-3CAB0BBE7645	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
...
Amiodarone is also known to be an inhibitor of CYP3A4. Therefore, amiodarone has the potential for interactions with drugs or substances that may be substrates, inhibitors or inducers of CYP3A4. While only a limited number of in vivo drug-drug interactions with amiodarone have been reported, the potential for other interactions should be anticipated. This is especially important for drugs associated with serious toxicity, such as other antiarrhythmics. If such drugs are needed, their dose should be reassessed and, where appropriate, plasma concentration measured. In view of the long and variable half-life of amiodarone, potential for drug interactions exists, not only with concomitant medication, but also with drugs administered after discontinuation of amiodarone."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/696	indinavir_inhibits_cyp2b6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00224	http://purl.obolibrary.org/obo/PR_000006116		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/indinavir_inhibits_cyp2b6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/699	R-demethylcitalopram_inhibits_cyp1a2	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/19	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-demethylcitalopram_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/704	indinavir_inhibits_cyp2e1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00224	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/indinavir_inhibits_cyp2e1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/713	clarithromycin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_inhibits_cyp3a4.html	DIKB	"06/05/2007 14:12:44
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/861	support	http://www.ncbi.nlm.nih.gov/pubmed/8880291	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

polymorphic enzyme: NO

study duration: 5 day petreatment with clarithromycin 

population: 4 male, 8 female

ages:24-53

In an open randomized crossover study of 3 phases 12 healthy volunteers received either clarithromycin (250 mg twice a day for 5 days), azithromycin (500 mg once a day for 3 days) or no pretreatment. On the last day of antibiotic treatment they ingested 15 mg midazolam. Plasma samples were collected for midazolam analysis up to 24 h and pharmacodynamic performance measured by a series of tests up to 12 h. Pretreatment with clarithromycin caused large and statistically significant changes in both the pharmacokinetic and pharmacodynamic parameters of midazolam compared to control. For example, the AUC was increased from 248.84-888.75 hng/ml (factor of 3.57, p < 0.0001) and the mean duration of sleep increased from 135.4 min to 281.3 min (p < 0.05)."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/713	clarithromycin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_inhibits_cyp3a4.html	DIKB	"06/30/2009 13:05:51
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/862	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP3A inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/713	clarithromycin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_inhibits_cyp3a4.html	DIKB	"01/11/2010 16:45:51
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/863	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/aa44552c-3cfe-4111-8aa5-4251aeed9be9	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Co-administration of clarithromycin, known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.

Clarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g., carbamazepine) and/or the substrate is extensively metabolized by this enzyme. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving clarithromycin."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/714	clarithromycin_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_inhibits_cyp3a5.html	DIKB	"06/30/2009 13:07:14
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/864	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/714	clarithromycin_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_inhibits_cyp3a5.html	DIKB	"01/11/2010 16:47:28
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/865	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/aa44552c-3cfe-4111-8aa5-4251aeed9be9	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Co-administration of clarithromycin, known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.

Clarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g., carbamazepine) and/or the substrate is extensively metabolized by this enzyme. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving clarithromycin."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/723	paliperidone_inhibits_cyp2a6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2a6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/730	montelukast_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/747	montelukast_inhibits_cyp2a6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2a6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/764	duloxetine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2d6.html	DIKB	"04/29/2009 20:02:14
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/932	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	duloxetine is listed as a moderate inhibitor in Table 6 (p23) but does not show up in Table 2 (a table listing several selective in viVo inhibitors)
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/764	duloxetine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2d6.html	DIKB	"05/05/2009 17:52:52
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/933	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.9 Drugs Metabolized by CYP2D6

Duloxetine is a moderate inhibitor of CYP2D6. When duloxetine was administered (at a dose of 60 mg twice daily) in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold [see Warnings and Precautions (5.10)].

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/764	duloxetine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2d6.html	DIKB	"06/20/2009 13:44:41
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/934	support	http://www.ncbi.nlm.nih.gov/pubmed/12621382	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"
route of administration: oral

study duration: &quot;Study 1 was conducted in 2 distinct periods separated by a 7-day washout. In period 1, a single 50-mg dose of desipramine was administered, and blood samples were obtained for the measurement of desipramine plasma concentrations immediately before the dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 144 hours after dosing. In period 2, duloxetine was administered at an initial dose of 40 mg twice daily. Subjects who did not tolerate this dose were allowed to have the dose lowered to 20 mg twice daily for up to 5 doses, after which dosing at 40 mg twice daily was resumed. On the seventh day of duloxetine dosing (day 14 of the overall protocol), the dose was increased to 60 mg twice daily and was continued at that level for an additional 14 days. On day 21 of the overall protocol (day 8 of duloxetine 60 mg twice daily dosing), a 50-mg dose of desipramine was administered. Blood samples were drawn to determine desipramine plasma concentrations as described for period 1, with additional samples at 168 and 192 hours after the desipramine dose. On the day before and the day of the period 2 desipramine dose (protocol days 20 and 21), blood samples for the measurement of duloxetine plasma concentrations were drawn immediately before duloxetine administration and at 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after administration.&quot;

population: 14 healthy, non-smoking, adults; 7 male, 7 female; nearly all were of apparent European decent (&quot;white&quot;)

tested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.

ages: 21 - 63

description:
&quot;Duloxetine increased the maximum plasma concentration of desipramine 1.7-fold and the area under the concentration-time curve 2.9-fold.&quot;

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/768	paliperidone_inhibits_cyp2e1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2e1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/774	S-didemethylcitalopram_inhibits_cyp1a2	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/66	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-didemethylcitalopram_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/777	N-desalkylquetiapine_inhibits_cyp2c9	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/24	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/N-desalkylquetiapine_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/778	R-didemethylcitalopram_inhibits_cyp3a4	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/26	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-didemethylcitalopram_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/783	ziprasidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/787	atazanavir_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/791	N-desalkylquetiapine_inhibits_cyp2c19	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/24	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/N-desalkylquetiapine_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/792	ziprasidone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/799	R-demethylcitalopram_inhibits_cyp2c9	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/19	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-demethylcitalopram_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/804	didemethylcitalopram_inhibits_cyp1a2	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/32	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/didemethylcitalopram_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/808	cinacalcet_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/818	rosiglitazone_inhibits_cyp2b6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006116		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2b6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/828	citalopram_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/835	escitalopram_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2d6.html	DIKB	"05/15/2009 10:11:58
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1020	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.19 Drugs Metabolized by Cytochrome P4502D6

In vitro studies did not reveal an inhibitory effect of escitalopram on CYP2D6. In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism. However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine. The clinical significance of this finding is unknown. Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/843	topiramate_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/845	rosiglitazone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/849	rosiglitazone_inhibits_cyp2c8	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2c8.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/852	fluphenazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00623	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluphenazine_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/854	bupropion_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01156	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/bupropion_inhibits_cyp2d6.html	DIKB	"05/15/2009 10:51:26
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1044	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-40dd-8168-6d0368e5d233	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme. Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro. In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150mg twice daily followed by a single dose of 50mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively. The effect was present for at least 7 days after the last dose of bupropion. Concomitant use of bupropion with other drugs metabolized by CYP2D6 has not been formally studied.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/854	bupropion_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01156	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/bupropion_inhibits_cyp2d6.html	DIKB	"06/20/2009 14:58:06
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1045	support	http://www.ncbi.nlm.nih.gov/pubmed/15876900	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"

route of administration: oral

study duration: &quot;dextromethorphan (30-mg oral dose) was administered to smokers at baseline and after 17 days of treatment with either bupropion sustained-release (150 mg twice daily) or matching placebo. Subjects quit smoking 3 days before the second dextromethorphan administration.&quot;

population: 21 smoking, 9 female, 11 male

tested for known CYP450 polymorphisms? yes ... all participants were considered CYP2D6 extensive metabolizers according to dextromethorphan:dextrorphan metabolite ratio

ages: 21 - 40

NOTE: &quot;24-hour period preceding each laboratory visit. Two subjects reported taking medications that could potentially affect CYP2D6 metabolism and therefore alter bupropion concentrations (one reported use of hormone replacement therapy and another oral contraceptives).&quot;

description:
&quot;Among those taking bupropion, DM/DX ratio in-
creased significantly at the second assessment relative to the first (0.012 ï¿½ 0.012 vs. 0.418 ï¿½ 0.302; P &lt; 0.0004) (Fig. 1). No such change was observed in those randomized to placebo (0.009 ï¿½ 0.010 vs. 0.017 ï¿½ 0.015; P = NS). Of those receiving bupropion, 46% (6/13) were phenotypically poor metabolizers after treatment.&quot;


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/860	eszopiclone_inhibits_CYP2C9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP2C9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/862	R-citalopram_inhibits_cyp2c19	inhibits		http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-citalopram_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/876	gemfibrozil_inhibits_cyp2c8	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01241	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/gemfibrozil_inhibits_cyp2c8.html	DIKB	"06/30/2009 13:37:42
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1074	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP2C8 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/881	voriconazole-N-oxide_inhibits_cyp2c9	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/34	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole-N-oxide_inhibits_cyp2c9.html	DIKB	09/24/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1079	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Effects of Voriconazole on Other Drugs

In vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/903	cinacalcet_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/906	mirtazapine_inhibits_cyp2e1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp2e1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/918	aripiprazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/925	N-desalkylquetiapine_inhibits_cyp1a2	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/24	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/N-desalkylquetiapine_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/929	fluvoxamine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_inhibits_cyp2c9.html	DIKB	"05/15/2009 09:08:19
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1140	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/53664f8d-3a93-9f2b-daee-380707e4062c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Warfarin

When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for 2 weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged. Thus patients receiving oral anticoagulants and fluvoxamine maleate tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly. No dosage adjustment is required for fluvoxamine maleate tablets."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/932	rosiglitazone_inhibits_cyp2e1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2e1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/936	pantoprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/938	demethylcitalopram_inhibits_cyp3a4	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/68	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/demethylcitalopram_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/956	thiothixene_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01623	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/thiothixene_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/959	escitalopram_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/961	nefazodone_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_inhibits_cyp3a5.html	DIKB	"06/30/2009 13:52:12
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1179	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/963	venlafaxine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/965	quetiapine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/968	R-citalopram_inhibits_cyp3a4	inhibits		http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-citalopram_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/969	pravastatin_inhibits_cyp2c8	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00175	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pravastatin_inhibits_cyp2c8.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/975	R-citalopram_inhibits_cyp2c9	inhibits		http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-citalopram_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/985	rosiglitazone_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/989	telithromycin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00976	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/telithromycin_inhibits_cyp3a4.html	DIKB	"06/30/2009 14:14:05
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1211	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/989	telithromycin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00976	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/telithromycin_inhibits_cyp3a4.html	DIKB	"01/11/2010 15:43:44
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1212	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/4471223e-9023-457e-be2e-8e4e0c2d94d1	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Midazolam

Concomitant administration of telithromycin with intravenous or oral midazolam resulted in 2- and 6-fold increases, respectively, in the AUC of midazolam due to inhibition of CYP 3A4-dependent metabolism of midazolam. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/989	telithromycin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00976	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/telithromycin_inhibits_cyp3a4.html	DIKB	"01/11/2010 15:46:06
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1213	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/4471223e-9023-457e-be2e-8e4e0c2d94d1	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug interactions

Telithromycin is a strong inhibitor of the cytochrome P450 3A4 system. Co-administration of KETEK tablets and a drug primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentration of the drug co-administered with telithromycin that could increase or prolong both the therapeutic and adverse effects. Therefore, appropriate dosage adjustments may be necessary for the drug co-administered with telithromycin."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1015	atorvastatin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_inhibits_cyp3a4.html	DIKB	"09/24/2007 10:42:50
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1241	support	http://www.ncbi.nlm.nih.gov/pubmed/12911366	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_Par_Grps	"
Route of administration: oral

polymorphic enzyme: no

study duration: this was a matched pair study; 7 patients already take atorvastatin were matched with patients who were not taking atorvastatin or any other known CYP3A4 inhibitor. Of the patients taking atorvastatin, 5 were on 10mg/day, 1 on 20mg/day, and one on 40mg/day. All patient's received a .25mg/kg bolus of IV midazolam.

population: 14 individuals; 10 male, 4 female

ages: generally older ~61 (unfortunately ages given in mean/std dev)

AUC_i/AUC of midazolam: 889.4/629.1=1.41


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1021	montelukast_inhibits_cyp2c8	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2c8.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1028	teriflunomide_inhibits_cyp2c9	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/55	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/teriflunomide_inhibits_cyp2c9.html	DIKB	"09/24/2009 12:12:08
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1256	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/151ffcf4-e503-4954-af7c-93d0a4f9f80	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drug Interactions:

...
In vitro studies of drug metabolism indicate that M1 inhibits CYP 450 2C9, which is responsible for the metabolism of phenytoin, tolbutamide, warfarin and many NSAIDs. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1032	quinidine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00908	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quinidine_inhibits_cyp2d6.html	DIKB	"01/11/2010 17:38:30
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1261	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/19a30c59-15da-4324-bc08-d09495dc1074	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Quinidine is not metabolized by cytochrome P450IID6, but therapeutic serum levels of quinidine inhibit the action of cytochrome P450IID6, effectively converting extensive metabolizers into poor metabolizers. Caution must be exercised whenever quinidine is prescribed together with drugs metabolized by cytochrome P450IID6.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1035	mirtazapine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1045	topiramate_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1046	topiramate_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1054	eszopiclone_inhibits_CYP1A2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP1A2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1055	fluvoxamine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_inhibits_cyp1a2.html	DIKB	"05/05/2009 17:26:22
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1293	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	Fluvoxamine is listed as a recommended inhibitor of CYP1A2 for in vivo studies in Table 2 (p. 19). Typically, this would qualify it as a in vivo selective inhibitor however, Table 2 also shows fluvoxamine as a recommended inhibitor of 2C19.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1055	fluvoxamine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_inhibits_cyp1a2.html	DIKB	"05/15/2009 09:03:48
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1294	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/53664f8d-3a93-9f2b-daee-380707e4062c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Theophylline

The effect of steady-state fluvoxamine (50 mg bid) on the pharmacokinetics of a single dose of theophylline (375 mg as 442 mg aminophylline) was evaluated in 12 healthy nonsmoking, male volunteers. The clearance of theophylline was decreased approximately 3-fold. Therefore, if theophylline is coadministered with fluvoxamine maleate, its dose should be reduced to one-third of the usual daily maintenance dose and plasma concentrations of theophylline should be monitored. No dosage adjustment is required for fluvoxamine maleate tablets."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1055	fluvoxamine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_inhibits_cyp1a2.html	DIKB	"06/20/2009 11:54:59
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1295	support	http://www.ncbi.nlm.nih.gov/pubmed/11719727	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_Pharmacokinetic	"
route of administration: oral

study duration: single-dose theophylline (250 mg) after  taking fluvoxamine for 9 days at 3 doses (0, 25, or 75 mg/day) in a randomized crossover design

population: 9 healthy non-smoking volunteers (5 male, 4 female)

participants tested known CYP450 phenotypes? No

ages: 23 - 40

Description: 
Table II shows AUC_i/AUC (0-48) for theophylline as follows:

fluvoxamine @ 25mg/day for 9 days: 504/349 = 1.44
fluvoxamine @ 75mg/day for 9 days: 710/349 = 2.03
 

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1056	rosuvastatin_inhibits_cyp2c8	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01098	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosuvastatin_inhibits_cyp2c8.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1057	cinacalcet_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp2d6.html	DIKB	"09/24/2009 12:22:35
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1297	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drug Interactions
...
Desipramine: The effect of cinacalcet (90 mg) on the pharmacokinetics of desipramine (50 mg) has been studied in healthy subjects who were CYP2D6 extensive metabolizers. The AUC and Cmax of desipramine increased by 3.6 (296.5-446.7%) and 1.75 (157.5-194.9%) fold, respectively, in the presence of cinacalcet. This indicates that cinacalcet is a strong in vivo inhibitor of CYP2D6 and can increase the blood concentrations of drugs metabolized by CYP2D6."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1057	cinacalcet_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp2d6.html	DIKB	"09/25/2009 10:03:28
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1298	support	http://www.ncbi.nlm.nih.gov/pubmed/16680561	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"

route of administration: oral

study duration: controls: a single dose of 50 mg of desipramine alone; exposed: a single dose of 50 mg of desipramine after seven days of 90 mg cinacalcet. The groups were randomized and then alternated after a 10-day washout period.

population: 14 healthy subjects; non-smokers; 8 female, 7 male

tested for known CYP450 polymorphisms? subjects were required to be CYP2D6 extensive metabolizers based on genotyping

ages: 18 - 55

description:
Relative to when desipramine was administered alone, a
3.6-fold increase in AUC(0-inf) and 1.8-fold increase in Cmax of desipramine was observed when cinacalcet was
administered for 5 days before and 2 days after dosing
with desipramine (Table 1, Fig. 1). Administration with
cinacalcet resulted in an increase in the AUC(0-inf) and Cmax of desipramine for all subjects (Fig. 2). Coadministration of desipramine and cinacalcet also resulted in a notable reduction in desipramine oral clearance. The terminal half-life of desipramine was also increased by approximately twofold when desipramine was coadministered with cinacalcet. The median tmax was 6 h following administration of desipramine alone and following administration
with cinacalcet.



"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1057	cinacalcet_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp2d6.html	DIKB	"09/25/2009 10:47:42
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1299	support	http://www.ncbi.nlm.nih.gov/pubmed/17652181	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"

route of administration: oral

study duration: Each subject received 50 mg of cinacalcet (25-mg [as free base] film tablets,
Kirin Brewery Co, Ltd, Tokyo, Japan) or a matched
placebo orally once daily for 8 days. On day 8, each
subject also received a single oral dose of 30 mg DEX
(Medicon, 15-mg film tablets, Shionogi &amp; Co, Ltd,
Osaka, Japan). 

population: 23 male volunteers 

tested for known CYP450 polymorphisms? all participants included in the PK analaysis wer classified as a CYP2D6 extensive metabolizers based on the dextromethorphan/dextorpham metabolic ratio

ages: 20 - 33

description:
The Cmax, AUC(0-t), and AUC(0-inf) of DEX were significantly higher during the cinacalcet treatment than with placebo, with a ratio of 7.481, 14.373, and 11.475, respectively. The Cmax of DOR was decreased, and the AUC(0-t) and AUC(0-inf) of DOR were slightly increased during cinacalcet treatment.


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1071	cimetidine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00501	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cimetidine_inhibits_cyp1a2.html	DIKB	"06/30/2009 12:57:08
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1314	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;weak&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1072	atomoxetine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1075	indinavir_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00224	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/indinavir_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1093	venlafaxine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp2d6.html	DIKB	"05/15/2009 10:30:24
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1339	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drugs Metabolized by Cytochrome P450 Isoenzymes

CYP2D6: In vitro studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6. These findings have been confirmed in a clinical drug interaction study comparing the effect of venlafaxine to that of fluoxetine on the CYP2D6-mediated metabolism of dextromethorphan to dextrorphan. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1096	atomoxetine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1102	cimetidine_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00501	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cimetidine_inhibits_cyp3a5.html	DIKB	"06/30/2009 12:55:42
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1349	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;weak&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1103	cimetidine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00501	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cimetidine_inhibits_cyp3a4.html	DIKB	"06/30/2009 12:54:27
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1350	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;weak&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1104	atazanavir_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1108	lansoprazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00448	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lansoprazole_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1121	topiramate_inhibits_cyp2a6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2a6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1124	montelukast_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1132	S-demethylcitalopram_inhibits_cyp3a4	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/35	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-demethylcitalopram_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1137	eszopiclone_inhibits_CYP2C19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP2C19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1141	voriconazole_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_inhibits_cyp2c19.html	DIKB	09/24/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1397	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Effects of Voriconazole on Other Drugs

In vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1145	aripiprazole_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1149	telithromycin_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00976	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/telithromycin_inhibits_cyp3a5.html	DIKB	"06/30/2009 14:15:06
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1407	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1151	ranolazine_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00243	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ranolazine_inhibits_cyp3a5.html	DIKB	09/25/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1409	support	http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.2 Effects of Ranolazine on Other Drugs

In vitro studies indicate that ranolazine and its O-demethylated metabolite are weak inhibitors of CYP3A, moderate inhibitors of CYP2D6 and moderate P-gp inhibitors. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1152	ranolazine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00243	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ranolazine_inhibits_cyp3a4.html	DIKB	09/25/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1410	support	http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.2 Effects of Ranolazine on Other Drugs

In vitro studies indicate that ranolazine and its O-demethylated metabolite are weak inhibitors of CYP3A, moderate inhibitors of CYP2D6 and moderate P-gp inhibitors. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1155	mexiletine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00379	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mexiletine_inhibits_cyp1a2.html	DIKB	"06/30/2009 13:42:29
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1415	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;moderate&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1155	mexiletine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00379	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mexiletine_inhibits_cyp1a2.html	DIKB	"01/11/2010 17:09:51
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1416	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/AB73778B-6794-441C-B127-610A6D0733EA	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Concurrent use of mexiletine and theophylline may lead to increased plasma theophylline levels. One controlled study in eight normal subjects showed a 72% mean increase (range 35 to 136%) in plasma theophylline levels. This increase was observed at the first test point which was the second day after starting mexiletine. Theophylline plasma levels returned to pre-mexiletine values within 48 hours after discontinuing mexiletine. If mexiletine and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexiletine dose is changed. An appropriate adjustment in theophylline dose should be considered.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1155	mexiletine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00379	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mexiletine_inhibits_cyp1a2.html	DIKB	"01/11/2010 17:15:31
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1417	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/AB73778B-6794-441C-B127-610A6D0733EA	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of mexiletine.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1158	itraconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01167	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/itraconazole_inhibits_cyp3a4.html	DIKB	"01/11/2010 17:03:24
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1420	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a4d555fa-787c-40fb-bb7d-b0d4f7318fd0	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions:

Concomitant administration of SPORANOXï¿½ (itraconazole) Capsules, Injection, or Oral Solution and certain drugs metabolized by the cytochrome P450 3A4 isoenzyme system (CYP3A4) may result in increased plasma concentrations of those drugs, leading to potentially serious and/or life-threatening adverse events. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1159	atazanavir_inhibits_cyp2b6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006116		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp2b6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1160	escitalopram_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1193	omeprazole_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00338	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/omeprazole_inhibits_cyp2c19.html	DIKB	"06/30/2009 13:55:41
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1466	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYPC19 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1195	nefazodone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_inhibits_cyp3a4.html	DIKB	"06/30/2009 13:51:06
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1468	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1195	nefazodone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_inhibits_cyp3a4.html	DIKB	"01/11/2010 17:20:39
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1469	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/b1d149db-ad43-4f3f-aef1-fb0395ba4191	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	CYP3A4 Isozymeï¿½Nefazodone has been shown in vitro to be an inhibitor of CYP3A4. This is consistent with the interactions observed between nefazodone and triazolam, alprazolam, buspirone, atorvastatin, and simvastatin, drugs metabolized by this isozyme. Consequently, caution is indicated in the combined use of nefazodone with any drugs known to be metabolized by CYP3A4. In particular, the combined use of nefazodone with triazolam should be avoided for most patients, including the elderly. The combined use of nefazodone with terfenadine, astemizole, cisapride, or pimozide is contraindicated (see CONTRAINDICATIONS and WARNINGS).
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1195	nefazodone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_inhibits_cyp3a4.html	DIKB	"01/11/2010 17:23:29
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1470	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/b1d149db-ad43-4f3f-aef1-fb0395ba4191	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Triazolam

When a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4-fold and peak concentrations increased 1.7-fold. Nefazodone plasma concentrations were unaffected by triazolam. Coadministration of nefazodone potentiated the effects of triazolam on psychomotor performance tests. If triazolam is coadministered with nefazodone, a 75% reduction in the initial triazolam dosage is recommended. Because not all commercially available dosage forms of triazolam permit sufficient dosage reduction, coadministration of triazolam with nefazodone should be avoided for most patients, including the elderly. In the exceptional case where coadministration of triazolam with nefazodone may be considered appropriate, only the lowest possible dose of triazolam should be used (see CONTRAINDICATIONS and PRECAUTIONS)."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1198	rosiglitazone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1205	terbinafine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00857	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/terbinafine_inhibits_cyp2d6.html	DIKB	"06/30/2009 14:16:34
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1481	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;moderate&quot; CYP2D6 inhibitor in vivo in it most recent guidance document. See Table 6, p23
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1205	terbinafine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00857	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/terbinafine_inhibits_cyp2d6.html	DIKB	"01/11/2010 17:40:55
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1482	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/7c6c1494-fb92-4442-bcff-764b77397495	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions

In vivo studies have shown that terbinafine is an inhibitor of the CYP450 2D6 isozyme. Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. Coadministration of LAMISILï¿½ should be done with careful monitoring and may require a reduction in dose of the 2D6-metabolized drug. In a study to assess the effects of terbinafine on desipramine in healthy volunteers characterized as normal metabolizers, the administration of terbinafine resulted in a 2-fold increase in Cmax and a 5-fold increase in AUC. In this study, these effects were shown to persist at the last observation at 4 weeks after discontinuation of LAMISILï¿½. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1209	montelukast_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1216	escitalopram_inhibits_cyp2e1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2e1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1223	paroxetine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00715	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paroxetine_inhibits_cyp2d6.html	DIKB	"05/05/2009 17:09:29
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1506	support	http://www.ncbi.nlm.nih.gov/pubmed/11910262	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_Par_Grps	"Route of administration: oral

study duration: read description below

population: (paroxetine group) 13 healthy volunteers (8 male and 5 female), all extensive metabolizers of dextromethorphan

ages: mean(std dev): 28 (unknown)

Description: 
In an open label, parallel group study of 45 healthy volunteers, the time course of CYP2D6 inhibition of the above SSRIs was evaluated. Subjects were randomized to receive paroxetine at 20 mg/day for 10 days; sertraline at 50 mg/day for 3 days, followed by sertraline at 100 mg/day for 10 days; or fluoxetine at 20 mg/day for 28 days. CYP2D6 activity was assessed using the dextromethorphan metabolic ratio (DMR) on antidepressant days 5 and 10 for sertraline and paroxetine and at weekly intervals for fluoxetine. Following SSRI discontinuation, calculation of a CYP2D6 inhibition half-life (t(1/2)inh) revealed the time course of fluoxetine inhibition (t(1/2)inh = 7.0 +/- 1.5 days) to be significantly longer than either paroxetine (t(1/2)inh = 2.9 +/- 1.9) or sertraline (t(1/2)inh = 3.0 +/- 3.0) (p &lt; 0.01), but the latter were not significantly different from each other (p &gt; 0.05). Time for the extrapolated DMR versus time log-linear plots to return to baseline was significantly different between fluoxetine (63.2 +/- 5.6 days) and both paroxetine (20.3 +/- 6.4 days) and sertraline (25.0 +/- 11.0 days) (p &lt; 0.01), making the rank order (from longest to shortest) of time for CYP2D6 inhibition to dissipate: fluoxetine &gt; sertraline &gt;or= paroxetine. Differences between mean baseline DMR values and measured values obtained after drug discontinuation for each drug group became nonsignificant on discontinuation day 5 for both paroxetine and sertraline and on discontinuation day 42 for fluoxetine. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1223	paroxetine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00715	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paroxetine_inhibits_cyp2d6.html	DIKB	"06/16/2009 17:10:18
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1507	support	http://www.ncbi.nlm.nih.gov/pubmed/12173784	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Phenotype	"

route of administration: oral

study duration: paroxetine 20mg qd for eight days

population: 32 healthy adults, all extensive CYP2D6 metabolizers based on DM:DX

ages: unmentioned

Description: 
The urinary concentration ratio of dextromethorphan:dextrorphan (interpreted as an in vivo index of CYP2D6 activity) was determined for each subject before and after the 8 days of receiving SSRIs. Plasma SSRI trough concentrations were measured on days 6-9. The CYP2D6 genotype was determined in a subject with an undetectable paroxetine concentration. Inhibition of CYP2D6 correlated significantly with plasma concentrations of paroxetine and fluoxetine. In contrast, no significant correlations emerged between CYP2D6 inhibition and plasma concentrations of sertraline or fluvoxamine. The subject with an undetectable paroxetine concentration was found to carry at least three functional CYP2D6 genes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1223	paroxetine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00715	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paroxetine_inhibits_cyp2d6.html	DIKB	"06/16/2009 17:12:46
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1508	support	http://www.ncbi.nlm.nih.gov/pubmed/12584155	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes

Quote:
To determine whether preincubation affects the inhibition of human liver microsomal dextromethorphan demethylation activity by paroxetine, we used a two-step incubation scheme in which all of the enzyme assay components, minus substrate, are preincubated with paroxetine...Time-dependent inhibition was demonstrated with an apparent K(I) of 4.85 microM and an apparent k(INACT) value of 0.17 min(-1). Spectral scanning of CYP2D6 with paroxetine yielded an increase in absorbance at 456 nm suggesting paroxetine inactivation of CYP2D6 via the formation of a metabolite intermediate complex.
...In contrast, quinidine and fluoxetine, both of which are inhibitors of CYP2D6 activity, did not exhibit a preincubation-dependent increase in inhibitory potency. These data are consistent with mechanism-based inhibition of CYP2D6 by paroxetine but not by quinidine or fluoxetine."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1223	paroxetine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00715	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paroxetine_inhibits_cyp2d6.html	DIKB	"06/16/2009 18:00:03
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1509	support	http://www.ncbi.nlm.nih.gov/pubmed/8513845	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Phenotype	"
route of administration: oral

study duration: 

population: 17 males, 9 sparteine EMs and 8 sparteine PMs

ages: 20-24

Description: 
During paroxetine, the median clearances were 22 l.h-1 and 18 l.h-1 in EMs and PMs respectively. The 5-fold decrease in clearance in EMs when desipramine was co-administered with paroxetine confirms that paroxetine is a potent inhibitor of CYP2D6. The lack of effect on clearance in PMs shows that paroxetine is a selective inhibitor of CYP2D6, which is absent from the livers of PMs. Before paroxetine, the median of desipramine clearance via 2-hydroxylation was 40-times higher in EMs than in PMs (56 and 1.4 l.h-1 respectively), but during paroxetine, it was only 2-times higher (6 and 2.9 l.h-1 respectively)."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1223	paroxetine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00715	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paroxetine_inhibits_cyp2d6.html	DIKB	"01/11/2010 17:35:08
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1510	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/89dd7e24-85fc-4152-89ea-47ec2b48a1ed	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug-Drug Interactions

In vitro drug interaction studies reveal that paroxetine inhibits CYP2D6. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 including desipramine, risperidone, and atomoxetine (see PRECAUTIONS: Drug Interactions). "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1224	mirtazapine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1231	chlorpromazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00477	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/chlorpromazine_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1242	indinavir_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00224	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/indinavir_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1244	thioridazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00679	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/thioridazine_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1250	amiodarone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/amiodarone_inhibits_cyp1a2.html	DIKB	"01/11/2010 16:37:52
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1540	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/99991CC3-7271-44FC-91C3-3CAB0BBE7645	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4. This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes. 
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1260	simvastatin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/2	eszopiclone_inhibits_CYP2E1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP2E1.html	DIKB	11/09/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/2	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/5	R-didemethylcitalopram_inhibits_cyp1a2	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/26	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-didemethylcitalopram_inhibits_cyp1a2.html	DIKB	"06/12/2009 11:40:41
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/5	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: phenacetin O-deethylation

Quote:

In all systems the positive control inhibitors produced the expected degree of inhibition of their respective index reactions (Table 1). CYP1A2. R- and S-CT and metabolites all were negligible inhibitors
of phenacetin O-deethylation, the index reaction for CYP1A2. None of these compounds produced 50% inhibition. The mean IC50 for alpha-naphthoflavone was 0.2micM, and the mean IC50 for fluvoxamine was 0.3micM. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/11	nefazodone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_inhibits_cyp1a2.html	DIKB	"01/11/2010 19:09:34
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/13	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/b1d149db-ad43-4f3f-aef1-fb0395ba4191	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Theophylline

When nefazodone (200 mg BID) was given to patients being treated with theophylline (600 to 1200 mg/day) for chronic obstructive pulmonary disease, there was no change in the steady-state pharmacokinetics of either nefazodone or theophylline. FEV1 measurements taken when theophylline and nefazodone were coadministered did not differ from baseline dosage (i.e., when theophylline was administered alone). Therefore, dosage adjustment is not necessary for either drug when coadministered."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/13	topiramate_inhibits_cyp2b6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006116		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2b6.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/15	refute	http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/22	mirtazapine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp2c9.html	DIKB	"02/12/2010 17:32:18
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/29	refute	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: tolbutamide

reaction: tolbutamide hydroxylation 

Quote: 
Mirtazapine reduced the rate of the reaction by much less than 50% even at concentrations of 250micM (see Table 3).


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/24	topiramate_inhibits_cyp2e1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2e1.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/31	refute	http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/24	topiramate_inhibits_cyp2e1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2e1.html	DIKB	"09/22/2009 18:00:34
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/32	refute	http://www.ncbi.nlm.nih.gov/pubmed/12102670	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: assumed based on the date of the article and authors

substrate used: p-nitrophenol

reaction: p-nitrophenol hydroxylation to p-nitrocatechol

Quote:
No inhibition was found in microsomal preparations made from human livers with adequate CYP2D6 activity or with expressed CYP2D or with adequate activity of CYPs 1A2, 2A6, 2C9, 2E1, and 3A4. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/29	fluconazole_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/54	quetiapine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp3a4.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/76	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/56	S-demethylcitalopram_inhibits_cyp2c9	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/35	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-demethylcitalopram_inhibits_cyp2c9.html	DIKB	"06/12/2009 11:30:27
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/78	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: tolbutamide --&gt; hydroxytolbutamide

Quote:

CYP2C9. R-CT, S-CT, R-DCT, and S-DCT were weak inhibitors of CYP2C9, represented by tolbutamide hydroxylation, with less than 50% inhibition produced even at 250micM. R-DDCT and S-DDCT produced a moderate degree of inhibition, with IC50 values of 30.7 (+/-6.3)micM and 25.7 (+/-8.0)micM, respectively. Sulfaphenazole was a strong inhibitor (IC50 1.3micM), and the SSRI fluvoxamine also was a moderately strong inhibitor (IC50 9.4micM). "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/63	zafirlukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/64	ritonavir_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/65	ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/68	R-citalopram_inhibits_cyp2e1	inhibits		http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-citalopram_inhibits_cyp2e1.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/78	aripiprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp2d6.html	DIKB	"04/29/2009 19:38:21
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/101	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/79	rosiglitazone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp1a2.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/102	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/80	rosiglitazone_inhibits_cyp1a1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006101		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp1a1.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/103	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/83	duloxetine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2c19.html	DIKB	"05/05/2009 17:40:26
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/106	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.12 Drugs Metabolized by CYP2C19

Results of in vitro studies demonstrate that duloxetine does not inhibit CYP2C19 activity at therapeutic concentrations. Inhibition of the metabolism of CYP2C19 substrates is therefore not anticipated, although clinical studies have not been performed."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/86	paliperidone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp3a4.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/109	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/90	verapamil_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/92	verapamil_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/105	atazanavir_inhibits_cyp2a6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp2a6.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/132	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/111	erythromycin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00199	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/erythromycin_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/112	montelukast_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2c19.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/142	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/123	omeprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00338	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/omeprazole_inhibits_cyp2d6.html	DIKB	"09/23/2009 11:38:21
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/155	refute	http://www.ncbi.nlm.nih.gov/pubmed/15258107	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: bufuralol

reaction: bufuralol 1'hydroxylation

IC50 &gt; 200micM (see Table 3)

Quote: 
CYP2D6 Activity. No significant effects on the formation of 1 -hydroxylated bufuralol (CYP2D6) were found, indicating that none of the five PPIs [including omeprazole, lansoprazole, pantoprazole rameprazole and esomeprazole] inhibited CYP2D6 activity in vitro (IC50 200micM). However, rabeprazole thioether inhibited CYP2D6 activity with a Ki of 12micM in HLM.



"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/145	S-demethylcitalopram_inhibits_cyp1a2	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/35	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-demethylcitalopram_inhibits_cyp1a2.html	DIKB	"06/12/2009 11:10:32
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/181	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: phenacetin O-deethylation

Quote:

In all systems the positive control inhibitors produced the expected degree of inhibition of their respective index reactions (Table 1). CYP1A2. R- and S-CT and metabolites all were negligible inhibitors
of phenacetin O-deethylation, the index reaction for CYP1A2. None of these compounds produced 50% inhibition. The mean IC50 for alpha-naphthoflavone was 0.2micM, and the mean IC50 for fluvoxamine was 0.3micM.
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/150	S-didemethylcitalopram_inhibits_cyp3a4	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/66	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-didemethylcitalopram_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/156	cinacalcet_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp2c19.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/194	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
...
An in vitro study indicates that cinacalcet is a strong inhibitor of CYP2D6, but not of CYP1A2, CYP2C9, CYP2C19, and CYP3A4."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/160	R-demethylcitalopram_inhibits_cyp2c19	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/19	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-demethylcitalopram_inhibits_cyp2c19.html	DIKB	"06/12/2009 11:34:15
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/197	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: S-mepheytoin 4'hydroxylation

Quote:

CYP2C19. R- and S-CT were very weak inhibitors, with less than 50% inhibition of S-mephenytoin hydroxylation even at 100micM. R- and S-DCT also were weak inhibitors. R- and S-DDCT were moderate inhibitors, with mean IC50 values of 18.7 and 12.1micM, respectively. Omeprazole was a strong inhibitor of CYP2C19, as was the SSRI
fluvoxamine (see Table 2). "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/162	escitalopram_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2c19.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/199	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	in vitro enzyme inhibition data did not reveal an inhibitory effect of escitalopram on CYP3A4, -1A2, -2C9, -2C19, and -2E1. Based on in vitro data, escitalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/162	escitalopram_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2c19.html	DIKB	"06/11/2009 16:10:21
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/200	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: S-mepheytoin 4'hydroxylation

Quote: 

CYP2C19. R- and S-CT were very weak inhibitors, with less than 50% inhibition of S-mephenytoin hydroxylation even at 100micM. R- and S-DCT also were weak inhibitors. R- and S-DDCT were moderate inhibitors, with mean IC50 values of 18.7 and 12.1micM, respectively. Omeprazole was a strong inhibitor of CYP2C19, as was the SSRI
fluvoxamine (see Table 2).


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/167	N-desalkylquetiapine_inhibits_cyp3a4	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/24	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/N-desalkylquetiapine_inhibits_cyp3a4.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/207	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/169	eszopiclone_inhibits_CYP2A6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP2A6.html	DIKB	11/09/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/209	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/170	ziprasidone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp1a2.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/210	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/170	ziprasidone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp1a2.html	DIKB	"06/19/2009 17:06:15
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/211	refute	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes

reaction: 7-ethoxyresoruvin O-deethylation

The IC50 for ziprasidone inhibition of this reaction was greater than 100micM 


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/171	citalopram_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2c9.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/212	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data did not reveal an inhibitory effect of citalopram on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak inhibitor of CYP1A2, -2D6, and -2C19. Citalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes. However, in vivo data to address this question are limited.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/171	citalopram_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2c9.html	DIKB	"02/12/2010 14:53:49
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/213	refute	http://www.ncbi.nlm.nih.gov/pubmed/9278211	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"

route of administration: oral

study duration: a single 25 mg dose of racemic warfarin either alone or on Day 15 of a 21-day oral dosing regimen of 40 mg citalopram daily. Blood samples for pharmacokinetic analysis were obtained over a 168 h period after warfarin dosing.

population: 12 healthy males 

tested for known CYP450 polymorphisms? no

ages: 21 - 32

description:
Citalopram produced no change in the pharmacokinetics of (R)- and (S)-warfarin, indicating that citalopram does not alter the metabolism of warfarin mediated via CYP1A2, CYP3A4 and CYP2C9.


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/177	fluoxetine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00472	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluoxetine_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/178	celecoxib_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp3a4.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/222	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug interactions:

In vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/184	paliperidone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp1a2.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/229	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/184	paliperidone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp1a2.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/230	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. In vitro studies have shown that paliperidone is a P-gp substrate.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/188	duloxetine_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp3a5.html	DIKB	"05/05/2009 17:39:38
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/234	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.11 Drugs Metabolized by CYP3A

Results of in vitro studies demonstrate that duloxetine does not inhibit or induce CYP3A activity. Therefore, an increase or decrease in the metabolism of CYP3A substrates (e.g., oral contraceptives and other steroidal agents) resulting from induction or inhibition is not anticipated, although clinical studies have not been performed. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/189	duloxetine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp3a4.html	DIKB	"05/05/2009 17:38:52
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/235	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.11 Drugs Metabolized by CYP3A

Results of in vitro studies demonstrate that duloxetine does not inhibit or induce CYP3A activity. Therefore, an increase or decrease in the metabolism of CYP3A substrates (e.g., oral contraceptives and other steroidal agents) resulting from induction or inhibition is not anticipated, although clinical studies have not been performed. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/201	fluconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/211	zafirlukast_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/218	R-demethylcitalopram_inhibits_cyp3a4	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/19	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-demethylcitalopram_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/221	fluvoxamine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/235	paliperidone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2c9.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/288	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/235	paliperidone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2c9.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/289	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. In vitro studies have shown that paliperidone is a P-gp substrate.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/236	paliperidone_inhibits_cyp2c8	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2c8.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/290	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/241	atazanavir_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/242	atazanavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/246	risperidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/risperidone_inhibits_cyp2c19.html	DIKB	"04/25/2009 09:58:43
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/303	refute	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/247	perphenazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_inhibits_cyp2c19.html	DIKB	"04/25/2009 10:18:23
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/304	refute	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/249	eszopiclone_inhibits_CYP3A4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP3A4.html	DIKB	11/09/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/306	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/251	voriconazole-N-oxide_inhibits_cyp3a4	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/34	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole-N-oxide_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/253	atazanavir_inhibits_cyp2e1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp2e1.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/309	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/255	N-desalkylquetiapine_inhibits_cyp2d6	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/24	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/N-desalkylquetiapine_inhibits_cyp2d6.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/311	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/270	cinacalcet_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp3a5.html	DIKB	"09/21/2009 15:22:09
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/329	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
...
Midazolam: There were no significant differences in the pharmacokinetics of midazolam, a CYP3A4 and CYP3A5 substrate, in subjects receiving 90 mg cinacalcet once daily for 5 days and a single dose of 2 mg midazolam on day 5 as compared to those of subjects receiving 2 mg midazolam alone.  This suggests that cinacalcet would not affect the pharmacokinetics of drugs predominantly metabolized by CYP3A4 and CYP3A5."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/271	cinacalcet_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp3a4.html	DIKB	"09/21/2009 15:20:18
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/330	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
....

Midazolam: There were no significant differences in the pharmacokinetics of midazolam, a CYP3A4 and CYP3A5 substrate, in subjects receiving 90 mg cinacalcet once daily for 5 days and a single dose of 2 mg midazolam on day 5 as compared to those of subjects receiving 2 mg midazolam alone.  This suggests that cinacalcet would not affect the pharmacokinetics of drugs predominantly metabolized by CYP3A4 and CYP3A5."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/271	cinacalcet_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp3a4.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/331	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
...
An in vitro study indicates that cinacalcet is a strong inhibitor of CYP2D6, but not of CYP1A2, CYP2C9, CYP2C19, and CYP3A4."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/276	beta-hydroxy-simvastatin_inhibits_cyp3a4	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/21	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/beta-hydroxy-simvastatin_inhibits_cyp3a4.html	DIKB	"11/13/2007 13:22:40
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/338	refute	http://www.ncbi.nlm.nih.gov/pubmed/11075313	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

polymorphic enzyme: NO

study duration: 7 days

population: 12 male

ages:21-41

description:
Potential for inhibition of CYP3A activity by simvastatin, an HMG-CoA reductase inhibitor, was evaluated in 12 healthy male subjects who received placebo or 80 mg of simvastatin, the maximal recommended dose, once daily for 7 consecutive days. On day 7, an intravenous injection of 3 microCi [14C N-methyl]erythromycin for the erythromycin breath test (EBT) was coadministered with a 2 mg oral solution of midazolam. The values for percent 14C exhaled during the first hour (for EBT) and the pharmacokinetic parameters of midazolam (AUC, Cmax, t1/2) were not affected following multiple once-daily oral doses of simvastatin 80 mg. The 95% confidence interval was 0.97 to 1.18 for EBT and 0.99 to 1.23 for midazolam AUC. In addition, the total urinary recoveries of midazolam and its 1'-hydroxy metabolites (free plus conjugate) obtained from both treatments were not statistically different (p &gt; 0.200). These data demonstrate that multiple dosing of simvastatin, at the highest recommended clinical dose, does not significantly alter the in vivo hepatic or intestinal CYP3A4/5 activity as measured by the commonly used EBT and oral midazolam probes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/280	R-citalopram_inhibits_cyp1a2	inhibits		http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-citalopram_inhibits_cyp1a2.html	DIKB	"06/11/2009 14:58:44
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/342	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: phenacetin O-deethylation

Quote: 

In all systems the positive control inhibitors produced the expected degree of inhibition of their respective index reactions (Table 1). CYP1A2. R- and S-CT and metabolites all were negligible inhibitors
of phenacetin O-deethylation, the index reaction for CYP1A2. None of these compounds produced 50% inhibition. The mean IC50 for alpha-naphthoflavone was 0.2micM, and the mean IC50 for fluvoxamine was 0.3micM.


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/287	modafinil_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/296	iloperidone_inhibits_cyp2d6	inhibits		http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/iloperidone_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/306	venlafaxine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp2c9.html	DIKB	"05/14/2009 13:49:46
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/371	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	CYP2C9: Venlafaxine did not inhibit CYP2C9 in vitro. In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide. 
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/306	venlafaxine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp2c9.html	DIKB	"02/12/2010 14:23:14
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/372	refute	http://www.ncbi.nlm.nih.gov/pubmed/9205822	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

reaction: tolbutamide-4-hydroxylation

Quote: 
The IC50 for venlafaxine's inhibition of the reaction was &gt; 1000micM "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/310	demethylcitalopram_inhibits_cyp2c9	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/68	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/demethylcitalopram_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/313	ciprofloxacin_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00537	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ciprofloxacin_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/318	propafenone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01182	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/propafenone_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/320	ritonavir_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/323	citalopram_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/324	celecoxib_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp2c9.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/391	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug interactions:

In vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/329	R-didemethylcitalopram_inhibits_cyp2d6	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/26	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-didemethylcitalopram_inhibits_cyp2d6.html	DIKB	"06/12/2009 11:44:35
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/396	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: dextromethorphan O-demethylation

Quote: 

CYP2D6. Only R-DCT had potentially important inhibiting potency versus CYP2D6, represented by dextromethorphan O-demethylation. The mean IC50 was 25.5 (+/-2.1)micM. This is very close to the inhibitory potency of sertraline and is consistent with clinical data suggesting that racemic citalopram and sertraline have comparably weak CYP2D6 inhibitory potency. The SSRI paroxetine was at least an order of magnitude more potent (IC50 2.6micM) than R-DCT as a CYP2D6 inhibitor (see Table 2). Fluoxetine and norfluoxetine (mean IC50 = 2.0 and 2.7micM, respectively) also were strong CYP2D6 inhibitors. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/335	escitalopram_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2c9.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/402	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	in vitro enzyme inhibition data did not reveal an inhibitory effect of escitalopram on CYP3A4, -1A2, -2C9, -2C19, and -2E1. Based on in vitro data, escitalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/335	escitalopram_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2c9.html	DIKB	"06/11/2009 15:15:34
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/403	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"


Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: tolbutamide --&gt; hydroxytolbutamide

Quote: 

CYP2C9. R-CT, S-CT, R-DCT, and S-DCT were weak inhibitors of CYP2C9, represented by tolbutamide hydroxylation, with less than 50% inhibition produced even at 250micM. R-DDCT and S-DDCT produced a moderate degree of inhibition, with IC50 values of 30.7  (+/-6.3)micM and 25.7 (+/-8.0)micM, respectively. Sulfaphenazole was a strong inhibitor (IC50 1.3micM), and the SSRI fluvoxamine also was a moderately strong inhibitor (IC50 9.4micM).


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/337	S-didemethylcitalopram_inhibits_cyp2d6	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/66	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-didemethylcitalopram_inhibits_cyp2d6.html	DIKB	"06/12/2009 11:45:39
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/405	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: dextromethorphan O-demethylation

Quote: 

CYP2D6. Only R-DCT had potentially important inhibiting potency versus CYP2D6, represented by dextromethorphan O-demethylation. The mean IC50 was 25.5 (+/-2.1)micM. This is very close to the inhibitory potency of sertraline and is consistent with clinical data suggesting that racemic citalopram and sertraline have comparably weak CYP2D6 inhibitory potency. The SSRI paroxetine was at least an order of magnitude more potent (IC50 2.6micM) than R-DCT as a CYP2D6 inhibitor (see Table 2). Fluoxetine and norfluoxetine (mean IC50 = 2.0 and 2.7micM, respectively) also were strong CYP2D6 inhibitors. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/345	eszopiclone_inhibits_CYP2D6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP2D6.html	DIKB	11/09/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/412	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/357	topiramate_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2c9.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/428	refute	http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/357	topiramate_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2c9.html	DIKB	"09/22/2009 17:58:27
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/429	refute	http://www.ncbi.nlm.nih.gov/pubmed/12102670	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: assumed based on the date of the article and authors

substrate used: S-warfarin

reaction: S-warfarin 7-hydroxylation

Quote:
No inhibition was found in microsomal preparations made from human livers with adequate CYP2D6 activity or with expressed CYP2D or with adequate activity of CYPs 1A2, 2A6, 2C9, 2E1, and 3A4. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/359	citalopram_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/369	ranolazine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00243	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ranolazine_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/371	diltiazem_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00343	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/diltiazem_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/388	celecoxib_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/391	citalopram_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/393	R-citalopram_inhibits_cyp2d6	inhibits		http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-citalopram_inhibits_cyp2d6.html	DIKB	"06/11/2009 16:25:20
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/471	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: dextromethorphan O-demethylation

Quote: 

CYP2D6. Only R-DCT had potentially important inhibiting potency versus CYP2D6, represented by dextromethorphan O-demethylation. The mean IC50 was 25.5 (+/-2.1)micM. This is very close to the inhibitory potency of sertraline and is consistent with clinical data suggesting that racemic citalopram and sertraline have comparably weak CYP2D6 inhibitory potency. The SSRI paroxetine was at least an order of magnitude more potent (IC50 2.6micM) than R-DCT as a CYP2D6 inhibitor (see Table 2). Fluoxetine and norfluoxetine (mean IC50 = 2.0 and 2.7micM, respectively) also were strong CYP2D6 inhibitors.

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/394	montelukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp3a4.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/472	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/397	clozapine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_inhibits_cyp2c19.html	DIKB	"04/25/2009 10:22:07
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/475	refute	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/403	amiodarone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/amiodarone_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/404	amiodarone_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/amiodarone_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/412	celecoxib_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp2c19.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/493	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug interactions:

In vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/428	paliperidone_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2d6.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/512	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/430	sertraline_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01104	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/sertraline_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/436	lansoprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00448	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lansoprazole_inhibits_cyp2d6.html	DIKB	"09/23/2009 11:41:27
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/525	refute	http://www.ncbi.nlm.nih.gov/pubmed/15258107	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: bufuralol

reaction: bufuralol 1'hydroxylation

IC50 &gt; 200micM (see Table 3)

Quote:
CYP2D6 Activity. No significant effects on the formation of 1 -hydroxylated bufuralol (CYP2D6) were found, indicating that none of the five PPIs [including omeprazole, lansoprazole, pantoprazole rameprazole and esomeprazole] inhibited CYP2D6 activity in vitro (IC50 200micM). However, rabeprazole thioether inhibited CYP2D6 activity with a Ki of 12micM in HLM. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/439	didemethylcitalopram_inhibits_cyp3a4	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/32	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/didemethylcitalopram_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/449	dehydro-aripiprazole_inhibits_cyp1a2	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/58	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/dehydro-aripiprazole_inhibits_cyp1a2.html	DIKB	"04/29/2009 19:42:40
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/537	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/452	paliperidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2c19.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/540	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. In vitro studies have shown that paliperidone is a P-gp substrate.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/454	voriconazole_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/456	demethylcitalopram_inhibits_cyp2c19	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/68	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/demethylcitalopram_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/457	S-demethylcitalopram_inhibits_cyp2c19	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/35	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-demethylcitalopram_inhibits_cyp2c19.html	DIKB	"06/12/2009 11:34:51
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/545	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: S-mepheytoin 4'hydroxylation

Quote:

CYP2C19. R- and S-CT were very weak inhibitors, with less than 50% inhibition of S-mephenytoin hydroxylation even at 100micM. R- and S-DCT also were weak inhibitors. R- and S-DDCT were moderate inhibitors, with mean IC50 values of 18.7 and 12.1micM, respectively. Omeprazole was a strong inhibitor of CYP2C19, as was the SSRI
fluvoxamine (see Table 2). "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/470	venlafaxine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp1a2.html	DIKB	"05/14/2009 13:48:13
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/560	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	CYP1A2: Venlafaxine did not inhibit CYP1A2 in vitro. This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/470	venlafaxine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp1a2.html	DIKB	"02/12/2010 14:12:02
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/561	refute	http://www.ncbi.nlm.nih.gov/pubmed/9205822	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

reaction: 7-O-deethylation of ethoxyresorufin to resorufin

Quote: 
The IC50 for venlafaxine's inhibition of the reaction was &gt; 1000micM 


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/470	venlafaxine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp1a2.html	DIKB	"02/12/2010 14:37:56
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/562	refute	http://www.ncbi.nlm.nih.gov/pubmed/10073324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"

route of administration: oral

study duration: single doses of caffeine (200mg NoDoz) on days 1 and 8; venlafaxine 37.5 mg bid days 2-4 and 75 mg bid days 5-8.

population:16 healthy volunteers (1 later dropped out); 9 male 7 female  

tested for known CYP450 polymorphisms? no

ages: 21 - 41

description:
The treatments did not differ significantly with respect to AUC, C_max, or clearance though there was a small but statistically significant decrease in caffeine half-life


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/474	demethylcitalopram_inhibits_cyp1a2	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/68	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/demethylcitalopram_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/479	rosiglitazone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2c19.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/569	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/485	indinavir_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00224	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/indinavir_inhibits_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/486	indinavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00224	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/indinavir_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/489	ziprasidone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2c9.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/583	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/489	ziprasidone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2c9.html	DIKB	"06/19/2009 17:08:33
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/584	refute	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes

reaction: tolbutamide hydroxylation

The IC50 for ziprasidone inhibition of this reaction was greater than 100micM 


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/502	aripiprazole_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp1a2.html	DIKB	"04/29/2009 19:41:31
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/599	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/504	atazanavir_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp2c19.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/601	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/510	didemethylcitalopram_inhibits_cyp2d6	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/32	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/didemethylcitalopram_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/511	voriconazole-N-oxide_inhibits_cyp2c19	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/34	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole-N-oxide_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/516	topiramate_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp1a2.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/613	refute	http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/516	topiramate_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp1a2.html	DIKB	"09/22/2009 17:50:11
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/614	refute	http://www.ncbi.nlm.nih.gov/pubmed/12102670	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: assumed based on the date of the article and authors

substrate used: R-warfarin

reaction: R-warfarin 6-hydroxylation

Quote: 
No inhibition was found in microsomal preparations made from human livers with adequate CYP2D6 activity or with expressed CYP2D or with adequate activity of CYPs 1A2, 2A6, 2C9, 2E1, and 3A4.



"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/517	quetiapine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp2c9.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/615	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/519	norfloxacin_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01059	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/norfloxacin_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/521	trimethoprim_inhibits_cyp2c8	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00440	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/trimethoprim_inhibits_cyp2c8.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/524	topiramate_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2d6.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/622	refute	http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/526	paliperidone_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp3a5.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/624	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/530	citalopram_inhibits_cyp2e1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2e1.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/628	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data did not reveal an inhibitory effect of citalopram on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak inhibitor of CYP1A2, -2D6, and -2C19. Citalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes. However, in vivo data to address this question are limited.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/534	aripiprazole_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp2c19.html	DIKB	"04/29/2009 19:39:57
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/633	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/549	mirtazapine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp2d6.html	DIKB	"02/12/2010 17:39:55
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/652	refute	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: dextromethorphan

reaction: dextromethorphan O-demethylation

Quote: 
Mirtazapine reduced the rate of the reaction by much less than 50% at concentrations of 100micM (see Table 3).


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/551	rosiglitazone_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp3a5.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/654	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/563	quetiapine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp1a2.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/669	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/584	haloperidol_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00502	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/haloperidol_inhibits_cyp2c19.html	DIKB	"04/25/2009 10:21:12
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/700	refute	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/595	voriconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/596	atazanavir_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp2d6.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/716	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/603	duloxetine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2c9.html	DIKB	"05/05/2009 17:37:51
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/723	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.10 Drugs Metabolized by CYP2C9

Duloxetine does not inhibit the in vitro enzyme activity of CYP2C9. Inhibition of the metabolism of CYP2C9 substrates is therefore not anticipated, although clinical studies have not been performed."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/621	rosiglitazone_inhibits_cyp2a6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2a6.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/743	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/627	atomoxetine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp1a2.html	DIKB	"09/21/2009 14:55:32
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/752	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.5  Effect of Atomoxetine on P450 Enzymes

Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/630	ketoconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01026	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ketoconazole_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/638	fluconazole_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/651	quetiapine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp2d6.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/788	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/667	ziprasidone_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2d6.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/805	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/667	ziprasidone_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2d6.html	DIKB	"05/14/2009 13:42:42
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/806	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Dextromethorphan

Consistent with in vitro results, a study in normal healthy volunteers showed that ziprasidone did not alter the metabolism of dextromethorphan, a CYP2D6 model substrate, to its major metabolite, dextrorphan. There was no statistically significant change in the urinary dextromethorphan/dextrorphan ratio."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/680	verapamil_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/688	modafinil-sulfone_inhibits_cyp2c19	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/1	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil-sulfone_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/695	amiodarone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/amiodarone_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/696	indinavir_inhibits_cyp2b6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00224	http://purl.obolibrary.org/obo/PR_000006116		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/indinavir_inhibits_cyp2b6.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/837	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on in vitro data in human liver microsomes, indinavir does not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However, indinavir may be a weak inhibitor of CYP2D6.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/699	R-demethylcitalopram_inhibits_cyp1a2	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/19	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-demethylcitalopram_inhibits_cyp1a2.html	DIKB	"06/12/2009 11:00:24
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/845	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: phenacetin O-deethylation

Quote:

In all systems the positive control inhibitors produced the expected degree of inhibition of their respective index reactions (Table 1). CYP1A2. R- and S-CT and metabolites all were negligible inhibitors
of phenacetin O-deethylation, the index reaction for CYP1A2. None of these compounds produced 50% inhibition. The mean IC50 for alpha-naphthoflavone was 0.2micM, and the mean IC50 for fluvoxamine was 0.3micM.
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/704	indinavir_inhibits_cyp2e1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00224	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/indinavir_inhibits_cyp2e1.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/852	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on in vitro data in human liver microsomes, indinavir does not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However, indinavir may be a weak inhibitor of CYP2D6.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/713	clarithromycin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/714	clarithromycin_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_inhibits_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/723	paliperidone_inhibits_cyp2a6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2a6.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/877	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/723	paliperidone_inhibits_cyp2a6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2a6.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/878	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. In vitro studies have shown that paliperidone is a P-gp substrate.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/730	montelukast_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2d6.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/888	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/747	montelukast_inhibits_cyp2a6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2a6.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/914	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/764	duloxetine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/768	paliperidone_inhibits_cyp2e1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2e1.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/939	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/774	S-didemethylcitalopram_inhibits_cyp1a2	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/66	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-didemethylcitalopram_inhibits_cyp1a2.html	DIKB	"06/12/2009 11:51:26
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/946	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: phenacetin O-deethylation

Quote:

In all systems the positive control inhibitors produced the expected degree of inhibition of their respective index reactions (Table 1). CYP1A2. R- and S-CT and metabolites all were negligible inhibitors
of phenacetin O-deethylation, the index reaction for CYP1A2. None of these compounds produced 50% inhibition. The mean IC50 for alpha-naphthoflavone was 0.2micM, and the mean IC50 for fluvoxamine was 0.3micM. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/777	N-desalkylquetiapine_inhibits_cyp2c9	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/24	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/N-desalkylquetiapine_inhibits_cyp2c9.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/950	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/778	R-didemethylcitalopram_inhibits_cyp3a4	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/26	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-didemethylcitalopram_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/783	ziprasidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2c19.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/956	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/783	ziprasidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2c19.html	DIKB	"06/19/2009 17:10:35
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/957	refute	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"

Enzyme system: human liver microsomes

NADPH added: yes

reaction: S-mephenytoin 4'-hydroxylatoin

The IC50 for ziprasidone inhibition of this reaction was greater than 100micM 


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/787	atazanavir_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp2c9.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/961	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/791	N-desalkylquetiapine_inhibits_cyp2c19	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/24	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/N-desalkylquetiapine_inhibits_cyp2c19.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/965	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/792	ziprasidone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp3a4.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/966	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/799	R-demethylcitalopram_inhibits_cyp2c9	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/19	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-demethylcitalopram_inhibits_cyp2c9.html	DIKB	"06/12/2009 11:22:50
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/975	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: tolbutamide --&gt; hydroxytolbutamide

Quote:

CYP2C9. R-CT, S-CT, R-DCT, and S-DCT were weak inhibitors of CYP2C9, represented by tolbutamide hydroxylation, with less than 50% inhibition produced even at 250micM. R-DDCT and S-DDCT produced a moderate degree of inhibition, with IC50 values of 30.7 (+/-6.3)micM and 25.7 (+/-8.0)micM, respectively. Sulfaphenazole was a strong inhibitor (IC50 1.3micM), and the SSRI fluvoxamine also was a moderately strong inhibitor (IC50 9.4micM). "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/804	didemethylcitalopram_inhibits_cyp1a2	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/32	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/didemethylcitalopram_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/808	cinacalcet_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp1a2.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/986	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
...
An in vitro study indicates that cinacalcet is a strong inhibitor of CYP2D6, but not of CYP1A2, CYP2C9, CYP2C19, and CYP3A4."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/818	rosiglitazone_inhibits_cyp2b6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006116		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2b6.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/996	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/828	citalopram_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp3a4.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1010	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data did not reveal an inhibitory effect of citalopram on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak inhibitor of CYP1A2, -2D6, and -2C19. Citalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes. However, in vivo data to address this question are limited.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/828	citalopram_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp3a4.html	DIKB	"06/11/2009 16:32:24
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1011	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"

Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: triazolam hydroxylation

Quote: 

CYP3A. CT and metabolites all were very weak or negligible inhibitors of CYP3A, as indicated by triazolam hydroxylation. None of the compounds (at 100micM) produced more than 50% inhibition. Fluvoxamine and nefazodone were moderately strong inhibitors (von
Moltke et al., 1996b, 1999c)."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/828	citalopram_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp3a4.html	DIKB	"02/12/2010 14:46:20
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1012	refute	http://www.ncbi.nlm.nih.gov/pubmed/10907965	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"

route of administration: oral

study duration: Subjects received triazolam 0.25 mg alone and another 0.25-mg dose after 4 weeks of citalopram 20 mg/day for 1 week, followed by 3 weeks of citalopram 40 mg/day

population: 17 (7 men and 10 women) completed the study)

tested for known CYP450 polymorphisms?

ages: 18 - 31

description:
The pharmacokinetics of triazolam and its metabolite alpha-hydroxytriazolam were unchanged by citalopram coadministration.

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/835	escitalopram_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2d6.html	DIKB	"05/14/2009 13:37:41
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1021	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.19 Drugs Metabolized by Cytochrome P4502D6

In vitro studies did not reveal an inhibitory effect of escitalopram on CYP2D6. In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism. However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine. The clinical significance of this finding is unknown. Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/835	escitalopram_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2d6.html	DIKB	"06/11/2009 16:23:37
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1022	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"

Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: dextromethorphan O-demethylation

Quote: 

CYP2D6. Only R-DCT had potentially important inhibiting potency versus CYP2D6, represented by dextromethorphan O-demethylation. The mean IC50 was 25.5 (+/-2.1)micM. This is very close to the inhibitory potency of sertraline and is consistent with clinical data suggesting that racemic citalopram and sertraline have comparably weak CYP2D6 inhibitory potency. The SSRI paroxetine was at least an order of magnitude more potent (IC50 2.6micM) than R-DCT as a CYP2D6 inhibitor (see Table 2). Fluoxetine and norfluoxetine (mean IC50 = 2.0 and 2.7micM, respectively) also were strong CYP2D6 inhibitors.

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/843	topiramate_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2c19.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1032	refute	http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/845	rosiglitazone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp3a4.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1035	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/849	rosiglitazone_inhibits_cyp2c8	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2c8.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1038	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/852	fluphenazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00623	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluphenazine_inhibits_cyp2c19.html	DIKB	"04/25/2009 10:16:03
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1042	refute	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/854	bupropion_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01156	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/bupropion_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/860	eszopiclone_inhibits_CYP2C9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP2C9.html	DIKB	11/09/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1052	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/862	R-citalopram_inhibits_cyp2c19	inhibits		http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-citalopram_inhibits_cyp2c19.html	DIKB	"06/11/2009 16:08:54
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1054	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: S-mepheytoin 4'hydroxylation

Quote: 

CYP2C19. R- and S-CT were very weak inhibitors, with less than 50% inhibition of S-mephenytoin hydroxylation even at 100micM. R- and S-DCT also were weak inhibitors. R- and S-DDCT were moderate inhibitors, with mean IC50 values of 18.7 and 12.1micM, respectively. Omeprazole was a strong inhibitor of CYP2C19, as was the SSRI
fluvoxamine (see Table 2).


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/876	gemfibrozil_inhibits_cyp2c8	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01241	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/gemfibrozil_inhibits_cyp2c8.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/881	voriconazole-N-oxide_inhibits_cyp2c9	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/34	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole-N-oxide_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/903	cinacalcet_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp2c9.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1105	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
...
An in vitro study indicates that cinacalcet is a strong inhibitor of CYP2D6, but not of CYP1A2, CYP2C9, CYP2C19, and CYP3A4."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/906	mirtazapine_inhibits_cyp2e1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp2e1.html	DIKB	"02/12/2010 17:54:38
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1109	refute	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: chlorzoxazone

reaction: chlorzoxazone hydroxylation

Quote: 
Mirtazapine reduced the rate of the reaction by much less than 50% even at concentrations of 250micM (see Table 3).


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/918	aripiprazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp3a4.html	DIKB	"04/29/2009 19:40:38
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1125	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/925	N-desalkylquetiapine_inhibits_cyp1a2	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/24	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/N-desalkylquetiapine_inhibits_cyp1a2.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1136	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/929	fluvoxamine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/932	rosiglitazone_inhibits_cyp2e1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2e1.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1143	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/936	pantoprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_inhibits_cyp2d6.html	DIKB	"09/23/2009 11:43:26
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1148	refute	http://www.ncbi.nlm.nih.gov/pubmed/15258107	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: bufuralol

reaction: bufuralol 1'hydroxylation

IC50 &gt; 200micM (see Table 3)

Quote:
CYP2D6 Activity. No significant effects on the formation of 1 -hydroxylated bufuralol (CYP2D6) were found, indicating that none of the five PPIs [including omeprazole, lansoprazole, pantoprazole rameprazole and esomeprazole] inhibited CYP2D6 activity in vitro (IC50 200micM). However, rabeprazole thioether inhibited CYP2D6 activity with a Ki of 12micM in HLM. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/938	demethylcitalopram_inhibits_cyp3a4	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/68	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/demethylcitalopram_inhibits_cyp3a4.html	DIKB	"06/12/2009 11:36:28
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1150	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: triazolam hydroxylation

Quote:

CYP3A. CT and metabolites all were very weak or negligible inhibitors of CYP3A, as indicated by triazolam hydroxylation. None of the compounds (at 100micM) produced more than 50% inhibition. Fluvoxamine and nefazodone were moderately strong inhibitors (von
Moltke et al., 1996b, 1999c)."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/956	thiothixene_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01623	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/thiothixene_inhibits_cyp2c19.html	DIKB	"04/25/2009 10:20:16
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1174	refute	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/959	escitalopram_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp1a2.html	DIKB	"06/11/2009 15:00:17
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1177	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: phenacetin O-deethylation

Quote: 

In all systems the positive control inhibitors produced the expected degree of inhibition of their respective index reactions (Table 1). CYP1A2. R- and S-CT and metabolites all were negligible inhibitors
of phenacetin O-deethylation, the index reaction for CYP1A2. None of these compounds produced 50% inhibition. The mean IC50 for alpha-naphthoflavone was 0.2micM, and the mean IC50 for fluvoxamine was 0.3micM.


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/961	nefazodone_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_inhibits_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/963	venlafaxine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp3a4.html	DIKB	"05/14/2009 13:07:10
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1181	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	CYP3A4: Venlafaxine did not inhibit CYP3A4 in vitro. This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/963	venlafaxine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp3a4.html	DIKB	"02/12/2010 14:20:00
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1182	refute	http://www.ncbi.nlm.nih.gov/pubmed/9205822	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

reaction: testosterone 6beta hydroxylation

Quote: 
The IC50 for venlafaxine's inhibition of the reaction was &gt; 1000micM "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/965	quetiapine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp2c19.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1185	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/968	R-citalopram_inhibits_cyp3a4	inhibits		http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-citalopram_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/969	pravastatin_inhibits_cyp2c8	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00175	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pravastatin_inhibits_cyp2c8.html	DIKB	"10/29/2007 10:11:10
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1188	refute	http://www.ncbi.nlm.nih.gov/pubmed/15998357	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes

reaction: paclitaxel --&gt; 6alpha-OH-paclitaxel

&quot;No IC50 values could be  determined for rosuvastatin and pravastatin with concentrations up to 100micM&quot;

Concentration of pravastatin in vivo based on the largest C_max in label in table 1 of http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=1652:

3650ng/1ml x 1g/1e9ng x 1e3ml/1L = .004g/L

.004g/L x 1M/853.9g = 4.68micM/L"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/975	R-citalopram_inhibits_cyp2c9	inhibits		http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/R-citalopram_inhibits_cyp2c9.html	DIKB	"06/11/2009 15:12:49
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1195	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"

Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: tolbutamide --&gt; hydroxytolbutamide

Quote: 

CYP2C9. R-CT, S-CT, R-DCT, and S-DCT were weak inhibitors of CYP2C9, represented by tolbutamide hydroxylation, with less than 50% inhibition produced even at 250micM. R-DDCT and S-DDCT produced a moderate degree of inhibition, with IC50 values of 30.7  (+/-6.3)micM and 25.7 (+/-8.0)micM, respectively. Sulfaphenazole was a strong inhibitor (IC50 1.3micM), and the SSRI fluvoxamine also was a moderately strong inhibitor (IC50 9.4micM).


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/985	rosiglitazone_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2d6.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1207	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/989	telithromycin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00976	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/telithromycin_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1015	atorvastatin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1021	montelukast_inhibits_cyp2c8	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2c8.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1247	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1028	teriflunomide_inhibits_cyp2c9	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/55	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/teriflunomide_inhibits_cyp2c9.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1032	quinidine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00908	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quinidine_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1035	mirtazapine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp2c19.html	DIKB	"02/12/2010 17:35:55
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1263	refute	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: S-mephenytoin

reaction: S-mephenytoin hydroxylation

Quote: 
Mirtazapine reduced the rate of the reaction by much less than 50% even at concentrations of 250micM (see Table 3).


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1045	topiramate_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp3a4.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1280	refute	http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1045	topiramate_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp3a4.html	DIKB	"09/22/2009 18:02:20
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1281	refute	http://www.ncbi.nlm.nih.gov/pubmed/12102670	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: assumed based on the date of the article and authors

substrate used: R-warfarin

reaction: R-warfarin 10-hydroxylation

Quote:
No inhibition was found in microsomal preparations made from human livers with adequate CYP2D6 activity or with expressed CYP2D or with adequate activity of CYPs 1A2, 2A6, 2C9, 2E1, and 3A4. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1046	topiramate_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp3a5.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1282	refute	http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1054	eszopiclone_inhibits_CYP1A2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP1A2.html	DIKB	11/09/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1292	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1055	fluvoxamine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1056	rosuvastatin_inhibits_cyp2c8	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01098	http://purl.obolibrary.org/obo/PR_000006119		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosuvastatin_inhibits_cyp2c8.html	DIKB	"10/29/2007 10:23:54
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1296	refute	http://www.ncbi.nlm.nih.gov/pubmed/15998357	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes

reaction: paclitaxel --&gt; 6alpha-OH-paclitaxel

&quot;No IC50 values could be determined for rosuvastatin and pravastatin with concentrations up to 100micM&quot;

Concentration of rosuvastatin in vivo based on the C_max from PMID:14667956 of a 10mg dose (small): .188nM/L; according to labeling both peak concentration (Cmax) and area under the plasma concentration-time curve (AUC) increased in approximate proportion to rosuvastatin dose. 

"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1057	cinacalcet_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1071	cimetidine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00501	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cimetidine_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1072	atomoxetine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp2d6.html	DIKB	"09/21/2009 14:57:14
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1315	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.5  Effect of Atomoxetine on P450 Enzymes

Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1072	atomoxetine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp2d6.html	DIKB	"09/21/2009 15:02:28
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1316	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.5  Effect of Atomoxetine on P450 Enzymes
...

CYP2D6 Substrate (e.g., Desipramine) ï¿½ Coadministration of STRATTERA (40 or 60 mg BID for 13 days) with desipramine, a model compound for CYP2D6 metabolized drugs (single dose of 50 mg), did not alter the pharmacokinetics of desipramine. No dose adjustment is recommended for drugs metabolized by CYP2D6."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1075	indinavir_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00224	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/indinavir_inhibits_cyp2c9.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1319	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on in vitro data in human liver microsomes, indinavir does not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However, indinavir may be a weak inhibitor of CYP2D6.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1093	venlafaxine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1096	atomoxetine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp2c9.html	DIKB	"09/21/2009 14:59:07
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1343	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.5  Effect of Atomoxetine on P450 Enzymes

Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1102	cimetidine_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00501	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cimetidine_inhibits_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1103	cimetidine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00501	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cimetidine_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1104	atazanavir_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp1a2.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1351	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1108	lansoprazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00448	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lansoprazole_inhibits_cyp3a4.html	DIKB	"09/23/2009 11:47:32
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1355	refute	http://www.ncbi.nlm.nih.gov/pubmed/15258107	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: midazolam

reaction: midazolam 1'hydroxylation

IC50 &gt; 200micM (see Table 3)

Quote:
Pantoprazole showed a stronger inhibitory effect (Ki 22mM) on midazolam 1'-hydroxylation than omeprazole (Ki 42micM), esomeprazole (Ki 47micM), and rabeprazole (Ki 51micM). The IC50 of lansoprazole was over 200 M. 
"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1121	topiramate_inhibits_cyp2a6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2a6.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1372	refute	http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1121	topiramate_inhibits_cyp2a6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006114		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2a6.html	DIKB	"09/22/2009 17:55:50
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1373	refute	http://www.ncbi.nlm.nih.gov/pubmed/12102670	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: assumed based on the date of the article and authors

substrate used: coumarin

reaction: coumarin 7-hydroxylation

Quote:
No inhibition was found in microsomal preparations made from human livers with adequate CYP2D6 activity or with expressed CYP2D or with adequate activity of CYPs 1A2, 2A6, 2C9, 2E1, and 3A4. "
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1124	montelukast_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2c9.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1377	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1124	montelukast_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2c9.html	DIKB	"01/11/2010 19:14:00
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1378	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1132	S-demethylcitalopram_inhibits_cyp3a4	inhibits	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Metabolite/35	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/S-demethylcitalopram_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1137	eszopiclone_inhibits_CYP2C19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP2C19.html	DIKB	11/09/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1393	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1141	voriconazole_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1145	aripiprazole_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp2c9.html	DIKB	"04/29/2009 19:39:11
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1402	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1149	telithromycin_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00976	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/telithromycin_inhibits_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1151	ranolazine_inhibits_cyp3a5	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00243	http://purl.obolibrary.org/obo/PR_000006132		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ranolazine_inhibits_cyp3a5.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1152	ranolazine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00243	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ranolazine_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1155	mexiletine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00379	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mexiletine_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1158	itraconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01167	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/itraconazole_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1159	atazanavir_inhibits_cyp2b6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006116		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp2b6.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1421	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1160	escitalopram_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1193	omeprazole_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00338	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/omeprazole_inhibits_cyp2c19.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1195	nefazodone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_inhibits_cyp3a4.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1198	rosiglitazone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006120		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2c9.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1473	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1205	terbinafine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00857	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/terbinafine_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1209	montelukast_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp1a2.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1486	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1209	montelukast_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp1a2.html	DIKB	"01/11/2010 19:12:06
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1487	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1216	escitalopram_inhibits_cyp2e1	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006122		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2e1.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1495	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	in vitro enzyme inhibition data did not reveal an inhibitory effect of escitalopram on CYP3A4, -1A2, -2C9, -2C19, and -2E1. Based on in vitro data, escitalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1223	paroxetine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00715	http://purl.obolibrary.org/obo/PR_000006121		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paroxetine_inhibits_cyp2d6.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1224	mirtazapine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp1a2.html	DIKB	"02/12/2010 15:01:51
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1511	refute	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: phenacetin

reaction: phenacetin O-deethylation

Quote: 
Mirtazapine reduced the rate of the reaction by much less than 50% even at concentrations of 250micM (see Table 3).


"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1231	chlorpromazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00477	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/chlorpromazine_inhibits_cyp2c19.html	DIKB	"04/25/2009 10:23:23
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1521	refute	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1242	indinavir_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00224	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/indinavir_inhibits_cyp1a2.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1532	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on in vitro data in human liver microsomes, indinavir does not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However, indinavir may be a weak inhibitor of CYP2D6.
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1244	thioridazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00679	http://purl.obolibrary.org/obo/PR_000006118		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/thioridazine_inhibits_cyp2c19.html	DIKB	"04/25/2009 10:13:19
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1534	refute	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1250	amiodarone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118	http://purl.obolibrary.org/obo/PR_000006102		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/amiodarone_inhibits_cyp1a2.html	DIKB							
https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/1260	simvastatin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130		http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_inhibits_cyp3a4.html	DIKB	"11/13/2007 13:26:37
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1551	refute	http://www.ncbi.nlm.nih.gov/pubmed/11075313	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

polymorphic enzyme: NO

study duration: 7 days

population: 12 male

ages:21-41

description:
Potential for inhibition of CYP3A activity by simvastatin, an HMG-CoA reductase inhibitor, was evaluated in 12 healthy male subjects who received placebo or 80 mg of simvastatin, the maximal recommended dose, once daily for 7 consecutive days. On day 7, an intravenous injection of 3 microCi [14C N-methyl]erythromycin for the erythromycin breath test (EBT) was coadministered with a 2 mg oral solution of midazolam. The values for percent 14C exhaled during the first hour (for EBT) and the pharmacokinetic parameters of midazolam (AUC, Cmax, t1/2) were not affected following multiple once-daily oral doses of simvastatin 80 mg. The 95% confidence interval was 0.97 to 1.18 for EBT and 0.99 to 1.23 for midazolam AUC. In addition, the total urinary recoveries of midazolam and its 1'-hydroxy metabolites (free plus conjugate) obtained from both treatments were not statistically different (p &gt; 0.200). These data demonstrate that multiple dosing of simvastatin, at the highest recommended clinical dose, does not significantly alter the in vivo hepatic or intestinal CYP3A4/5 activity as measured by the commonly used EBT and oral midazolam probes."
